{"id":857,"date":"2019-02-21T09:20:16","date_gmt":"2019-02-21T01:20:16","guid":{"rendered":"http:\/\/www.puriactives.com\/en\/?page_id=857"},"modified":"2019-02-21T09:44:58","modified_gmt":"2019-02-21T01:44:58","slug":"platform-technology","status":"publish","type":"page","link":"http:\/\/www.puriactives.com\/en\/?page_id=857","title":{"rendered":"Platform Technology"},"content":{"rendered":"
\n\n\t\t\n\t\t\n
\n\n\t\n\t
\n\n\t\t\n\t\t
\n\t\t\t\n\t\t\t

<\/a><\/h1>\n\n\t\t\t\t\t\t\t
\n\t\t\t\t\tPosted on L, Y<\/a><\/span><\/span> \t\t\t\t<\/div>\n\t\t\t\n\t\t<\/header>\n\n\t\t\t\t\t
\n\t\t\t\t

ENGLISH VERSION<\/p>\n

NanoActive Alavelle™Aminolevulinic Acid Nanoliposomes<\/h2>\n

Product overview<\/p>\n

NanoActive Alavelle™<\/h2>\n

Aminolevulinic Acid Nanoliposomes \u00b7 Advanced ALA Delivery for Skin and Scalp Innovation<\/p>\n

Powered by PURISOME\u00ae FlexVes™ Liposome Technology<\/p>\n

\"\"<\/p>\n

Purui Biomedical Technology Co., Ltd. \u00b7 Innovation for Health and Beauty<\/p>\n

Product identity<\/p>\n

One active ingredient, engineered for delivery<\/h2>\n

Product name<\/p>\n

NanoActive Alavelle™ Aminolevulinic Acid Nanoliposomes<\/p>\n

Active ingredient INCI name<\/p>\n

AMINOLEVULINIC ACID<\/p>\n

Scientific identity<\/p>\n

5-Aminolevulinic acid (5-ALA)<\/p>\n

Delivery platform<\/p>\n

PURISOME\u00ae FlexVes™ Liposome Technology<\/p>\n

AMINOLEVULINIC ACID identifies the active component. The complete raw material is a multicomponent liposomal composition; see the technical documentation for the full INCI list.<\/p>\n

5-ALA is a natural biochemical precursor of protoporphyrin IX (PpIX) in the heme pathway.<\/p>\n

Application development landscape<\/p>\n

\u25a0 Sprays for facial and scalp coverage<\/p>\n

\u25a0 Topical aqueous gels<\/p>\n

\u25a0 Scalp serums and tonics<\/p>\n

\u25a0 Professional photoactivated treatments<\/p>\n

\u25a0 Daylight photodynamic applications<\/p>\n

\u25a0 Oral formulation development<\/p>\n

Why this ingredient, why now<\/p>\n

Development opportunities<\/h2>\n

5-ALA is one of the most extensively studied actives in photodynamic dermatology\u2014and one of the most challenging to formulate.<\/p>\n

4 Interconnected opportunities, one delivery platform<\/p>\n

01 Stabilize the active. Protect a pH-sensitive hydrophilic molecule within engineered vesicles, turning aqueous stability measured in days into a usable shelf life.<\/p>\n

02 Deliver where it matters. Improve transport to target skin compartments and sebum-rich follicles, rather than leaving the active on the surface.<\/p>\n

One platform, multiple formats. Sprays, gels, scalp care, professional photoactivation and daylight photodynamic applications, with a separate oral development pathway.<\/p>\n

Design for comfort. Build dose, incubation and light exposure into the protocol so efficacy and tolerability are developed together.<\/p>\n

 <\/p>\n

Mechanism of action<\/p>\n

ALA in cell biology: the heme pathway<\/h2>\n

\"\"<\/p>\n

What happens when ALA is supplied externally?<\/p>\n

Exogenous ALA bypasses the rate-limiting ALA synthase step and heme feedback control. In metabolically active cells, including sebaceous glands and proliferative epidermis, limited ferrochelatase capacity favors PpIX accumulation in target tissue.<\/p>\n

Schematic of heme biosynthesis. 5-ALA is a metabolic precursor of PpIX; it is not itself a photoactivated photosensitizer.<\/p>\n

Innovation pathways<\/p>\n

Two routes to application innovation<\/h2>\n

Route A\u2014photoactivated chemistry<\/p>\n

Vesicular delivery \u2192 intracellular PpIX \u2192 controlled illumination \u2192 photodynamic response<\/p>\n

Skin renewal and photorejuvenation: 0.5% liposomal ALA spray + IPL has been studied for wrinkles and photodamage.<\/p>\n

Pilosebaceous care: follicular delivery combined with IPL has been studied in inflammatory acne.<\/p>\n

Daylight protocols: continuous low-dose activation has clinical validation in actinic keratosis studies.<\/p>\n

Piccioni et al. | J Dermatolog Treat | 2011 \u00b7 Yeung et al. | Dermatol Surg | 2011 \u00b7 Dirschka et al. | JEADV | 2019<\/p>\n

Route B\u2014non-photodynamic combinations<\/p>\n

ALA + iron\/peptide cofactors \u2192 dermal papilla signaling \u2192 follicle research<\/p>\n

No light required. ALA combined with ferric ammonium citrate activates ERK\/AKT signaling in dermal papilla cells and supports hair-shaft elongation in ex vivo human follicles.<\/p>\n

Combination logic. Peptide (GHK) and iron partners define the studied systems; results belong to the combination, not to ALA alone.<\/p>\n

Ryu et al. | FEBS Open Bio | 2026 \u00b7 Lee et al. | Ann Dermatol | 2016 \u00b7 Morokuma et al. | Int J Dermatol | 2008<\/p>\n

Formulation science<\/p>\n

Why formulation matters: ALA is highly formulation-sensitive<\/h2>\n

1 \u00b7 A hydrophilic zwitterion facing a lipid barrier<\/p>\n

At physiological pH, ALA carries both positive and negative groups and partitions poorly into the lipid-rich stratum corneum. Unformulated aqueous ALA largely remains on the surface.<\/p>\n

2 \u00b7 pH-triggered dimerization, followed by oxidation<\/p>\n

Above approximately pH 5, the deprotonated amino group of one ALA molecule attacks another molecule\u2019s ketone group. The resulting dihydropyrazine (DHPY) oxidizes in air to inactive pyrazine (PY), with loss of PpIX-forming activity.<\/p>\n

3 \u00b7 Second-order decay that antioxidants cannot stop<\/p>\n

Degradation accelerates with the square of the free ALA concentration. Chelators and antioxidants cannot stop the primary pathway; effective controls are pH, temperature and oxygen exclusion.<\/p>\n

Measured half-life of 1% aqueous ALA (50 \u00b0C)<\/p>\n

3 h<\/p>\n

pH 7.42\u2014near physiological pH<\/p>\n

257 h<\/p>\n

pH 4.81\u2014mild acidification<\/p>\n

37 d<\/p>\n

Stable at pH 2.35\u2014fully protonated amino group<\/p>\n

The active\u2019s microenvironment\u2014pH, oxygen and molecular mobility\u2014determines shelf life. Formulation creates the challenge and provides the solution.<\/p>\n

Bunke et al. | J Pharm Sci | 2000 | PMID: 10980508 \u00b7 Elfsson et al. | Eur J Pharm Sci | 1999 | PMID: 9845784<\/p>\n

Delivery platform<\/p>\n

PURISOME\u00ae FlexVes™: an architecture for hydrophilic actives<\/h2>\n

\"\"<\/p>\n

Phospholipid bilayer membrane<\/p>\n

Aqueous core\u2014hydrophilic ALA payload<\/p>\n

Flexible, skin-compatible vesicle design<\/p>\n

What this architecture does<\/p>\n

Accommodates the payload correctly. ALA resides in aqueous and interfacial regions, associating with phospholipid headgroups rather than dissolving in oil.<\/p>\n

Stabilizes the chemistry. Restricted molecular mobility and controlled local pH slow the dimerization that degrades aqueous ALA.<\/p>\n

Prepares for delivery. A deformable lipid membrane supports partitioning into the stratum corneum and sebum-rich follicles.<\/p>\n

Published studies of liposomal ALA delivery and treatment protocols are cited as technical background for this platform class.<\/p>\n

PURISOME\u00ae FlexVes™ Liposome Technology<\/p>\n

Formulation science<\/p>\n

Stability through formulation design<\/h2>\n

01 Interfacial association. ALA associates with phospholipid headgroups, reducing free-molecule collisions that drive second-order dimerization.<\/p>\n

02 Microenvironmental pH. A mildly acidic interface keeps amino groups protonated and unable to attack neighboring ketone groups.<\/p>\n

03 Compartmentalization. Interfacial membranes restrict orientation and contact, turning one bulk phase into many isolated microenvironments.<\/p>\n

04 Locally reduced oxygen. The lipid environment limits oxygen access to DHPY intermediates, slowing irreversible oxidation to inactive PY.<\/p>\n

Published precedent. In a phospholipid nanovesicular gel containing 7.8% ALA, reported association with phosphatidylcholine polar headgroups extended stability from days in water to a shelf life of 24\u201336 months. PURISOME\u00ae vesicles apply the same physical rationale.<\/p>\n

Days Aqueous solution \u2192 24\u201336 months<\/p>\n

Reported shelf life of a 7.8% ALA nanovesicular gel<\/p>\n

Quality note: measure chemical stability (ALA content and pyrazine impurities) separately from vesicle size and appearance. Colloidal stability alone does not prove chemical stability. Antioxidants have little effect on the main condensation pathway; effective measures include pH below approximately 5 and oxygen exclusion.<\/p>\n

Reinhold | Future Oncol | 2017 | PMID: 28805092 \u00b7 Bunke et al. | J Pharm Sci | 2000 | PMID: 10980508<\/p>\n

Formulation science<\/p>\n

Aqueous vs nanovesicular systems: what changes for ALA?<\/h2>\n

Table expanded in original row order; all column labels and data are retained.<\/p>\n

\"\"<\/p>\n

Read the shelf-life row correctly: 24\u201336 months refers to that specific proprietary nanovesicular gel. It is neither a general emulsion claim nor a NanoActive Alavelle™ specification. Every formulation needs its own stability program with ALA content and pyrazine impurities as endpoints; size and appearance alone cannot prove chemical stability.<\/p>\n

Bunke et al. | J Pharm Sci | 2000 | PMID: 10980508 \u00b7 Reinhold | Future Oncol | 2017 | PMID: 28805092 \u00b7 Elfsson et al. | Eur J Pharm Sci | 1999<\/p>\n

Delivery evidence<\/p>\n

Delivery into skin and follicular compartments<\/h2>\n

\"\"<\/p>\n

Schematic: smaller vesicles can pass between corneocytes<\/p>\n

\"\"<\/p>\n

Confocal cross-sections: as particle size decreases (a \u2192 c), fluorescent material reaches deeper skin layers<\/p>\n

Particle size defines the depth budget<\/p>\n

Vesicle size and membrane deformability determine how far the carrier delivers its payload. Comparative studies show that deformable liposomes can substantially improve ALA delivery into skin.<\/p>\n

Follicles provide a fast route<\/p>\n

Hair follicles and sebaceous glands bypass the stratum corneum and extend into the dermis. Lipid vesicles readily partition into this sebum-rich environment.<\/p>\n

Local retention rather than systemic absorption<\/p>\n

The goal is retention in skin compartments where PpIX forms. After topical ALA application, plasma levels remained within normal reference ranges; delivery is intended to be local.<\/p>\n

Oh et al. | Eur J Pharm Sci | 2011 | PMID: 21782942 \u00b7 Schmitz et al. | Photodiagn Photodyn Ther | 2016 \u00b7 Rick et al. | J Photochem Photobiol B | 1997<\/p>\n

Evidence\u2014delivery<\/p>\n

Low-concentration liposomal ALA: rapid, self-limiting PpIX formation<\/h2>\n

A 0.5% liposomal ALA spray saturates skin fluorescence in approximately 2 hours, with clearance within 8 hours.<\/p>\n

\"\"<\/p>\n

Mean peak skin PpIX fluorescence, expressed as a percentage of maximum (healthy volunteers, n = 10). The source describes the protocols as statistically equivalent (P = 0.47).<\/p>\n

Plateau at about 2 h. Non-occluded 0.5% liposomal ALA reaches a fluorescence plateau after approximately two hours.<\/p>\n

Return to baseline within 8 h. The signal declines within minutes after removal and clears fully within eight hours, giving a short photosensitivity window.<\/p>\n

Comparison with 20% cream. Fluorescence continues rising for approximately eight hours after removal of the high-concentration cream, producing a longer, less controllable exposure tail.<\/p>\n

Concentrations here describe dose and kinetics, not a fold-increase in bioavailability.<\/p>\n

Christiansen et al. | Lasers Surg Med | 2007 | PMID: 17457834<\/p>\n

Mechanism\u2014light<\/p>\n

Photoactivation: PpIX photochemistry needs photons and oxygen<\/h2>\n

\"\"<\/p>\n

PpIX absorption profile: Soret band (approximately 405 nm) and Q bands (approximately 510\u2013635 nm). Schematic, not to scale.<\/p>\n

Blue light, 405\u2013417 nm<\/p>\n

Red light, 630\u2013635 nm<\/p>\n

Daylight and IPL cover the full activation spectrum<\/p>\n

1 \u00b7 Excitation. PpIX absorbs a photon and enters a long-lived triplet state.<\/p>\n

2 \u00b7 Energy transfer. Triplet PpIX transfers energy to dissolved molecular oxygen (Type II photochemistry), producing singlet oxygen and ROS.<\/p>\n

3 \u00b7 Local response. ROS act within micrometers of PpIX, mapping the response to the tissue reached by delivery.<\/p>\n

4 \u00b7 Dose rate is a design variable. Spectrum, irradiance and duration shape efficacy and comfort. Continuous low-rate daylight activation can deliver a comparable cumulative dose with much less pain than high-intensity lamps.<\/p>\n

For photochemistry and PpIX photophysics, see Bunke et al. | J Pharm Sci | 2000 and Christiansen et al. | Lasers Surg Med | 2007.<\/p>\n

Evidence\u2014skin renewal<\/p>\n

Photodynamic photorejuvenation: a measurable light dose guided by the skin<\/h2>\n

The liposomal ALA concept was developed for photodamaged skin: deliver a low-dose precursor, use skin fluorescence to indicate PpIX formation, then activate it with light.<\/p>\n

1.7 vs 1.1<\/p>\n

Mean participant-rated improvement in skin quality in a fluorescence-guided photodynamic rejuvenation study (0\u20134 scale)<\/p>\n

2007<\/p>\n

Mapping the fluorescence kinetics of 0.5% liposomal ALA in normal skin<\/p>\n

2009<\/p>\n

Fluorescence-controlled photorejuvenation: skin signals determine the light dose<\/p>\n

2011<\/p>\n

Wrinkle study: 30 participants, three liposomal ALA + IPL sessions<\/p>\n

2011<\/p>\n

A pilot study in inflammatory facial acne using the same spray + IPL approach<\/p>\n

Implication for development: spray format, a 0.5% dose and IPL use have been published together, providing a literature template for professional photoactivated skin care.<\/p>\n

Christiansen et al. | Lasers Surg Med | 2007 \u00b7 Bjerring et al. | Lasers Surg Med | 2009; 41:327\u2013336 \u00b7 Piccioni et al. | 2011 \u00b7 Yeung et al. | 2011<\/p>\n

Clinical evidence\u2014photorejuvenation<\/p>\n

Wrinkle scores fall after three 0.5% liposomal ALA + IPL sessions<\/h2>\n

\"\"<\/p>\n

Mean modified Fitzpatrick wrinkle scores (lower is milder). These are means on an ordinal scale, not direct percentage measurements of wrinkle depth.<\/p>\n

Study design<\/p>\n

30 participants with facial photodamage<\/p>\n

Three sessions of 0.5% liposomal ALA spray + IPL<\/p>\n

Three-week intervals<\/p>\n

Follow-up three months after the final session<\/p>\n

Scores improved further between the last session and follow-up, consistent with ongoing post-treatment remodeling.<\/p>\n

Piccioni et al. | J Dermatolog Treat | 2011 | DOI: 10.3109\/09546634.2011.590791 | PMID: 21801099<\/p>\n

Clinical evidence\u2014dermal remodeling<\/p>\n

Beyond wrinkle scores: the procollagen response after ALA-PDT<\/h2>\n

\"\"<\/p>\n

Mean target-antigen staining (%), paired biopsies before and one month after two ALA-PDT sessions. Values are approximate readings from Figure 2C. This is a photoactivation protocol, not evidence for unilluminated ALA.<\/p>\n

Original histology (Figure 2B): Masson\u2019s trichrome staining of dermal collagen<\/p>\n

\"\"<\/p>\n

Study protocol<\/p>\n

Two ALA-PDT sessions one month apart; 14 patients with facial actinic keratoses; 25 paired biopsies before treatment and one month afterward.<\/p>\n

Histological findings<\/p>\n

\u2191 Total dermal collagen; \u2191 type I\/III procollagen<\/p>\n

\u2191 Epidermal TGF-\u03b2 and TGF-\u03b2 receptor II<\/p>\n

\u2193 MMP-1, MMP-3 and MMP-12 (collagen-degrading enzymes)<\/p>\n

\u2193 Solar elastosis; \u2193 inflammatory infiltrates<\/p>\n

ALA-PDT \u2192 \u2191 TGF-\u03b2 \u2192 \u2191 procollagen I\/III \u2192 \u2193 MMP-1\/3\/12 \u2192 \u2193 elastosis<\/p>\n

Park MY, Sohn S, Lee ES, Kim YC | J Am Acad Dermatol | 2010;62:85\u201395 | DOI: 10.1016\/j.jaad.2009.06.025 | PMID: 19926165<\/p>\n

Clinical evidence\u2014acne<\/p>\n

Follicular delivery supports improvement in inflammatory acne<\/h2>\n

\"\"<\/p>\n

Pilosebaceous unit: the hair follicle and sebaceous gland as delivery targets<\/p>\n

Why follicles matter. Inflammatory acne is a disease of the pilosebaceous unit, a structure preferentially accessed by lipid vesicles.<\/p>\n

Delivery rationale. The lipophilic vesicle surface mixes with sebum, carrying the hydrophilic precursor down the follicular canal.<\/p>\n

Activation rationale. PpIX forms in sebaceous tissue; IPL then drives a local photodynamic response.<\/p>\n

\"\"<\/p>\n

Mean reduction in inflammatory lesion counts (%) after 0.5% liposomal ALA spray + IPL; pilot study in 12 participants.<\/p>\n

Yeung et al. | Dermatol Surg | 2011 | DOI: 10.1111\/j.1524-4725.2011.01929.x | PMID: 21414073<\/p>\n

Evidence\u2014tissue level<\/p>\n

Tissue evidence: PpIX forms where the carrier delivers ALA<\/h2>\n

\"\"<\/p>\n

Full-thickness ex vivo skin\u2014Maisch 2010<\/p>\n

An ALA nanoemulsion induced measurable PpIX fluorescence in a full-thickness skin model: the delivered precursor reached viable epidermis and was metabolized there.<\/p>\n

Ex vivo human skin comparison\u2014Schmitz 2016<\/p>\n

Formulation choice changed both epidermal ALA delivery and PpIX formation. The carrier, as well as the active, determines the tissue dose.<\/p>\n

\"\"<\/p>\n

PpIX in tissue lysates (nmol\/L, median), ex vivo human eyelid skin from 10 donors; redrawn from the reported data (Schmitz et al., 2016).<\/p>\n

Maisch et al. | Exp Dermatol | 2010 | DOI: 10.1111\/j.1600-0625.2009.01001.x \u00b7 Schmitz et al. | Photodiagn Photodyn Ther | 2016 | DOI: 10.1016\/j.pdpdt.2015.11.004<\/p>\n

Evidence\u2014imaging<\/p>\n

Imaging evidence: fluorescence follows the carrier, not just the active<\/h2>\n

Schmitz 2016, Figure 2\u2014original image<\/p>\n

Placebo<\/p>\n

Nanoemulsion gel<\/p>\n

20% cream<\/p>\n

\"\"<\/p>\n

Image labels: 3 h, 6 h and 12 h; hematoxylin & eosin; PpIX fluorescence. Columns: placebo, nanoemulsion gel, 20% cream.<\/p>\n

H&E and PpIX fluorescence cryosections; ex vivo human eyelid skin from 10 donors.<\/p>\n

Christiansen 2007, Figure 6\u2014original image<\/p>\n

Follicle\/lesion-selective signal (A) vs uniform signal (B)<\/p>\n

\"\"<\/p>\n

Measured skin-surface PpIX fluorescence: 0.5% liposomal ALA spray for 3 h without occlusion (A) vs occluded 20% ALA cream (B). The lipid carrier concentrates the signal in follicles and lesions.<\/p>\n

de Leeuw 2010, Figure 3\u2014original image<\/p>\n

Split-face comparison, one day after identical IPL settings<\/p>\n

\"\"<\/p>\n

Image labels: 0.5% 5-ALA liposomes; 20% 5-ALA cream; after IPL treatment.<\/p>\n

Non-occluded 0.5% liposomal ALA spray (left circled area) vs occluded 20% ALA cream (right). Tolerability differs with delivery and protocol, rather than with the active alone.<\/p>\n

Original images reproduced from the cited publications for scientific reference. Third-party trademarks appearing in the source images were neutralized in the supplied PPT. Microscopy supports localization, not quantitative depth measurement.<\/p>\n

Schmitz et al. | Photodiagn Photodyn Ther | 2016 | DOI: 10.1016\/j.pdpdt.2015.11.004 \u00b7 Christiansen et al. | Lasers Surg Med | 2007 | PMID: 17457834 \u00b7 de Leeuw et al. | JEADV | 2010 | DOI: 10.1111\/j.1468-3083.2009.03447.x<\/p>\n

 <\/p>\n

Protocol design<\/p>\n

Designing for efficacy and comfort together<\/h2>\n

Table expanded in original row order; all column labels and data are retained.<\/p>\n

\"\"<\/p>\n

Comfort is a property of the whole protocol\u2014formulation, incubation and illumination\u2014not encapsulation alone.<\/p>\n

Christiansen et al. | Lasers Surg Med | 2007 | PMID: 17457834 \u00b7 Dirschka et al. | JEADV | 2019 | PMID: 30022544<\/p>\n

Daylight photodynamic applications<\/p>\n

Daylight as the light source: a simple, continuous protocol<\/h2>\n

\"\"<\/p>\n

Why continuous low-intensity light can remain comfortable<\/p>\n

During two hours of daylight, PpIX is activated and photobleached almost as soon as cells synthesize it. Tissue PpIX stays at a low steady state, delivering cumulative photochemical exposure without the concentration spikes associated with treatment pain.<\/p>\n

Protocol flexibility: seasonal natural daylight or simulated-daylight lamps that avoid weather and latitude constraints, both evaluated clinically.<\/p>\n

\"\"<\/p>\n

Image label: assessment after 12 weeks.<\/p>\n

Original daylight PDT treatment schematic (Wiegell et al., 2008, Figure 1). A professional clinical protocol, not consumer sun-exposure guidance.<\/p>\n

Schematic: Wiegell et al. | Br J Dermatol | 2008 | PMID: 18294318 \u00b7 Protocol: Dirschka et al. | JEADV | 2019 | PMID: 30022544 \u00b7 Simulated daylight: Bai-Habelski et al. | 2021<\/p>\n

 <\/p>\n

Clinical evidence\u2014daylight<\/p>\n

Daylight PDT: comparable clearance, lower recurrence and very little pain<\/h2>\n

\"\"<\/p>\n

Values are percentages. Single-session daylight PDT; randomized intraindividual controlled phase III study in 52 patients with actinic keratoses. Non-inferiority P < 0.0001; recurrence difference P = 0.01.<\/p>\n

1.2 vs >4<\/p>\n

Mean maximum pain during daylight exposure (VAS 0\u201310), compared with reported mean values above 4 for conventional lamp-based PDT<\/p>\n

Reading the evidence correctly<\/p>\n

Indication: actinic keratosis, a clinical endpoint shown here as delivery-platform evidence, not cosmetic efficacy.<\/p>\n

Carrier: a phospholipid nanoemulsion gel, related to liposomal technology, clinically demonstrating daylight-compatible ALA delivery.<\/p>\n

Design: randomized split-face non-inferiority study; 52 randomized, 49 per protocol; gel = 10% ALA hydrochloride (approximately 7.8% free acid), versus 16% methyl aminolevulinate cream.<\/p>\n

Dirschka et al. | J Eur Acad Dermatol Venereol | 2019 | DOI: 10.1111\/jdv.15185 | PMID: 30022544<\/p>\n

Scalp science<\/p>\n

Follicle biology: a second home for vesicular delivery<\/h2>\n

\"\"<\/p>\n

Image labels: nanoparticle, drug; SC = stratum corneum, E = epidermis, D = dermis; dermal\u2013epidermal junction; blood vessel.<\/p>\n

Particle-delivery pathways at the follicle: surface film, follicular canal and deeper follicular penetration<\/p>\n

The follicle is a living, cycling mini-organ<\/p>\n

Dermal papilla cells at its base drive the anagen\u2013catagen\u2013telogen cycle. Their metabolic activity makes them a relevant target for active combinations.<\/p>\n

Follicles bypass the barrier<\/p>\n

The follicular canal extends into the dermis, with no mature stratum corneum in deeper regions\u2014a natural bypass available to vesicles.<\/p>\n

Sebum supports lipid vesicles<\/p>\n

The sebum-rich canal is chemically compatible with phospholipid vesicles, supporting retention and release near the papilla.<\/p>\n

This development route requires no photoactivation: the non-photodynamic track for NanoActive Alavelle™.<\/p>\n

Scalp science<\/p>\n

Inside the papilla: ERK\/AKT signaling triggered by ALA + iron<\/h2>\n

\"\"<\/p>\n

HMOX1 (HO-1) remained unchanged. Signaling involved ERK\/AKT, rather than the sometimes-assumed ALA + iron heme oxygenase pathway.<\/p>\n

Reading the evidence correctly<\/p>\n

A combination, not ALA alone. Cellular and follicular responses were observed with joint 5-ALA and iron exposure and cannot be attributed to ALA itself.<\/p>\n

Models, not patients. Immortalized dermal papilla cells and ex vivo follicle organ culture are mechanistic models. Clinical endpoints require clinical studies.<\/p>\n

Ryu et al. | FEBS Open Bio | 2026 | DOI: 10.1002\/2211-5463.70230 | PMID: 41873782<\/p>\n

Scalp science<\/p>\n

Original data from follicle models (open access)<\/h2>\n

Phospho-kinase array\u2014Figure 3A (original)<\/p>\n

\"\"<\/p>\n

Image labels: Control_spot_1\/2 and 5-ALA\/FAC_spot_1\/2. The supplied PPT image has no visible x-axis item names; none have been inferred.<\/p>\n

Relative phosphorylation in dermal papilla cells, 1 \u00b5M 5-ALA\/FAC vs control: increased kinases along the ERK\/AKT axis.<\/p>\n

Follicle organ culture\u2014Figure 4B (original)<\/p>\n

\"\"<\/p>\n

Image labels: D0\/D5 = days 0\/5; control; 5-ALA\/FAC combination; increased hair length (mm). The asterisk is the original significance marker; P < 0.05 is specified in the text.<\/p>\n

Hair-shaft elongation after five days of ex vivo human follicle organ culture, combination vs control, n = 20, P < 0.05.<\/p>\n

Original images reproduced under CC BY 4.0 (\u00a9 2026 the authors; FEBS Open Bio \/ John Wiley & Sons). Results belong to the 5-ALA + FAC combination, not ALA alone, and to model systems rather than human clinical outcomes.<\/p>\n

Ryu et al. | FEBS Open Bio | 2026;16:1527\u20131536 | DOI: 10.1002\/2211-5463.70230 | PMID: 41873782 | Open access CC BY 4.0<\/p>\n

Scalp science<\/p>\n

Three levels of hair evidence: cells, follicles and humans<\/h2>\n

Table expanded in original row order; all column labels and data are retained.<\/p>\n

\"\"<\/p>\n

What the three studies have in common<\/p>\n

Every positive hair-related result combined ALA with an iron source or peptide partner: the combination is the active principle. None used photoactivation; this is a chemistry-and-delivery pathway, not PDT.<\/p>\n

Ryu et al. | FEBS Open Bio | 2026 | PMID: 41873782 \u00b7 Lee et al. | Ann Dermatol | 2016 | PMID: 27489425 \u00b7 Morokuma et al. | Int J Dermatol | 2008 | PMID: 19126021<\/p>\n

Product formats<\/p>\n

Sprays and aqueous gels: built around vesicles<\/h2>\n

Leave-on spray<\/p>\n

Forms a thin, even film without rubbing, treating the application site gently. Covers large areas and reaches the scalp through hair. Low viscosity naturally suits aqueous vesicle dispersions.<\/p>\n

Precedent: the published liposomal ALA skin studies used spray formulations.<\/p>\n

Aqueous gel<\/p>\n

Provides longer residence at precisely targeted sites, with accurate, repeatable dosing.<\/p>\n

A water-based gel keeps hydrophilic ALA in a compatible environment while vesicles handle delivery.<\/p>\n

Formulation guardrails from the stability literature<\/p>\n

pH approximately 5\u20136. Balance ALA chemical stability with skin compatibility.<\/p>\n

Protect from oxygen and light. Packaging is part of the stability strategy.<\/p>\n

Test chemistry, not just colloids. Track ALA content and pyrazine condensation impurities; size and PDI alone cannot establish active integrity.<\/p>\n

Watch cosolvent levels. Published ALA nanoemulsion data associate excess polyols with impurity formation.<\/p>\n

Bunke et al. | J Pharm Sci | 2000 | PMID: 10980508 \u00b7 Christiansen et al. | Lasers Surg Med | 2007 | PMID: 17457834<\/p>\n

Scalp science<\/p>\n

Scalp-care concepts: the non-photodynamic route<\/h2>\n

Leave-on scalp serum<\/p>\n

A vesicle dispersion targeting the follicular canal, designed for overnight residence near the papilla\u2019s \u201cdoorway.\u201d<\/p>\n

Daily nourishing mist<\/p>\n

A lightweight aqueous formula provides broad, even coverage through hair, using a format with published precedent in ALA scalp applications.<\/p>\n

Pretreatment gel<\/p>\n

Controlled, timed contact before rinsing, for consumers who prefer a defined exposure window.<\/p>\n

Combination-first design<\/p>\n

Published hair-study results belong to ALA combined with iron or peptide partners. Formulate the concept around the combination, not ALA alone.<\/p>\n

Concepts, not specifications. These are development directions for brand partners. Concentration, packaging and shelf life depend on each partner\u2019s formulation and stability studies. None of these concepts involves photoactivation.<\/p>\n

Basis: Ryu et al. | FEBS Open Bio | 2026 | PMID: 41873782 \u00b7 Lee et al. | Ann Dermatol | 2016 | PMID: 27489425 \u00b7 Morokuma et al. | Int J Dermatol | 2008 | PMID: 19126021<\/p>\n

Professional applications<\/p>\n

Photoactivated formats: formulation, light and evidence<\/h2>\n

Table expanded in original row order; all column labels and data are retained.<\/p>\n

\"\"<\/p>\n

How Purui Biomedical positions this evidence<\/p>\n

These are professional protocols studied in clinical settings. For NanoActive Alavelle™, they provide platform evidence that low-concentration ALA in engineered carriers works under real illumination, rather than cosmetic product claims.<\/p>\n

Piccioni et al. | J Dermatolog Treat | 2011 | PMID: 21801099 \u00b7 Yeung et al. | Dermatol Surg | 2011 | PMID: 21414073 \u00b7 Dirschka et al. | JEADV | 2019 | PMID: 30022544 \u00b7 Bai-Habelski et al. | Photodiagn Photodyn Ther | 2021 | DOI: 10.1016\/j.pdpdt.2021.102692<\/p>\n

Route-specific science<\/p>\n

Another route: lessons from oral ALA pharmacokinetics<\/h2>\n

\u224860%<\/p>\n

Oral 5-ALA bioavailability in healthy volunteers<\/p>\n

\u224845 min<\/p>\n

Elimination half-life\u2014rapid systemic clearance<\/p>\n

Rapid absorption, onset and clearance: kinetics fundamentally different from a topical leave-on product.<\/p>\n

Route-specific data cannot be transferred across routes<\/p>\n

No cross-route extrapolation. Oral bioavailability and clearance do not establish topical penetration, and vesicular skin-delivery data do not establish oral exposure.<\/p>\n

A separate development program is required. Any oral concept based on ALA chemistry needs its own regulatory and clinical pathway. The PURISOME\u00ae platform discussed here targets topical delivery.<\/p>\n

Dalton et al. | J Pharmacol Exp Ther | 2002 | DOI: 10.1124\/jpet.301.2.507 | PMID: 11961050<\/p>\n

Formulator\u2019s checklist<\/p>\n

Six decisions that determine whether ALA survives and performs<\/h2>\n

Table expanded in original row order; all column labels and data are retained.<\/p>\n

\"\"<\/p>\n

Elfsson et al. | Eur J Pharm Sci | 1999 | PMID: 9845784 \u00b7 Bunke et al. | J Pharm Sci | 2000 | PMID: 10980508 \u00b7 Dalton et al. | J Pharmacol Exp Ther | 2002 | PMID: 11961050<\/p>\n

Platform overview<\/p>\n

One platform, four evidence-informed directions<\/h2>\n

Table expanded in original row order; all column labels and data are retained.<\/p>\n

\"\"<\/p>\n

Each evidence label corresponds to a full citation in the reference section. NanoActive Alavelle™ product specifications are provided by Purui Biomedical under project-specific agreements.<\/p>\n

Closing perspective<\/p>\n

One molecule, one platform, multiple thoughtfully designed formats.<\/h2>\n

01 Stabilize the chemistry<\/p>\n

Control pH and oxygen; demonstrate integrity by testing ALA and its condensation impurities.<\/p>\n

02 Deliver where it matters<\/p>\n

Flexible phospholipid vesicles carry hydrophilic ALA across the barrier and along the follicular bypass.<\/p>\n

03 Design for comfort<\/p>\n

Low loading, short contact and gentle illumination: comfort is a protocol property.<\/p>\n

Purui Biomedical Technology Co., Ltd.<\/p>\n

NanoActive Alavelle™ Aminolevulinic Acid Nanoliposomes\u2014powered by PURISOME\u00ae Liposome Technology<\/p>\n

Innovation for Health and Beauty<\/p>\n

Regulatory statement: finished products containing NanoActive Alavelle™ must comply with the laws and regulations of the countries or regions where they are manufactured and sold. The brand is responsible for final-product regulatory compliance.<\/p>\n

References<\/p>\n

References (Part 1 of 2)<\/h2>\n

01 \u00b7 Rick K, Sroka R, Stepp H, Kriegmair M, Huber RM, Jacob K, Baumgartner R. Pharmacokinetics of 5-aminolevulinic acid-induced protoporphyrin IX in skin and blood. J Photochem Photobiol B. 1997;40(3):313\u2013319. DOI: 10.1016\/S1011-1344(97)00076-6 \u00b7 PMID: 9372622<\/p>\n

02 \u00b7 Elfsson B, Wallin I, Eksborg S, Rudaeus K, Ros AM, Ehrsson H. Stability of 5-aminolevulinic acid in aqueous solution. Eur J Pharm Sci. 1999;7(2):87\u201391. DOI: 10.1016\/S0928-0987(98)00098-8 \u00b7 PMID: 9845784<\/p>\n

03 \u00b7 Bunke A, Zerbe O, Schmid H, Burmeister G, Merkle HP, Gander B. Degradation mechanism and stability of 5-aminolevulinic acid. J Pharm Sci. 2000;89(10):1335\u20131341. PMID: 10980508<\/p>\n

04 \u00b7 Dalton JT, Yates CR, Yin D, Straughn A, Marcus SL, Golub AL, Meyer MC. Clinical pharmacokinetics of 5-aminolevulinic acid in healthy volunteers and patients at high risk for recurrent bladder cancer. J Pharmacol Exp Ther. 2002;301(2):507\u2013512. DOI: 10.1124\/jpet.301.2.507 \u00b7 PMID: 11961050<\/p>\n

05 \u00b7 Christiansen K, Bjerring P, Troilius A. 5-ALA for photodynamic photorejuvenation \u2014 optimization of treatment regime based on normal-skin fluorescence measurements. Lasers Surg Med. 2007;39(4):302\u2013310. PMID: 17457834<\/p>\n

06 \u00b7 Morokuma Y, Yamazaki M, Maeda T, Yoshino I, Ishizuka M, Tanaka T, Ito Y, Tsuboi R. Hair growth stimulatory effect by a combination of 5-aminolevulinic acid and iron ion. Int J Dermatol. 2008;47(12):1298\u20131303. PMID: 19126021<\/p>\n

07 \u00b7 Bjerring P, Christiansen K, Troilius A, Bekhor P, de Leeuw J. Skin fluorescence controlled photodynamic photorejuvenation (wrinkle reduction). Lasers Surg Med. 2009;41(5):327\u2013336.<\/p>\n

08 \u00b7 Maisch T, Santarelli F, Schreml S, Babilas P, Szeimies RM. Fluorescence induction of protoporphyrin IX by a new 5-aminolevulinic acid nanoemulsion used for photodynamic therapy in a full-thickness ex vivo skin model. Exp Dermatol. 2010;19(8):e302\u2013e305. DOI: 10.1111\/j.1600-0625.2009.01001.x \u00b7 PMID: 19845760<\/p>\n

09 \u00b7 Oh EK, Jin SE, Kim JK, Park JS, Park Y, Kim CK. Retained topical delivery of 5-aminolevulinic acid using cationic ultradeformable liposomes for photodynamic therapy. Eur J Pharm Sci. 2011;44(1\u20132):149\u2013157. DOI: 10.1016\/j.ejps.2011.07.003 \u00b7 PMID: 21782942<\/p>\n

10 \u00b7 Piccioni A, Fargnoli MC, Schoinas S, Suppa M, Frascione P, Ginebri A, Chimenti S, Peris K. Efficacy and tolerability of 5-aminolevulinic acid 0.5% liposomal spray and intense pulsed light in wrinkle reduction of photodamaged skin. J Dermatolog Treat. 2011;22(5):247\u2013253. DOI: 10.3109\/09546634.2011.590791 \u00b7 PMID: 21801099<\/p>\n

References<\/p>\n

References (Part 2 of 2)<\/h2>\n

11 \u00b7 Yeung CK, Shek SY, Yu CS, Kono T, Chan HH. Liposome-encapsulated 0.5% 5-aminolevulinic acid with intense pulsed light for the treatment of inflammatory facial acne: a pilot study. Dermatol Surg. 2011;37(4):450\u2013459. DOI: 10.1111\/j.1524-4725.2011.01929.x \u00b7 PMID: 21414073<\/p>\n

12 \u00b7 Lee WJ, et al. Efficacy of a complex of 5-aminolevulinic acid and glycyl-histidyl-lysine peptide on hair growth. Ann Dermatol. 2016;28(4). PMID: 27489425<\/p>\n

13 \u00b7 Schmitz L, Novak B, Hoeh AK, Luebbert H, Dirschka T. Epidermal penetration and protoporphyrin IX formation of two different 5-aminolevulinic acid formulations in ex vivo human skin. Photodiagnosis Photodyn Ther. 2016;14:40\u201346. DOI: 10.1016\/j.pdpdt.2015.11.004 \u00b7 PMID: 26607556<\/p>\n

14 \u00b7 Ryu et al. Combined 5-aminolevulinic acid and ferric ammonium citrate treatment promotes hair follicle growth by activating dermal papilla cells. FEBS Open Bio. 2026. DOI: 10.1002\/2211-5463.70230 \u00b7 PMID: 41873782<\/p>\n

15*Reinhold U. Review of a 7.8% ALA nanoemulsion gel for the photodynamic treatment of mild-to-moderate actinic keratosis. Future Oncol. 2017;13(27):2413\u20132428. DOI: 10.2217\/fon-2017-0247 \u00b7 PMID: 28805092<\/p>\n

16*Dirschka T, Ekanayake-Bohlig S, Dominicus R, et al. Randomized, intraindividual, non-inferiority phase III study of daylight photodynamic therapy comparing a 7.8% ALA nanoemulsion gel with MAL cream in actinic keratosis. J Eur Acad Dermatol Venereol. 2019;33(2):288\u2013297. DOI: 10.1111\/jdv.15185 \u00b7 PMID: 30022544<\/p>\n

17*Bai-Habelski JC, Medrano K, Palacio A, Reinhold U. Prospective study of simulated daylight photodynamic therapy with an indoor daylight-reproducing system and a 7.8% ALA nanoemulsion gel in actinic keratosis. Photodiagnosis Photodyn Ther. 2021;37:102692. DOI: 10.1016\/j.pdpdt.2021.102692<\/p>\n

18 \u00b7 Park MY, Sohn S, Lee ES, Kim YC. Photorejuvenation induced by 5-aminolevulinic acid photodynamic therapy in patients with actinic keratosis: a histologic analysis. J Am Acad Dermatol. 2010;62(1):85\u201395. DOI: 10.1016\/j.jaad.2009.06.025 \u00b7 PMID: 19926165<\/p>\n

19de Leeuw J, van der Beek N, Bjerring P, Neumann HA. Photodynamic therapy of acne vulgaris using 5-aminolevulinic acid 0.5% liposomal spray and intense pulsed light in combination with topical keratolytic agents. J Eur Acad Dermatol Venereol. 2010;24(4):460\u2013469. DOI: 10.1111\/j.1468-3083.2009.03447.x<\/p>\n

20 \u00b7 Wiegell SR, Haedersdal M, Philipsen PA, Eriksen P, Enk CD, Wulf HC. Continuous activation of PpIX by daylight is as effective as and less painful than conventional photodynamic therapy for actinic keratoses; a randomized, controlled, single-blinded study. Br J Dermatol. 2008;158(4):740\u2013746. DOI: 10.1111\/j.1365-2133.2008.08450.x \u00b7 PMID: 18294318<\/p>\n

*Descriptive titles are used to avoid third-party trademarks in this document. Each publication can be identified uniquely by its DOI\/PMID.<\/p>\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\n\t\t\n\t<\/div>\n\n<\/article>\n\n\t\n\t\t\n

\n\n\t\n\t
\n\n\t\t\n\t\t
\n\t\t\t\n\t\t\t

PuriActives\u00ae TocoPhos™ \u751f\u80b2\u915a\u78f7\u9178\u916f\u94a0<\/a><\/h1>\n\n\t\t\t\t\t\t\t
\n\t\t\t\t\tPosted on L, Y<\/a><\/span><\/span> \t\t\t\t<\/div>\n\t\t\t\n\t\t<\/header>\n\n\t\t\t\t\t
\n\t\t\t\t

PuriActives\u00ae TocoPhos™Sodium Tocopheryl Phosphate<\/p>\n

PRODUCT & BRAND<\/p>\n

PuriActives\u00ae TocoPhos™ Sodium Tocopheryl Phosphate<\/b><\/h2>\n

\"\"<\/p>\n

PuriPharm Co., Ltd.<\/b><\/p>\n

Vitamin E, reimagined for skin and scalp.<\/b><\/p>\n

INCI: SODIUM TOCOPHERYL PHOSPHATE<\/b><\/p>\n

A phosphorylated vitamin E active with aqueous compatibility and biological activation in skin, supported by peer-reviewed studies on oxidative-stress protection and moisturization.<\/p>\n

INGREDIENT OPPORTUNITY<\/p>\n

One molecule, four formulation-relevant advantages<\/b><\/h2>\n

DESIGNED FOR AQUEOUS COMPATIBILITY<\/b><\/p>\n

A 6-O-phosphate group masks the oxidation-sensitive phenolic hydroxyl, with sodium counterions converting an oily antioxidant into a water-dispersible powder for serums, essences and gels. Kato et al. 2011; Zingg 2018.<\/p>\n

ACTIVATION AT THE SITE OF ACTION<\/b><\/p>\n

After uptake, cellular phosphatases hydrolyze the phosphate to release active \u03b1-tocopherol within cells. Hydrolysis was not observed in the culture medium itself. Nishio et al. 2011; Saleh et al. 2021.<\/p>\n

DUAL STRESS PROTECTION<\/b><\/p>\n

In human keratinocytes, the sodium salt suppressed UVB-induced reactive nitrogen species (RNS) and reduced prostaglandin E2 (PGE2) responses to UVB, IL-1\u03b2 and peroxide challenges. Nakama et al. 2009; Kato et al. 2011.<\/p>\n

MOISTURE AND BARRIER SUPPORT<\/b><\/p>\n

Topical treatment increased stratum corneum ceramides through serine palmitoyltransferase (SPT) and keratinocyte-differentiation pathways, improving moisture retention in hairless mouse skin. Kato & Takahashi 2012.<\/p>\n

Phosphorylated vitamin E connects skin-defense research, moisturization mechanisms and contemporary formulation opportunities.<\/p>\n

FORMULATION CHALLENGES<\/p>\n

Why rethink vitamin E?<\/b><\/h2>\n

THE CLASSIC MOLECULE AND ITS FORMULATION CHALLENGES<\/b><\/p>\n

OXIDATION SENSITIVITY<\/b><\/p>\n

The phenolic hydroxyl is \u03b1-tocopherol\u2019s antioxidant site and a key site of oxidation. Oxidation can deplete its activity.<\/p>\n

AN OIL IN AN AQUEOUS WORLD<\/b><\/p>\n

A viscous, hydrophobic liquid requires solubilization or emulsification for aqueous serums, essences and scalp formats.<\/p>\n

ESTERS SOLVE ONLY PART OF THE PROBLEM<\/b><\/p>\n

Tocopheryl acetate is stable but remains oily and depends on skin esterases. It produced much less tocopherol than the phosphate salt after 24 hours in a reconstructed human skin model. Kato et al. 2011, Figure 2A.<\/p>\n

WHAT PHOSPHATE CHEMISTRY CHANGES<\/b><\/p>\n

PROTECTED PHENOLIC HYDROXYL<\/b><\/p>\n

The 6-O-phosphate masks the oxidizable hydroxyl until enzymatic hydrolysis. Kato et al. 2011.<\/p>\n

A WATER-COMPATIBLE SALT<\/b><\/p>\n

Sodium counterions yield a powder suitable for incorporation into the aqueous phase.<\/p>\n

ACTIVATION AFTER UPTAKE<\/b><\/p>\n

Cellular phosphatases release \u03b1-tocopherol after uptake, rather than in the culture medium. Nishio et al. 2011.<\/p>\n

This chemistry supports development of water-based serums, essences, gels and leave-on scalp products.<\/p>\n

MOLECULAR IDENTITY<\/p>\n

A chromanol core with distinct functional regions<\/b><\/h2>\n

VITAMIN E FAMILY STRUCTURES<\/b><\/p>\n

\"\"<\/p>\n

Adapted from Kato et al. 2011, Figure 1. Compound 1 is disodium tocopheryl phosphate, the TocoPhos™ active, shown with \u03b1-tocopherol and tocopheryl acetate.<\/p>\n

IONIZATION OF THE PHOSPHATE GROUP<\/b><\/p>\n

\"\"<\/p>\n

Adapted from Saleh et al. 2020, Figure 1. The phosphate undergoes two ionization steps, with pKa values of approximately 1.8 and 6.7. A predominantly dianionic state is described near pH 7.4.<\/p>\n

CHROMANOL HEAD: ANTIOXIDANT CORE<\/b><\/p>\n

The 6-position phenolic hydroxyl captures radicals in vitamin E; phosphorylation protects this site.<\/p>\n

6-O-PHOSPHATE: AN IONIZABLE HANDLE<\/b><\/p>\n

Ionization depends on pH. Near pH 7.4, the predominantly dianionic form supports water affinity while the phosphate protects the phenolic hydroxyl until hydrolysis.<\/p>\n

SODIUM SALT: THE INCI-DEFINED FORM<\/b><\/p>\n

Supplied as Sodium Tocopheryl Phosphate, a water-dispersible powder. The free acid has formula C29H51O5P, PubChem CID 94493.<\/p>\n

PHYTYL TAIL: LIPID ANCHOR<\/b><\/p>\n

After hydrolysis, the hydrophobic tail anchors released \u03b1-tocopherol in membranes, where it intercepts lipid peroxyl radicals.<\/p>\n

Near pH 7.4, this anionic amphiphile self-associates into approximately 9 nm aggregates, with a critical aggregation concentration (CAC) of approximately 4.2 mM. At pH 9 it is monomeric, providing a formulation variable. Saleh et al. 2020.<\/p>\n

VITAMIN E OPTIONS<\/p>\n

Choosing the appropriate vitamin E form<\/b><\/h2>\n

Conventional forms and formulation comparison<\/b><\/p>\n

\"\"<\/p>\n

Corresponding phosphate-salt properties<\/b><\/p>\n

\"\"<\/p>\n

*Reconstructed human skin model: tocopherol accumulation after topical treatment, Kato et al. 2011, Figure 2A. General chemistry: Zingg 2018. Photostability of the phosphorylated form: Saleh et al. 2021.<\/p>\n

Different systems call for different tools. The phosphate salt provides a route for aqueous and scalp-oriented formats.<\/p>\n

UPTAKE \u00b7 BIOCONVERSION \u00b7 ANTIOXIDANT ACTION<\/p>\n

Delivered as phosphate, activated as vitamin E<\/b><\/h2>\n

ACTIVATION PATHWAY<\/b><\/p>\n

1 APPLICATION: an aqueous formulation deposits sodium tocopheryl phosphate at the skin surface.<\/b><\/p>\n

2 UPTAKE: keratinocytes internalize the phosphorylated active.<\/b><\/p>\n

3 BIOCONVERSION: cellular phosphatases hydrolyze the phosphate, releasing \u03b1-tocopherol.<\/b><\/p>\n

4 ANTIOXIDANT ACTION: \u03b1-tocopherol associates with membranes and intercepts lipid peroxyl radicals.<\/b><\/p>\n

\u2022 Deuterium tracing showed hydrolysis of \u03b1-TP to \u03b1-tocopherol in cells and mice, but not in culture medium, with lower plasma and liver lipid peroxidation. Nishio et al. 2011.<\/p>\n

\u2022 In reconstructed human skin, tocopherol accumulation was approximately 190 nmol\/g tissue at 24 hours with the phosphate salt; acetate remained near baseline. Kato et al. 2011, Figure 2A.<\/p>\n

EVIDENCE: INTRACELLULAR BIOCONVERSION<\/b><\/p>\n

\"\"<\/p>\n

HaCaT keratinocytes were incubated with 133 \u00b5g\/mL \u03b1-TP. Intracellular \u03b1-TP increased, and \u03b1-tocopherol (\u03b1-T) appeared in cell lysates at 2\u201324 hours, supporting uptake and enzymatic hydrolysis. Adapted from Saleh et al. 2021, Figure 8.<\/p>\n

Saleh et al. Scientific Reports. 2021. doi:10.1038\/s41598-021-01299-y<\/p>\n

STRESS BIOLOGY<\/p>\n

Addressing oxidative and nitrosative stress<\/b><\/h2>\n

\"\"<\/p>\n

PUBLISHED EVIDENCE<\/b><\/p>\n

UVB AND RNS IN HUMAN KERATINOCYTES<\/p>\n

Real-time fluorescence imaging showed UVB-triggered RNS generation involving neuronal nitric oxide synthase (nNOS). Sodium dl-\u03b1-tocopheryl phosphate suppressed this response. Nakama et al. 2009.<\/p>\n

SOOTHING-RELATED SIGNALS<\/p>\n

In UVB-exposed NHEK, the sodium salt reduced Cox-2 mRNA by 33\u201351% at 0.5 \u00b5M, inhibited p38 MAPK phosphorylation and lowered PGE2. Kato et al. 2011.<\/p>\n

MODEL CONTEXT MATTERS<\/p>\n

Intact \u03b1-TP is a weak radical scavenger in cell-free DPPH \/ ORAC assays. Cellular protection follows bioconversion to \u03b1-tocopherol, making the experimental model essential to interpretation. Saleh et al. 2021, Figure 7.<\/p>\n

KEY TERMS<\/p>\n

ROS: reactive oxygen species. RNS: reactive nitrogen species. nNOS: neuronal nitric oxide synthase. PGE2: prostaglandin E2. NHEK: normal human epidermal keratinocytes.<\/p>\n

EVIDENCE FOCUS: UV STRESS<\/p>\n

Pretreated keratinocytes withstand high-dose UVA1 stress<\/b><\/h2>\n

\"\"<\/p>\n

HaCaT keratinocytes were pretreated for 24 hours before UVA1 exposure. Viability was measured by Alamar Blue 24 hours later. Mean \u00b1 SD; *p < 0.05 and **p < 0.01 versus irradiated control. From Saleh et al. 2021, Figure 5.<\/p>\n

Saleh et al. Scientific Reports. 2021. doi:10.1038\/s41598-021-01299-y<\/p>\n

VIABILITY AFTER 226 J\/cm\u00b2 UVA1<\/b><\/p>\n

88% versus 70% cell viability<\/b><\/p>\n

80 \u00b5M \u03b1-TP pretreatment versus irradiated control. \u03b1-Tocopherol at the same concentration provided no significant protection in this model.<\/p>\n

INTRACELLULAR ROS AFTER 57 J\/cm\u00b2<\/b><\/p>\n

24.1% lower ROS versus control<\/b><\/p>\n

100 \u00b5M \u03b1-TP; H2DCFDA measurement within 2 hours after irradiation. \u03b1-Tocopherol reduced ROS by 23.9%.<\/p>\n

Protection coincided with phosphatase-mediated conversion to \u03b1-tocopherol. Intact \u03b1-TP was weak in cell-free assays but protective in cells. The phosphorylated form also had a higher LD50 in this model: 1676 versus 1070 \u00b5M.<\/p>\n

Additional UVB evidence: suppression of UVB-induced RNS in human keratinocytes. Nakama et al. 2009. J SCCJ 43(1):19. doi:10.5107\/sccj.43.19.<\/p>\n

MOISTURIZATION MECHANISM<\/p>\n

Supporting the skin\u2019s ceramide-production machinery<\/b><\/h2>\n

Ceramides are part of the lipid mortar of the stratum corneum. In keratinocytes, sodium tocopheryl phosphate acts on upstream processes involved in their synthesis.<\/p>\n

\"\"<\/p>\n

In NHEK, the sodium salt increased intracellular ceramides to approximately 1.8-fold at 50 \u00b5M (*), SPTLC2 expression to approximately 2.2-fold (**), differentiation markers and intracellular Ca\u00b2\u207a. Kato & Takahashi 2012.<\/p>\n

WHY THIS MATTERS TO FORMULATORS<\/b><\/p>\n

\u2022 Support for endogenous ceramide synthesis complements formulations that directly supply ceramides.<\/p>\n

\u2022 Differentiation markers such as TG1, involucrin and loricrin inform barrier-care positioning.<\/p>\n

\u2022 Supporting literature reports vitamin E upregulation of transglutaminase-1 and PPAR\u03b3 in human keratinocytes. De Pascale et al. 2006.<\/p>\n

Kato & Takahashi. Bioorg Med Chem. 2012;20(12):3837\u20133842. PMID 22579618. The schematic synthesizes the study pathway. Fold changes are approximate readings from the original figures. SPT: serine palmitoyltransferase. TG1: transglutaminase-1. CK10: cytokeratin 10. PPAR\u03b3: peroxisome proliferator-activated receptor \u03b3.<\/p>\n

EVIDENCE FOCUS: MOISTURIZATION<\/p>\n

From keratinocyte signaling to a more hydrated barrier<\/b><\/h2>\n

IN VITRO: HUMAN KERATINOCYTES, NHEK<\/b><\/p>\n

\u25b2 Intracellular ceramides: approximately 1.8-fold versus control at 50 \u00b5M (*).<\/p>\n

\u25b2 SPT genes: SPTLC2 mRNA approximately 2.2-fold (**); SPTLC1 also increased (*).<\/p>\n

\u25b2 Differentiation markers TGM1, KRT10, IVL and LOR: approximately 2.2\u20133.3-fold (*\/**).<\/p>\n

\u25b2 Intracellular Ca\u00b2\u207a: significantly higher at 50\u201375 \u00b5M (*), consistent with differentiation signaling.<\/p>\n

\"\"<\/p>\n

Original figure, panel 4A: intracellular NHEK ceramides increase with dose at 0 \/ 10 \/ 50 \u00b5M, measured as \u00b5g\/mg protein.<\/p>\n

IN VIVO: HAIRLESS MICE, TOPICAL 1% \/ 2% FOR 4 WEEKS<\/b><\/p>\n

\u25b2 Stratum corneum ceramides: approximately 4.8\u20135.0 \u00b5g\/cm\u00b2 in the 1% (*) and 2% (**) groups, versus approximately 3 \u00b5g\/cm\u00b2 in untreated and placebo groups.<\/p>\n

\u25b2 Hygroscopicity at 30 seconds: higher with both 1% (*) and 2% (**) versus untreated \/ placebo.<\/p>\n

\u25b2 Moisture retention at 60 seconds: significantly higher with both concentrations (*).<\/p>\n

These findings link improved stratum corneum hydration with endogenous lipid processes.<\/p>\n

\"\"<\/p>\n

Original figure, panel 2B: stratum corneum hygroscopicity at 30 seconds and moisture retention at 60 seconds; untreated \/ placebo \/ 1% \/ 2%.<\/p>\n

Kato & Takahashi. Bioorg Med Chem. 2012;20(12):3837\u20133842. doi:10.1016\/j.bmc.2012.04.029. PMID 22579618. Panels 2B and 4A are excerpts from the paper. Fold changes are approximate readings from original axes; * \/ ** reproduce the authors\u2019 significance notation.<\/p>\n

EVIDENCE FOCUS: SKIN COMFORT<\/p>\n

Modulating inflammatory cascades in stressed keratinocytes<\/b><\/h2>\n

\"\"<\/p>\n

NHEK were pretreated with the sodium salt at 0.1\u20132 \u00b5M for 24 hours before UVB, IL-1\u03b2, tBHP or H2O2 challenge. PGE2 was measured in culture medium. Kato et al. 2011, Figure 3.<\/p>\n

Kato et al. Bioorg Med Chem. 2011;19(21):6348\u20136355. doi:10.1016\/j.bmc.2011.08.067<\/p>\n

PGE2 REDUCTION VERSUS STIMULATED CONTROL<\/p>\n

UVB: 44 \/ 65 \/ 69% at 0.1 \/ 0.5 \/ 2 \u00b5M.<\/p>\n

tBHP: 74 \/ 87 \/ 90%; IL-1\u03b2: 41 \/ 58 \/ 57%.<\/p>\n

H2O2: approximately 50%; UVB alone increased PGE2 approximately fivefold.<\/p>\n

The acetate was weaker, and \u03b1-tocopherol had little effect at these concentrations.<\/p>\n

CELL DEATH UNDER OXIDATIVE STRESS<\/b><\/p>\n

\"\"<\/p>\n

Redrawn from US20090104258A1, Example 1. Keratinocytes, 1 mM H2O2 for 24 hours; flow cytometry. The y-axis is the percentage of apoptotic cells.<\/p>\n

Example 2 of the same patent publication: \u03b1-TP at 1 \u00b5g\/mL increased large stem-cell-derived colonies by 104% in a clonogenic assay under oxidative stress.<\/p>\n

DELIVERY SCIENCE<\/p>\n

The vehicle influences delivery to viable skin<\/b><\/h2>\n

\u03b1-TP FLUX ACROSS A SYNTHETIC MEMBRANE<\/b><\/p>\n

\"\"<\/p>\n

Redrawn from Saleh et al. 2023: steady-state flux of 2% \u03b1-TP from four vehicles across a synthetic membrane.<\/p>\n

In human skin, the emulsion outperformed the gel-like system:<\/p>\n

3\u00d7 viable-layer deposition at 3 hours and 5\u00d7 at 24 hours.<\/p>\n

Human-skin flux: 328.6 versus 175.2 \u00b5g\/cm\u00b2\/h. Cell-free DPPH activity of the delivered dose was higher: 73% versus 46%.<\/p>\n

SKIN DEPOSITION: pH 7.4 VERSUS \u03b1-TOCOPHEROL<\/b><\/p>\n

\"\"<\/p>\n

Porcine skin, 3 hours, infinite dose: \u03b1-TP at pH 7.4 reached approximately 506 \u00b1 296 \u00b5g in the stratum corneum and 170 \u00b1 29 \u00b5g in the epidermis. From Saleh et al. 2020, Figure 5. The source slide also describes approximately 8-fold \/ 4-fold differences; the comparison basis requires checking against the original paper.<\/p>\n

At pH 7.4, \u03b1-TP forms approximately 9 nm aggregates that fuse with stratum corneum lipids in cryo-electron microscopy. At pH 9, monomer deposition is lower. Formulation pH therefore affects aggregation and skin interactions.<\/p>\n

Saleh et al. Int J Pharm. 2023. doi:10.1016\/j.ijpharm.2023.122781. PMID 36849039. Saleh et al. Int J Pharm. 2020. doi:10.1016\/j.ijpharm.2020.120000.<\/p>\n

SKINCARE APPLICATION PORTFOLIO<\/p>\n

Five formats with a shared evidence base<\/b><\/h2>\n

Formats and rationale<\/b><\/p>\n

\"\"<\/p>\n

Corresponding evidence anchors<\/b><\/p>\n

\"\"<\/p>\n

SCALPIFICATION<\/p>\n

The scalp is skin with additional challenges<\/b><\/h2>\n

The scalp shares keratinocytes, a ceramide barrier and UV \/ pollution exposure with facial skin, together with dense follicles and sebum.<\/p>\n

SHARED STRESS BIOLOGY<\/p>\n

UV reaches the scalp surface. ROS \/ RNS responses documented in keratinocytes inform this application rationale. Nakama 2009; Saleh 2021.<\/p>\n

SHARED HYDRATION MACHINERY<\/p>\n

The ceramide barrier also matters to scalp dryness and tightness. Kato & Takahashi 2012.<\/p>\n

SHARED COMFORT-RELATED SIGNALS<\/p>\n

PGE2-related stress pathways provide a basis for conceptual extension to scalp comfort. Kato et al. 2011.<\/p>\n

The scalp is a development extension for TocoPhos™. PuriPharm technical and application teams support joint scalp-formulation projects.<\/p>\n

\"\"<\/p>\n

SCALP PROTECTION AND COMFORT<\/p>\n

Three scalp-care opportunities<\/b><\/h2>\n

FOLLICULAR-ENVIRONMENT PROTECTION<\/b><\/p>\n

The scalp surface is UV-exposed skin. Keratinocyte findings on UVA1 survival and UVB-triggered RNS provide a rationale for leave-on antioxidant scalp care. Nakama et al. 2009; Saleh et al. 2021.<\/p>\n

HYDRATION BALANCE AND BARRIER SUPPORT<\/b><\/p>\n

SPT-related ceramide synthesis and improved stratum corneum moisture retention inform concepts for dry, tight-feeling scalps. Kato & Takahashi 2012.<\/p>\n

COMFORT FOR STRESSED SCALPS<\/b><\/p>\n

PGE2 \/ Cox-2 \/ p38 modulation and reduced stress-induced keratinocyte death provide a rationale for comfort-oriented products. Kato et al. 2011; US20090104258A1, Example 1.<\/p>\n

All three are development opportunities extrapolated from published epidermal evidence. Work with PuriPharm Co., Ltd. to translate them into scalp-care products.<\/p>\n

HAIRCARE FORMATS<\/p>\n

TocoPhos™ in scalp and haircare formulations<\/b><\/h2>\n

\"\"<\/p>\n

PRACTICAL FORMULATION<\/p>\n

Six practical principles for phosphate formulations<\/b><\/h2>\n

\"\"<\/p>\n

SOLUBILITY VERSUS pH<\/b><\/p>\n

\"\"<\/p>\n

Adapted from Saleh et al. 2020, Figure 1. \u03b1-TP solubility rises with pH alongside changes in aggregation.<\/p>\n

Contact PuriPharm technical and application teams for grade-specific use levels, processing-temperature limits, shelf life and full technical documentation.<\/p>\n

Saleh et al. Int J Pharm. 2020. doi:10.1016\/j.ijpharm.2020.120000. Saleh et al. Int J Pharm. 2023. doi:10.1016\/j.ijpharm.2023.122781.<\/p>\n

SKINCARE CONCEPT GALLERY<\/p>\n

Three concepts to start development<\/b><\/h2>\n

FORMULATION CONCEPT<\/b><\/p>\n

DAILY DEFENSE ANTIOXIDANT SERUM<\/b><\/p>\n

Aqueous gel serum \u00b7 Daily leave-on use<\/b><\/p>\n

Suggested ingredients: Niacinamide \u00b7 Panthenol \u00b7 Glycerin<\/b><\/p>\n

Aqueous delivery of a biologically activated antioxidant: keratinocyte uptake and conversion to \u03b1-tocopherol provide a rationale for ROS \/ RNS stress care.<\/p>\n

Evidence: Nishio 2011; Saleh 2021; Nakama 2009.<\/p>\n

FORMULATION CONCEPT<\/b><\/p>\n

CERAMIDE-SUPPORTING MOISTURIZER<\/b><\/p>\n

Oil-in-water cream \u00b7 Daily moisturization<\/b><\/p>\n

Suggested ingredients: Ceramide NP \u00b7 Glycerin \u00b7 Squalane<\/b><\/p>\n

Two complementary routes: direct ceramide supplementation and support for endogenous SPT-related synthesis.<\/p>\n

Evidence: Kato & Takahashi 2012.<\/p>\n

FORMULATION CONCEPT<\/b><\/p>\n

AFTER-SUN CARE LOTION<\/b><\/p>\n

Light emulsion \u00b7 After-sun comfort<\/b><\/p>\n

Suggested ingredients: Sodium Ascorbyl Phosphate \u00b7 Bisabolol \u00b7 Betaine<\/p>\n

A reported combination with magnesium ascorbyl phosphate inhibited PGE2 more than either ingredient alone. This informs a vitamin C phosphate combination concept; the proposed sodium derivative is not the identical tested combination.<\/p>\n

Evidence: Kato 2011, Figure 6; Nakama 2009.<\/p>\n

These concepts have published mechanistic evidence anchors. Contact PuriPharm Co., Ltd. for formulation collaboration.<\/p>\n

SCALP AND HAIRCARE CONCEPT GALLERY<\/p>\n

Scalp-first formats informed by skin science<\/b><\/h2>\n

FORMULATION CONCEPT<\/b><\/p>\n

ANTIOXIDANT SCALP SERUM<\/b><\/p>\n

Aqueous leave-on serum \u00b7 Daily use<\/b><\/p>\n

Suggested ingredients: Niacinamide \u00b7 Panthenol \u00b7 Glycerin<\/b><\/p>\n

A scalp-surface serum with biologically activated antioxidant positioning, derived from epidermal UV-stress evidence.<\/p>\n

Evidence: Nakama 2009; Saleh 2021.<\/p>\n

FORMULATION CONCEPT<\/b><\/p>\n

LIGHT SCALP COMFORT EMULSION<\/b><\/p>\n

Fluid emulsion \u00b7 Leave-on comfort<\/b><\/p>\n

Suggested ingredients: Bisabolol \u00b7 Betaine \u00b7 Glycerin<\/b><\/p>\n

Emulsion vehicles provided greater viable-skin deposition in the cited comparison. PGE2 modulation informs a scalp-comfort concept.<\/p>\n

Evidence: Saleh 2023; Kato 2011.<\/p>\n

FORMULATION CONCEPT<\/b><\/p>\n

MOISTURIZING SCALP MASK<\/b><\/p>\n

Cream mask \u00b7 Weekly intensive care<\/b><\/p>\n

Suggested ingredients: Ceramide NP \u00b7 Butyrospermum Parkii (Shea) Butter<\/p>\n

Longer contact is consistent with a ceramide-synthesis rationale for dry, tight-feeling scalps.<\/p>\n

Evidence: Kato & Takahashi 2012.<\/p>\n

Develop a coordinated scalp-care range, from serums to masks, with PuriPharm Co., Ltd.<\/p>\n

FOUR KEY POINTS<\/p>\n

Why PuriActives\u00ae TocoPhos™?<\/b><\/h2>\n

\"\"<\/p>\n

PROTECTED AND BIOLOGICALLY AVAILABLE<\/b><\/p>\n

Phosphate chemistry protects the antioxidant site, with cellular phosphatases releasing \u03b1-tocopherol after uptake.<\/p>\n

EVIDENCE FROM RELEVANT MODELS<\/b><\/p>\n

Human keratinocytes, reconstructed skin, in vivo barrier models and human skin delivery studies provide traceable evidence.<\/p>\n

FORMULATION DEVELOPMENT SUPPORT<\/b><\/p>\n

Aqueous-phase use, published vehicle and pH data, and preservative-testing evidence from an emulsion prototype.<\/p>\n

ONE ACTIVE, TWO CARE AREAS<\/b><\/p>\n

Skin defense and moisturization, alongside scalp-care concepts extrapolated from the same evidence base.<\/p>\n

Vitamin E, reimagined for formulation development.<\/p>\n

Work with us on your next skincare or scalp-care concept.<\/p>\n

PuriPharm Co., Ltd. \u00b7 Technical and Application Team<\/p>\n

SCIENTIFIC REFERENCES<\/p>\n

Scientific references<\/b><\/h2>\n

1. Nakama M. et al. Inhibitory effect of sodium dl-\u03b1-tocopheryl-6-O-phosphate on UVB-induced reactive nitrogen species in human keratinocytes. J Soc Cosmet Chem Jpn 43(1):19\u201325, 2009. doi:10.5107\/sccj.43.19<\/p>\n

2. Kato E., Sasaki Y., Takahashi N. Sodium dl-\u03b1-tocopheryl-6-O-phosphate inhibits PGE2 production in keratinocytes induced by UVB, IL-1\u03b2 and peroxidants. Bioorg Med Chem 19(21):6348\u20136355, 2011. doi:10.1016\/j.bmc.2011.08.067. PMID 21945458.<\/p>\n

3. Kato E., Takahashi N. Improvement by sodium dl-\u03b1-tocopheryl-6-O-phosphate treatment of moisture-retaining ability in stratum corneum through increased ceramide levels. Bioorg Med Chem 20(12):3837\u20133842, 2012. doi:10.1016\/j.bmc.2012.04.029. PMID 22579618.<\/p>\n

4. Nishio K. et al. \u03b1-Tocopheryl phosphate is hydrolyzed to \u03b1-tocopherol in cells and in vivo. Free Radic Biol Med 50(12):1794\u20131800, 2011. PMID 21443945.<\/p>\n

5. Saleh M. et al. Tocopheryl phosphate in keratinocyte UV-stress models. Scientific Reports 11:22400, 2021. doi:10.1038\/s41598-021-01299-y<\/p>\n

6. Gianello R. et al. \u03b1-Tocopheryl phosphate: chemistry and biological activity. Free Radic Biol Med 39(7):970\u2013976, 2005. PMID 16140216.<\/p>\n

7. Nakayama S. et al. Protective effect of \u03b1-tocopheryl phosphate against UVB-induced damage in cultured mouse skin. J Invest Dermatol 121:406\u2013411, 2003.<\/p>\n

8. De Pascale M.C. et al. Vitamin E upregulates transglutaminase-1 and PPAR\u03b3 in human keratinocytes. Arch Biochem Biophys 447:97\u2013106, 2006.<\/p>\n

9. Zingg J.-M. Vitamin E: regulatory role beyond antioxidant activity. Adv Food Nutr Res 83:311\u2013363, 2018.<\/p>\n

10. Ghayour-Mobarhan M. et al. Tocopheryl phosphate: a review of biological properties. J Diet Suppl, 2014. doi:10.3109\/19390211.2014.952859<\/p>\n

11. Ogru E. et al. Vitamin E phosphate: an endogenous form of vitamin E. Free Radic Res, 2003.<\/p>\n

FORMULATION AND PATENT REFERENCES<\/p>\n

Formulation and patent references<\/b><\/h2>\n

12. Saleh M. et al. Ionization, pH-dependent solubility, self-association and skin deposition of \u03b1-tocopheryl phosphate. Int J Pharm 594:120000, 2020. doi:10.1016\/j.ijpharm.2020.120000<\/p>\n

13. Saleh M. et al. Vehicle-dependent delivery of \u03b1-tocopheryl phosphate to viable skin. Int J Pharm 636:122781, 2023. PMID 36849039 \u00b7 doi:10.1016\/j.ijpharm.2023.122781<\/p>\n

14. Patent publication US20090104258A1 (published 2009), cited by publication number and examples: Example 1 (oxidative-stress-induced keratinocyte apoptosis, flow cytometry) and Example 2 (clonogenic assay; large stem-cell-derived colonies +104%).<\/p>\n

15. Gavin A. et al. Tocopheryl phosphate mixture (TPM) as a skin-delivery enhancer for co-formulated actives. Drug Deliv Transl Res, 2016. doi:10.1007\/s13346-016-0331-x<\/p>\n

16. Mozafari M. et al. Tocopheryl phosphate-based delivery systems (review). Int J Transl Res.<\/p>\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\n\t\t\n\t<\/div>\n\n<\/article>\n\n\t\n\t\t\n

\n\n\t\n\t
\n\n\t\t\n\t\t
\n\t\t\t\n\t\t\t

NanoActive EGCG \u7eb3\u7c73\u8102\u8d28\u4f53<\/a><\/h1>\n\n\t\t\t\t\t\t\t
\n\t\t\t\t\tPosted on L, Y<\/a><\/span><\/span> \t\t\t\t<\/div>\n\t\t\t\n\t\t<\/header>\n\n\t\t\t\t\t
\n\t\t\t\t

NanoActive EGCGLiposomal Epigallocatechin Gallate<\/p>\n

PRODUCT & BRAND<\/p>\n

NanoActive EGCG \u00b7 Nanoliposomes<\/b><\/h2>\n

\"\"<\/p>\n

Powered by PURISOME\u00ae FlexVes™ Liposome Technology<\/b><\/p>\n

PuriPharm Co., Ltd. \u00b7 NanoActive platform ingredient<\/b><\/p>\n

PRODUCT PLATFORM<\/p>\n

One catechin platform, multiple formulation opportunities<\/b><\/h2>\n

EGCG is one of the most studied polyphenols in skin biology, but its practical formulation value depends on protection and delivery.<\/p>\n

NanoActive EGCG combines this multifunctional active with liposomal delivery across five evidence-informed skin and scalp development areas.<\/p>\n

SKIN<\/b><\/p>\n

ANTIOXIDANT DEFENSE<\/b><\/p>\n

Resilience under UV and urban environmental stress.<\/b><\/p>\n

PHOTOAGING-RELATED MATRIX PROTECTION<\/b><\/p>\n

Support for collagen-matrix signaling and youthful skin texture.<\/p>\n

SEBUM BALANCE AND BLEMISH-PRONE SKIN<\/b><\/p>\n

Sebocyte lipid biology supported by clinical lesion-count evidence.<\/p>\n

A MORE EVEN-TONED APPEARANCE<\/b><\/p>\n

Melanogenesis signaling rationale from cell studies.<\/b><\/p>\n

SCALP AND FOLLICLES<\/b><\/p>\n

SCALP COMFORT AND FOLLICULAR VITALITY<\/b><\/p>\n

Evidence from dermal papilla cells and human follicle organ culture.<\/p>\n

Each development area is based on the scientific literature cited in its corresponding section.<\/p>\n

KEY ACTIVE<\/p>\n

The active behind the platform<\/b><\/h2>\n

\"\"<\/p>\n

Epigallocatechin gallate (EGCG): 2D structure, PubChem CID 65064.<\/p>\n

ACTIVE INCI<\/p>\n

EPIGALLOCATECHIN GALLATE<\/p>\n

MOLECULAR FORMULA: C22H18O11 \u00b7 MOLAR MASS: 458.37 g\/mol<\/p>\n

BOTANICAL SOURCE: the principal catechin in green tea (Camellia sinensis), formed by esterification of a flavan-3-ol with gallic acid.<\/p>\n

STRUCTURE\u2013ACTIVITY RELATIONSHIP: eight phenolic hydroxyl groups support radical scavenging but also confer oxidation sensitivity.<\/p>\n

PRODUCT POSITIONING<\/p>\n

NanoActive EGCG presents the catechin in a liposomal format built on PuriPharm\u2019s PURISOME\u00ae platform to protect the active and support delivery to skin.<\/p>\n

The INCI shown identifies the active ingredient. Refer to product technical documentation for the complete composition of the liposomal dispersion.<\/p>\n

Structure source: PubChem CID 65064, NIH National Library of Medicine.<\/p>\n

FORMULATION RATIONALE<\/p>\n

Formulation determines EGCG performance<\/b><\/h2>\n

EGCG IN SOLUTION<\/b><\/p>\n

DEGRADATION DRIVERS<\/p>\n

Oxygen and light<\/p>\n

Higher temperature<\/p>\n

Neutral to alkaline pH<\/p>\n

Vehicle and ionic environment<\/p>\n

Oxidation and degradation of catechins in solution<\/p>\n

IMPLICATIONS FOR FORMULATORS<\/p>\n

Protect the active from oxygen, light and heat during processing and storage.<\/p>\n

Design the vehicle and pH carefully.<\/p>\n

Consider encapsulation to protect the catechin before use.<\/p>\n

Design a delivery route to relevant skin compartments.<\/p>\n

EGCG is valuable but chemically vulnerable. Solution studies show that pH, temperature and vehicle affect how much intact EGCG remains available, providing the rationale for protection and delivery engineering.<\/p>\n

Proniuk S, Liederer BM, Blanchard J. J Pharm Sci. 2002;91(1):111\u2013116. DOI: 10.1002\/jps.10009. PMID: 11782902.<\/p>\n

DELIVERY TECHNOLOGY<\/p>\n

Powered by PURISOME\u00ae FlexVes™ Liposome Technology<\/b><\/h2>\n

EGCG<\/b><\/p>\n

Skin-compatible phospholipid bilayer vesicles<\/b><\/p>\n

Schematic, not to scale. Refer to PuriPharm technical documentation for the actual structure.<\/p>\n

1 PROTECT VULNERABLE ACTIVES<\/b><\/p>\n

Protect oxidation- and degradation-sensitive ingredients such as EGCG to support shelf-life quality.<\/p>\n

2 SUPPORT LOCAL SKIN DELIVERY<\/b><\/p>\n

Enhance stratum corneum penetration and the bioavailability of encapsulated actives.<\/p>\n

3 SUSTAINED AND CONTROLLED RELEASE<\/b><\/p>\n

Extend release, with a design rationale for reducing irritation risk.<\/p>\n

4 FORMULATION COMPATIBILITY<\/b><\/p>\n

Support compatibility and skin feel in leave-on and rinse-off systems.<\/p>\n

All NanoActive products use the PURISOME\u00ae platform, drawing on PuriPharm\u2019s more than ten years of nanodelivery R&D and industrial production experience.<\/p>\n

PURISOME\u00ae platform source: PuriPharm Co., Ltd. brand documentation, V1.0 (2026).<\/p>\n

DELIVERY RATIONALE: PUBLISHED RESEARCH<\/p>\n

Delivery research informs formulation design<\/b><\/h2>\n

PUBLISHED FIGURE: SKIN DEPOSITION OF EGCG (\u00b5g\/cm\u00b2)<\/b><\/p>\n

\"\"<\/p>\n

Reproduced from Li et al. 2022, Figure 5 (CC BY 4.0). Mean \u00b1 SD, n = 3. EGCG-loaded niosomes are surfactant vesicles. This study informs delivery design and did not measure PURISOME\u00ae performance.<\/p>\n

PUBLISHED FIGURE: CUMULATIVE EGCG RELEASE (%)<\/b><\/p>\n

\"\"<\/p>\n

Compared with a simple solution, vesicular encapsulation approximately doubled EGCG deposition in human skin and provided sustained release over 24 hours.<\/p>\n

Vesicle engineering can support surface residence, time-dependent release and delivery into viable skin. These findings inform the design rationale for the PURISOME\u00ae liposome platform.<\/p>\n

Li D et al. Pharmaceutics. 2022;14(4):726. DOI: 10.3390\/pharmaceutics14040726. PMID: 35456560.<\/p>\n

ADDITIONAL DATA FROM THE SOURCE SPEAKER NOTES<\/p>\n

Ex vivo human skin deposition at 12 hours was 69.0 \u00b1 13.87 \u00b5g\/cm\u00b2 with niosomes versus 30.02 \u00b1 2.45 \u00b5g\/cm\u00b2 with solution. At 24 hours, values were 54.38 \u00b1 8.86 versus 29.00 \u00b1 1.36 \u00b5g\/cm\u00b2 (mean \u00b1 SD, n = 3). Niosomes showed biphasic release, approximately 35% at 3 hours and 73% at 24 hours; Korsmeyer\u2013Peppas fit r\u00b2 = 0.996. These are Li et al.\u2019s niosome results, not PURISOME\u00ae measurements.<\/p>\n

MECHANISM OVERVIEW<\/p>\n

From molecular activity to skin appearance<\/b><\/h2>\n

EGCG<\/p>\n

One active, five pathways<\/p>\n

INFLAMMATORY SIGNALING<\/p>\n

Sebocytes and PM10-exposed keratinocytes. Yoon 2013; Seok 2018.<\/p>\n

REDOX DEFENSE<\/p>\n

Human UV-challenged skin and oxidative endpoints in fibroblasts. Katiyar 2001; Jia 2023.<\/p>\n

SEBOCYTE LIPID BIOLOGY<\/p>\n

AMPK \/ SREBP-1 in human sebocytes. Yoon 2013.<\/p>\n

MATRIX PROTECTION<\/p>\n

MMP-1\/3\/10, TIMP-1 and TGF-\u03b21 expression. Jia 2023.<\/p>\n

MELANOGENESIS SIGNALING<\/p>\n

cAMP \/ CREB \/ MITF in B16F10 cells. Zhang 2020.<\/p>\n

These experimentally studied pathways inform formulation concepts for resilience, clarity, even tone and follicular vitality.<\/p>\n

Pathway overview based on Katiyar 2001; Yoon 2013; Seok 2018; Zhang 2020; Jia 2023. Full references appear at the end.<\/p>\n

SKIN SCIENCE: ANTIOXIDANT DEFENSE<\/p>\n

Antioxidant evidence in human skin<\/b><\/h2>\n

HYDROGEN PEROXIDE GENERATION IN UV-CHALLENGED SKIN<\/b><\/p>\n

\u221268%<\/b><\/p>\n

\u221290%<\/b><\/p>\n

0 25 50 75 100 \u2014 Reduction versus UV-only control (%)<\/p>\n

EPIDERMAL LIPID PEROXIDATION<\/b><\/p>\n

\u221241%<\/b><\/p>\n

\u221284%<\/b><\/p>\n

0 25 50 75 100 \u2014 Reduction versus UV-only control (%)<\/p>\n

STUDY CONTEXT<\/p>\n

EGCG was applied topically to human skin before a single UV challenge of four minimal erythema doses. The ranges cover post-exposure assessment time points. EGCG also helped preserve glutathione-related antioxidant defenses.<\/p>\n

These are biological stress-defense endpoints, not SPF values or evidence of UV filtering.<\/p>\n

FORMULATION RATIONALE<\/p>\n

UV exposure can generate ROS faster than endogenous defenses can clear them.<\/p>\n

The reduced oxidative burden observed in human skin supports antioxidant and resilience-oriented daily-care concepts.<\/p>\n

Katiyar SK et al. Carcinogenesis. 2001;22(2):287\u2013294. DOI: 10.1093\/carcin\/22.2.287. PMID: 11181450.<\/p>\n

SKIN SCIENCE: PHOTOAGING<\/p>\n

Matrix support under photoaging stress<\/b><\/h2>\n

PUBLISHED FIGURE: MATRIX MARKERS IN UVA-STRESSED FIBROBLASTS<\/p>\n

\"\"<\/p>\n

Reproduced from Jia et al. 2023, Figure 6, panels A\u2013E. Human dermal fibroblasts, UVA model, EGCG 25 \u00b5g\/mL.<\/p>\n

REPORTED FINDINGS<\/b><\/p>\n

MMP-1 \/ MMP-3 \/ MMP-10 expression decreased versus UVA alone (panels A\u2013C).<\/p>\n

TGF-\u03b21 secretion increased (panel D; matrix-building signal).<\/p>\n

TIMP-1 mRNA increased (panel E; metalloproteinase inhibitor).<\/p>\n

Degradation-associated signals decreased as matrix-supporting signals recovered.<\/p>\n

ENDPOINTS<\/p>\n

MMP-1\/3\/10 and TIMP-1 mRNA were measured by RT-PCR. Secreted TGF-\u03b21 protein was measured in culture supernatants (*p < 0.05).<\/p>\n

Photoaging involves an imbalance between matrix degradation and renewal. EGCG modulated this balance in cultured human fibroblasts, providing a mechanistic basis for photoaging-oriented formulations.<\/p>\n

Jia Y et al. Clin Cosmet Investig Dermatol. 2023;16. DOI: 10.2147\/CCID.S398547. PMID: 36704608.<\/p>\n

SKIN SCIENCE: CELLULAR SENESCENCE<\/p>\n

Reducing the cellular burden of UVA stress<\/b><\/h2>\n

Repeated UVA exposure can promote cellular senescence, with loss of cell division and altered tissue signaling.<\/p>\n

Senescence-associated \u03b2-galactosidase (SA-\u03b2-gal) staining identifies blue-stained cells, quantified as a percentage.<\/p>\n

In human fibroblasts, EGCG nearly halved the senescent-cell proportion after UVA exposure.<\/p>\n

MODEL<\/p>\n

Human dermal fibroblasts; EGCG 25 \u00b5g\/mL for 24 hours. Mean \u00b1 SD from three independent experiments (*p < 0.05).<\/p>\n

PUBLISHED FIGURE: SA-\u03b2-GAL STAINING AND QUANTIFICATION<\/b><\/p>\n

\"\"<\/p>\n

Approximately 45% lower senescent-cell proportion relative to UVA alone.<\/p>\n

Reproduced from Jia et al. 2023, Figure 2. (A) SA-\u03b2-gal staining. (B) Quantification: 23.07% with UVA versus 12.75% with UVA + EGCG.<\/p>\n

Jia Y et al. Clin Cosmet Investig Dermatol. 2023;16. DOI: 10.2147\/CCID.S398547. PMID: 36704608.<\/p>\n

SKIN SCIENCE: URBAN ENVIRONMENTAL STRESS<\/p>\n

A scientific rationale for urban skin care<\/b><\/h2>\n

AIRBORNE PARTICULATE MATTER: PM10<\/p>\n

Particles that contact facial skin and the scalp during everyday exposure.<\/p>\n

KERATINOCYTE STRESS RESPONSE<\/p>\n

Oxidative stress and inflammatory signaling increase in exposed cells.<\/p>\n

EGCG AT 3\u201310 \u00b5M<\/p>\n

Attenuation of oxidative and inflammatory responses in PM10-exposed cells.<\/p>\n

Urban exposure places an ongoing particulate burden on skin and scalp. Micromolar EGCG attenuated exposure-related stress in primary human keratinocytes.<\/p>\n

These findings support a mechanistic rationale for antioxidant day creams, serums and leave-on scalp products focused on environmental resilience.<\/p>\n

MODEL<\/p>\n

Primary human keratinocytes exposed to PM10; EGCG tested at 3\u201310 \u00b5M.<\/p>\n

Mechanistic evidence only: the study did not measure a pollution-blocking percentage for a finished product.<\/p>\n

Seok JK et al. Skin Pharmacol Physiol. 2018;31(3):134\u2013143. DOI: 10.1159\/000487400. PMID: 29566388.<\/p>\n

SKIN SCIENCE: TONE<\/p>\n

Supporting a more even-toned appearance<\/b><\/h2>\n

\"\"<\/p>\n

PUBLISHED FIGURES: ZHANG ET AL. 2020, B16F10 CELLS<\/b><\/p>\n

\"\"\"\"<\/p>\n

Figure 4: cellular tyrosinase activity (A) and melanin content (B). Figure 5: MITF \/ TYR \/ TRP-1 \/ TRP-2 proteins (B) and cAMP (C).<\/p>\n

Melanogenesis follows a signaling cascade: increased cAMP, CREB activation and MITF-driven tyrosinase expression and melanin synthesis. EGCG modulated this cascade in B16F10 cells, supporting a mechanistic rationale for even-tone and targeted-care concepts. These are cell-level findings, not clinical age-spot results.<\/p>\n

CELL CONTEXT<\/p>\n

B16F10 melanocyte model. The schematic presents the pathway, while the published figures show experimental data.<\/p>\n

Zhang X et al. Fitoterapia. 2020;145:104634. DOI: 10.1016\/j.fitote.2020.104634. PMID: 32454171.<\/p>\n

SKIN SCIENCE: SEBUM BIOLOGY<\/p>\n

Addressing excess lipid production at the cellular level<\/b><\/h2>\n

\"\"<\/p>\n

AMPK: AMP-activated protein kinase, a cellular energy sensor that suppresses anabolic processes.<\/p>\n

SREBP-1: sterol regulatory element-binding protein 1, a transcription factor that activates sebocyte lipid-synthesis genes.<\/p>\n

Sebum synthesis in sebocytes is regulated by SREBP-1. In cultured human sebocytes, EGCG activated AMPK and reduced this lipogenic program.<\/p>\n

This provides cellular evidence relevant to oil-balancing and blemish-prone-skin concepts.<\/p>\n

MODEL<\/p>\n

Cultured human sebocytes. Clinical evidence from the same study is presented below.<\/p>\n

PUBLISHED FIGURE: YOON ET AL. 2013, FIGURE 1<\/b><\/p>\n

\"\"<\/p>\n

Sebum, AMPK and SREBP-1 measurements in human sebocytes.<\/b><\/p>\n

Yoon JY et al. J Invest Dermatol. 2013;133(2):429\u2013440. DOI: 10.1038\/jid.2012.292. PMID: 23096708.<\/p>\n

SKIN SCIENCE: CLINICAL EVIDENCE<\/p>\n

Clinical evidence in blemish-prone skin<\/b><\/h2>\n

\u221289%<\/p>\n

Reported reduction in inflammatory lesion count versus baseline in the 1% EGCG group.<\/p>\n

PUBLISHED FIGURES: YOON ET AL. 2013, SPLIT-FACE CONTROLLED TRIAL<\/p>\n

\"\"\"\"<\/p>\n

Figure 4 presents clinical photographs, Leeds scores and lesion-count changes. The other supplied image is a mechanistic summary schematic, rather than a split-face photograph.<\/p>\n

STUDY DESIGN<\/b><\/p>\n

Split-face, vehicle-controlled study; the contralateral side received vehicle.<\/p>\n

1% or 5% EGCG, twice daily for 8 weeks.<\/p>\n

35 of 37 participants completed: 17 in the 1% group and 18 in the 5% group.<\/p>\n

Endpoints: inflammatory and non-inflammatory lesion counts.<\/p>\n

This controlled human study connects sebocyte biology with visible changes in blemish-prone skin, providing a clinical anchor within the evidence base.<\/p>\n

Yoon JY et al. J Invest Dermatol. 2013;133(2):429\u2013440. DOI: 10.1038\/jid.2012.292. PMID: 23096708.<\/p>\n

SKIN SCIENCE: SEBUM, MICROBIAL INTERACTIONS AND COMFORT<\/p>\n

Linking sebum, microbial interactions and skin comfort<\/b><\/h2>\n

1 \u00b7 LIPID ENVIRONMENT<\/p>\n

Excess sebum contributes to blemish-prone conditions.<\/p>\n

2 \u00b7 MICROBIAL INTERACTIONS<\/p>\n

Cutibacterium acnes proliferates in lipid-rich follicles.<\/p>\n

3 \u00b7 INFLAMMATION AND DISCOMFORT<\/p>\n

Inflammatory signaling contributes to visible blemishes.<\/p>\n

EXPERIMENTALLY STUDIED EGCG EFFECTS<\/b><\/p>\n

GROWTH INHIBITION<\/p>\n

EGCG showed in vitro inhibition of C. acnes, tested under its historical name Propionibacterium acnes ATCC 6919.<\/p>\n

INFLAMMATORY SIGNALING<\/p>\n

EGCG attenuated NF-\u03baB-related responses in human sebocytes.<\/p>\n

Together with effects on sebocyte lipids, these findings provide a multi-level rationale for blemish-care formulation: less lipid substrate, measured microbial inhibition and reduced inflammatory signaling.<\/p>\n

PUBLISHED FIGURE: YOON 2013, FIGURE 2<\/b><\/p>\n

\"\"<\/p>\n

Sebocyte NF-\u03baB \/ AP-1 inflammatory measurements.<\/b><\/p>\n

Yoon JY et al. J Invest Dermatol. 2013;133:429\u2013440. Widyaningrum N et al. Asian J Biol Sci. 2015;8(2):93\u2013101. DOI: 10.3923\/ajbs.2015.93.101.<\/p>\n

APPLICATION CONCEPTS: SKIN<\/p>\n

Skin application concepts<\/b><\/h2>\n

Targets and scientific rationale<\/b><\/p>\n

\"\"<\/p>\n

Formats and formulation focus<\/b><\/p>\n

\"\"<\/p>\n

These are formulation-development concepts, not tested finished products. Confirm performance at the product level.<\/p>\n

Evidence sources are cited in the skin-science sections; full references appear at the end.<\/p>\n

SCALP AND FOLLICLE SCIENCE<\/p>\n

Bringing skincare science to scalp care<\/b><\/h2>\n

The scalp faces oxidative and inflammatory challenges similar to facial skin, alongside a distinctive structure: the follicle, a living mini-organ that produces hair.<\/p>\n

SCALP ENVIRONMENT<\/p>\n

Surface skin exposed to UV, pollution and sebum oxidation.<\/p>\n

FOLLICLE<\/p>\n

Living cells that drive the hair cycle, including dermal papilla signaling cells.<\/p>\n

HAIR SHAFT<\/p>\n

A non-living fiber whose surface can be conditioned but whose structure is produced by the follicle.<\/p>\n

\"\"<\/p>\n

Scalp and follicle anatomy: conceptual illustration from PuriPharm\u2019s asset collection.<\/p>\n

Anatomical schematic for structural reference only.<\/b><\/p>\n

SCALP AND FOLLICLE SCIENCE<\/p>\n

A rationale for a more resilient scalp environment<\/b><\/h2>\n

EVERYDAY SCALP STRESSORS<\/p>\n

UV, airborne particles, sebum oxidation and styling stress also challenge the scalp.<\/p>\n

OXIDATIVE AND INFLAMMATORY LOAD<\/p>\n

Redox and inflammatory pathways documented in skin are relevant to perifollicular scalp tissue.<\/p>\n

EGCG DEVELOPMENT RATIONALE<\/p>\n

Antioxidant defense and inflammatory modulation formulated for the scalp surface.<\/p>\n

A resilient scalp surface provides a basis for follicle-focused care.<\/p>\n

NanoActive EGCG brings documented redox and inflammatory biology to leave-on scalp concepts, where longer contact supports local availability.<\/p>\n

This is a mechanistic extension from skin studies to scalp-care development. Specific cell and follicle evidence follows.<\/p>\n

Rationale based on Katiyar 2001; Seok 2018; Jia 2023. Full references appear at the end.<\/p>\n

SCALP AND FOLLICLE SCIENCE: DERMAL PAPILLA<\/p>\n

Activity in human dermal papilla cells<\/b><\/h2>\n

Dermal papilla cells (DPCs), located at the follicle base, are signaling cells involved in the hair cycle.<\/p>\n

In cultured human DPCs, EGCG at 0.01\u20130.5 \u00b5M produced a significant, dose-dependent proliferative response by MTT assay (p < 0.05).<\/p>\n

These micromolar responses provide a cellular basis for follicular-vitality concepts.<\/p>\n

EXPERIMENT<\/p>\n

MTT proliferation assay in cultured human DPCs; Kwon et al. 2007, Figure 1. This is a cellular response, not a clinical hair-density measurement.<\/p>\n

PUBLISHED FIGURE: KWON ET AL. 2007, FIGURE 1, MTT ASSAY<\/b><\/p>\n

\"\"<\/p>\n

DPC proliferation increased with dose versus control at 0.01\u20130.5 \u00b5M (*p < 0.05). The source figure has low resolution.<\/p>\n

Kwon OS et al. Phytomedicine. 2007;14(7\u20138):551\u2013555. DOI: 10.1016\/j.phymed.2006.09.009. PMID: 17092697.<\/p>\n

SCALP AND FOLLICLE SCIENCE: SIGNALING<\/p>\n

Signals associated with follicular vitality<\/b><\/h2>\n

\"\"<\/p>\n

EGCG<\/b><\/p>\n

p-ERK \u2191, DOSE-DEPENDENT<\/p>\n

Mitogen-activated growth signaling.<\/p>\n

p-AKT \u2191, DOSE-DEPENDENT<\/p>\n

Cell survival and growth signaling.<\/p>\n

Bcl-2 \/ Bax RATIO \u2191<\/p>\n

Balance shifts toward cell survival.<\/p>\n

PROLIFERATION AND ANTI-APOPTOTIC SUPPORT IN DPCs<\/b><\/p>\n

INTERPRETING THE RESULTS<\/p>\n

Directional summary of Kwon et al. 2007, Figures 2\u20134, in cultured human DPCs.<\/p>\n

This differs from the sebocyte apoptosis reported with EGCG: different cell types can have different outcomes.<\/p>\n

PUBLISHED FIGURES: KWON ET AL. 2007, FIGURES 2\u20134<\/b><\/p>\n

\"\"<\/p>\n

Responses of p-ERK, p-AKT and Bcl-2\/Bax to EGCG in human DPCs. The source figures have low resolution.<\/p>\n

EGCG modulated growth (ERK), survival (Akt) and apoptotic balance (Bcl-2\/Bax) signals, providing complementary mechanisms relevant to follicular formulation concepts.<\/p>\n

Kwon OS et al. Phytomedicine. 2007;14(7\u20138):551\u2013555. DOI: 10.1016\/j.phymed.2006.09.009. PMID: 17092697.<\/p>\n

SCALP AND FOLLICLE SCIENCE: ORGAN CULTURE<\/p>\n

Evidence from human follicle organ culture<\/b><\/h2>\n

FOLLICLE ELONGATION AFTER 10 DAYS, AS A PERCENTAGE OF VEHICLE CONTROL<\/p>\n

\"\"<\/p>\n

Redrawn from Kwon et al. 2007. Mean \u00b1 SD: the three EGCG groups had SDs of 9.0, 7.1 and 15.8 percentage points, respectively; p < 0.05 versus vehicle. Human follicles came from three donors and were cultured for 10 days.<\/p>\n

Beyond isolated cells, EGCG increased elongation of whole human follicles over 10 days in organ culture.<\/p>\n

This model bridges cellular experiments and clinical research and provides preclinical support for follicular-vitality concepts in leave-on scalp care.<\/p>\n

EX VIVO HUMAN FOLLICLE MODEL<\/p>\n

The same paper also reports a separate, small scalp-biomarker experiment, summarized in the source speaker notes. Neither constitutes a clinical hair-growth outcome.<\/p>\n

Kwon OS et al. Phytomedicine. 2007;14(7\u20138):551\u2013555. DOI: 10.1016\/j.phymed.2006.09.009. PMID: 17092697.<\/p>\n

ADDITIONAL CONTEXT FROM THE SOURCE SPEAKER NOTES<\/p>\n

The paper separately reports a 4-day scalp-biomarker experiment in three volunteers using 10% EGCG in ethanol, with increased dermal papilla p-Erk\/p-Akt and Bcl-2\/Bax. This small experiment is distinct from ex vivo follicle elongation, is not a clinical hair-growth outcome and is not a product use-level recommendation.<\/p>\n

SCALP AND FOLLICLE SCIENCE: DELIVERY DESIGN<\/p>\n

Designing local skin and follicular delivery<\/b><\/h2>\n

\"\"<\/p>\n

Conceptual schematic of follicular accumulation of nanocarriers, from PuriPharm\u2019s asset collection.<\/p>\n

\"\"<\/p>\n

Published figure: Li et al. 2022, Figure 6. FITC-loaded vesicles concentrated at follicular openings in ex vivo human skin.<\/p>\n

\"\"<\/p>\n

This delivery-design concept is consistent with published vesicle research (Li 2022). The image does not establish transport of intact vesicles to the dermal papilla, and smaller particle size does not automatically mean deeper penetration.<\/p>\n

Delivery reference: Li D et al. Pharmaceutics. 2022;14(4):726. DOI: 10.3390\/pharmaceutics14040726.<\/p>\n

APPLICATION CONCEPTS: HAIR AND SCALP<\/p>\n

Hair and scalp formulation concepts<\/b><\/h2>\n

Targets and formulation focus<\/b><\/p>\n

\"\"<\/p>\n

Formats and contact patterns<\/b><\/p>\n

\"\"<\/p>\n

These are development concepts. Follicle-focused positioning centers on leave-on formats, where contact duration supports local activity.<\/p>\n

Evidence sources are cited in the scalp and follicle sections. Full references appear at the end.<\/p>\n

FORMULATION DESIGN<\/p>\n

Targeted active combinations<\/b><\/h2>\n

NanoActive EGCG provides the core active, while complementary ingredients refine the concept. These are formulation choices; confirm compatibility in the final vehicle.<\/p>\n

+ NIACINAMIDE<\/p>\n

OIL-BALANCING CONCEPT<\/p>\n

EGCG addresses sebocyte lipid biology, while niacinamide adds barrier and tone support. Complementary pathways inform oily- and blemish-prone-skin positioning.<\/p>\n

+ PANTHENOL<\/p>\n

COMFORT AND SOOTHING CONCEPT<\/p>\n

EGCG modulates stress signaling, while panthenol supports hydration and comfort. This pairing is proposed for sensitive-skin and scalp formats.<\/p>\n

+ CAFFEINE<\/p>\n

SCALP-VITALITY CONCEPT<\/p>\n

EGCG dermal papilla biology complements the established use of caffeine in leave-on scalp tonics and serums.<\/p>\n

Check vehicle pH, ionic environment, oxidation drivers and preservation together. Factors governing EGCG stability (Proniuk 2002) also apply to multi-active formulations.<\/p>\n

Combination concepts: PuriPharm. Stability principles: Proniuk 2002, discussed in the formulation-rationale section.<\/p>\n

FORMULATION PRACTICE<\/p>\n

Practical formulation integration<\/b><\/h2>\n

ADDITION AND HANDLING<\/b><\/p>\n

Evaluate cool-down addition to reduce heat exposure.<\/p>\n

Review shear exposure during homogenization and pumping.<\/p>\n

Minimize residence at high temperature.<\/p>\n

BASE ENVIRONMENT<\/b><\/p>\n

Set pH deliberately; EGCG is more stable in acidic conditions.<\/p>\n

Control ionic conditions that may challenge vesicle integrity.<\/p>\n

Manage dissolved oxygen, light and pro-oxidant metals.<\/p>\n

COMPATIBILITY<\/b><\/p>\n

Screen surfactants for vesicle compatibility; high levels may disrupt lipid vesicles.<\/p>\n

Check interactions with other actives, electrolytes and thickeners.<\/p>\n

Confirm preservative-system compatibility.<\/p>\n

These are development considerations, not validated processing limits. Refer to PuriPharm\u2019s NanoActive EGCG technical documentation for product-specific addition stage, temperature and use-level guidance.<\/p>\n

Stability principles: Proniuk 2002. Product instructions follow PuriPharm technical documentation.<\/p>\n

FORMULATION PRACTICE<\/p>\n

Protecting active quality through formulation and packaging<\/b><\/h2>\n

FORMULATION<\/b><\/p>\n

Liposomal encapsulation protects EGCG from bulk-phase oxidation.<\/p>\n

Design pH and antioxidant support around catechin chemistry.<\/p>\n

Assess metal interactions and use chelation where appropriate.<\/p>\n

PACKAGING<\/b><\/p>\n

Limit light using opaque or UV-protective packaging.<\/p>\n

Limit oxygen ingress using airless or low-headspace formats.<\/p>\n

Match the pack to application and dose control.<\/p>\n

MONITORING<\/b><\/p>\n

Track color and EGCG content during stability studies.<\/p>\n

Characterize carrier integrity, vesicle structure and size.<\/p>\n

Use sensory changes as early-warning signals.<\/p>\n

Active quality is a system property involving chemistry, packaging and monitoring. Finished-product shelf life and stability claims require product-level testing.<\/p>\n

Framework based on EGCG solution chemistry (Proniuk 2002) and vesicular delivery research (Li 2022).<\/p>\n

FROM SCIENCE TO BRAND<\/p>\n

Translating science into brand value<\/b><\/h2>\n

\"\"<\/p>\n

Consumer wording is limited to cosmetic positioning and anchored to the cited skin and follicle studies.<\/p>\n

Evidence anchors: Katiyar 2001; Jia 2023; Yoon 2013; Zhang 2020; Kwon 2007.<\/p>\n

CONCLUSION<\/p>\n

NanoActive EGCG: from catechin science to formulation opportunity<\/b><\/h2>\n

1 MULTIFUNCTIONAL ACTIVE<\/b><\/p>\n

Published biological evidence covers antioxidant defense, photoaging, sebum balance, tone and follicular vitality.<\/p>\n

2 PURPOSEFUL DELIVERY<\/b><\/p>\n

PURISOME\u00ae liposome technology is designed to protect the catechin and support local, sustained delivery.<\/p>\n

3 SKIN AND SCALP OPPORTUNITIES<\/b><\/p>\n

One platform spans serums, gels, moisturizers, essences, treatments and scalp-care products.<\/p>\n

Powered by PURISOME\u00ae FlexVes™ Liposome Technology<\/b><\/p>\n

PuriPharm Co., Ltd.<\/p>\n

www.puriactives.com<\/p>\n

REFERENCES \u00b7 SKIN BIOLOGY<\/p>\n

Key scientific references: skin biology<\/b><\/h2>\n

Katiyar SK et al. Green tea polyphenol (\u2212)-epigallocatechin-3-gallate treatment of human skin inhibits UV-induced oxidative stress. Carcinogenesis. 2001;22(2):287\u2013294. DOI: 10.1093\/carcin\/22.2.287. PMID: 11181450.<\/p>\n

Jia Y et al. (\u2212)-Epigallocatechin-3-gallate protects human skin fibroblasts from ultraviolet A induced photoaging. Clinical, Cosmetic and Investigational Dermatology. 2023;16. DOI: 10.2147\/CCID.S398547. PMID: 36704608. PMCID: PMC9871046.<\/p>\n

Seok JK, Lee JW, Kim YM, Boo YC. Punicalagin and (\u2212)-epigallocatechin-3-gallate rescue cell viability and attenuate inflammatory responses of human epidermal keratinocytes exposed to airborne particulate matter PM10. Skin Pharmacology and Physiology. 2018;31(3):134\u2013143. DOI: 10.1159\/000487400. PMID: 29566388.<\/p>\n

Yoon JY et al. Epigallocatechin-3-gallate improves acne in humans by modulating intracellular molecular targets and inhibiting P. acnes. Journal of Investigative Dermatology. 2013;133(2):429\u2013440. DOI: 10.1038\/jid.2012.292. PMID: 23096708.<\/p>\n

Zhang X et al. Anti-melanogenic effects of epigallocatechin-3-gallate (EGCG), epicatechin-3-gallate (ECG) and gallocatechin-3-gallate (GCG) via down-regulation of cAMP\/CREB\/MITF signaling pathway in B16F10 melanoma cells. Fitoterapia. 2020;145:104634. DOI: 10.1016\/j.fitote.2020.104634. PMID: 32454171.<\/p>\n

Widyaningrum N, Fudholi A, Sudarsono, Setyowati EP. Stability of epigallocatechin gallate (EGCG) from green tea (Camellia sinensis) and its antibacterial activity against Staphylococcus epidermidis ATCC 35984 and Propionibacterium acnes ATCC 6919. Asian Journal of Biological Sciences. 2015;8(2):93\u2013101. DOI: 10.3923\/ajbs.2015.93.101.<\/p>\n

Only literature cited in the presentation is listed. Microbial names retain the historical terminology used at publication.<\/p>\n

Skin biology references. Hair, delivery and formulation references follow.<\/p>\n

REFERENCES \u00b7 HAIR, DELIVERY AND FORMULATION<\/p>\n

Key scientific references: hair, delivery and formulation<\/b><\/h2>\n

HAIR AND SCALP<\/b><\/p>\n

Kwon OS, Han JH, Yoo HG, Chung JH, Cho KH, Eun HC, Kim KH. Human hair growth enhancement in vitro by green tea epigallocatechin-3-gallate (EGCG). Phytomedicine. 2007;14(7\u20138):551\u2013555. DOI: 10.1016\/j.phymed.2006.09.009. PMID: 17092697.<\/p>\n

DELIVERY AND FORMULATION<\/b><\/p>\n

Li D et al. Niosomal nanocarriers for enhanced dermal delivery of epigallocatechin gallate for protection against oxidative stress of the skin. Pharmaceutics. 2022;14(4):726. DOI: 10.3390\/pharmaceutics14040726. PMID: 35456560. PMCID: PMC9029719.<\/p>\n

Proniuk S, Liederer BM, Blanchard J. Preformulation study of epigallocatechin gallate, a promising antioxidant for topical skin care products. Journal of Pharmaceutical Sciences. 2002;91(1):111\u2013116. DOI: 10.1002\/jps.10009. PMID: 11782902.<\/p>\n

Structure reference: Epigallocatechin gallate, PubChem CID 65064, NIH National Library of Medicine (active-identity section).<\/p>\n

Only literature cited in the presentation is listed. PURISOME\u00ae platform descriptions are based on PuriPharm Co., Ltd. brand documentation.<\/p>\n

NanoActive EGCG nanoliposomes: scientific marketing report. PuriPharm Co., Ltd.<\/p>\n

 <\/p>\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\n\t\t\n\t<\/div>\n\n<\/article>\n\n\t\n\t\t\n

\n\n\t\n\t
\n\n\t\t\n\t\t
\n\t\t\t\n\t\t\t

PuriActives\u00ae Crystal Retinal<\/a><\/h1>\n\n\t\t\t\t\t\t\t
\n\t\t\t\t\tPosted on L, Y<\/a><\/span><\/span> \t\t\t\t<\/div>\n\t\t\t\n\t\t<\/header>\n\n\t\t\t\t\t
\n\t\t\t\t

PuriActives\u00ae Crystal RetinalCyclodextrin-Included Retinal<\/p>\n

PuriPharm Co., Ltd. \u00b7 Retinal science<\/p>\n

PuriActives\u00ae Crystal Retinal Cyclodextrin-Included Retinal<\/b><\/h2>\n

\"\"<\/p>\n

High-performance retinal through molecular inclusion science<\/p>\n

Retinal \u00b7 Cyclodextrin inclusion \u00b7 Skin and scalp renewal<\/b><\/p>\n

Scientific and technical report for cosmetic formulators and brand R&D teams<\/p>\n

PART I \u00b7 NEXT-GENERATION RETINAL<\/p>\n

The evolution of vitamin A skincare<\/b><\/h2>\n

RETINYL ESTERS<\/p>\n

Storage forms requiring hydrolysis before entering metabolism.<\/p>\n

RETINOL<\/p>\n

An established cosmetic benchmark, oxidized to retinal in skin.<\/p>\n

RETINAL (RAL)<\/p>\n

One oxidation step from retinoic acid: its direct metabolic precursor.<\/p>\n

RETINOIC ACID<\/p>\n

The receptor-active form; prescription-only in many markets.<\/p>\n

Esterases \u00b7 Retinol dehydrogenases (RDH\/ADH) \u00b7 Retinaldehyde dehydrogenases (ALDH1A)<\/p>\n

FROM STORAGE FORM TO SIGNALING MOLECULE<\/b><\/p>\n

Cosmetic vitamin A ingredients follow the skin\u2019s own metabolic pathway. Moving closer to retinoic acid reduces the number of enzymatic conversions.<\/p>\n

Retinal is the direct biosynthetic precursor of retinoic acid, the active form that binds nuclear retinoid receptors and drives epidermal renewal.<\/p>\n

Metabolic proximity is a mechanistic rationale, not a clinical conclusion. Relative efficacy requires controlled human studies, reviewed in Part III.<\/p>\n

2 \u2192 1<\/p>\n

Oxidation steps to retinoic acid: two for retinol, one for retinal.<\/p>\n

1994<\/p>\n

Topical retinal was first biologically characterized in human skin (Saurat et al.).<\/p>\n

125+<\/p>\n

Participants indicated in the source\u2019s milestone vehicle-controlled profilometry trial comparing retinal with retinoic acid (1998).<\/p>\n

Saurat JH et al. J Invest Dermatol. 1994;103(6):770\u2013774. Creidi P et al. J Am Acad Dermatol. 1998;39(6):960\u2013965. Retinoid metabolism: RDH\/ADH and ALDH1A enzyme families.<\/p>\n

PART I \u00b7 NEXT-GENERATION RETINAL<\/p>\n

One conversion from retinoic acid: retinal biology<\/b><\/h2>\n

All-trans-retinal (C20H28O; molecular weight 284.4)<\/b><\/p>\n

\"\"<\/p>\n

The \u03b2-ionone ring, conjugated polyene chain and terminal aldehyde underlie both biological activity and chemical vulnerability.<\/p>\n

The conjugated system responsible for sensitivity to light and oxidation also contributes to retinal\u2019s biological activity.<\/p>\n

Stabilizing this molecule without changing its chemistry is the formulation challenge addressed by cyclodextrin inclusion.<\/p>\n

A NATURAL INTERMEDIATE IN VITAMIN A METABOLISM<\/p>\n

Retinal forms from retinol in skin and can convert further to retinoic acid.<\/p>\n

DIRECT PRECURSOR<\/p>\n

One oxidation by retinaldehyde dehydrogenases produces retinoic acid, a ligand for nuclear RAR receptors involved in epidermal gene regulation.<\/p>\n

DOCUMENTED BIOACTIVITY IN HUMAN SKIN<\/p>\n

Early human studies reported measurable effects of topical retinal, including epidermal hyperplasia and increased dermal elastin, with good tolerability.<\/p>\n

THREE DECADES OF CLINICAL LITERATURE<\/p>\n

Human studies since 1994 have assessed texture, wrinkles, elasticity, tone, hydration and tolerability.<\/p>\n

COSMETIC POSITIONING<\/p>\n

The source identifies retinal (INCI: RETINAL) as a cosmetic retinoid, in contrast to retinoic acid, supporting science-led formulation development.<\/p>\n

Saurat JH et al. J Invest Dermatol. 1994;103(6):770\u2013774. Sorg O, Saurat JH. Dermatology. 2014;228(4):314\u2013325. Formula and molecular weight: PubChem CID 638015.<\/p>\n

PART I \u00b7 NEXT-GENERATION RETINAL<\/p>\n

High potential with demanding formulation requirements<\/b><\/h2>\n

Retinal\u2019s conjugated polyene chain and terminal aldehyde are chemically reactive. In conventional formulations, degradation through several documented pathways can reduce the available active.<\/p>\n

PHOTOCHEMICAL SENSITIVITY<\/p>\n

UV and visible light induce polyene photoisomerization and photodegradation.<\/p>\n

OXIDATIVE DEGRADATION<\/p>\n

Autoxidation of the conjugated chain generates peroxide intermediates and breakdown products.<\/p>\n

THERMAL INSTABILITY<\/p>\n

Heat accelerates degradation, affecting manufacturing, transport and shelf life.<\/p>\n

ISOMERIZATION<\/p>\n

Light and heat can convert the all-trans form into cis isomers with altered biological activity.<\/p>\n

VERY LOW WATER SOLUBILITY<\/p>\n

The lipophilic molecule is difficult to disperse uniformly in aqueous and emulsified systems.<\/p>\n

ACTIVE RETENTION IN FORMULATIONS<\/p>\n

Interactions with oils, surfactants and packaging may reduce the retinal available at the point of use.<\/p>\n

PATENT STRESS TESTS<\/p>\n

Under accelerated UV aging (200\u2013400 nm, 48 hours), an unstabilized retinal gel faded from deep yellow toward near-complete degradation, with a color score of 1\/20. Under thermal stress (45 \u00b0C, 7 days), the unstabilized group showed complete degradation, scored 20\/20.<\/p>\n

US 10,864,148 B2 (2020), Example 3, Table 6: visual color-scoring degradation tests of retinal formulations.<\/p>\n

Selecting retinal is the first step. Its molecular environment determines how it can be formulated.<\/p>\n

PART II \u00b7 THE SCIENCE OF CRYSTAL RETINAL<\/p>\n

Introducing PuriActives\u00ae Crystal Retinal Cyclodextrin-Included Retinal<\/b><\/h2>\n

A cyclodextrin-included retinal system designed around molecular stabilization and formulation flexibility, connecting retinal biology with host\u2013guest chemistry.<\/p>\n

PRODUCT<\/p>\n

PuriActives\u00ae Crystal Retinal Cyclodextrin-Included Retinal<\/p>\n

INCI NAME<\/p>\n

RETINAL<\/p>\n

CORE TECHNOLOGY<\/p>\n

Cyclodextrin molecular inclusion<\/p>\n

APPLICATIONS<\/p>\n

Premium skincare and science-led scalp care<\/p>\n

RETINAL BIOLOGY<\/p>\n

The direct metabolic precursor of retinoic acid, supported by three decades of human research.<\/p>\n

MOLECULAR INCLUSION<\/p>\n

Cyclodextrin host\u2013guest chemistry provides a protective environment for a vulnerable active.<\/p>\n

FORMULATION INNOVATION<\/p>\n

A solid, dispersible ingredient format opens formulation routes that are difficult for free retinal.<\/p>\n

Designed for formulators seeking a stabilization strategy at the ingredient level while retaining retinal\u2019s biological identity.<\/p>\n

PART II \u00b7 THE SCIENCE OF CRYSTAL RETINAL<\/p>\n

Cyclodextrins: molecular architecture from starch<\/b><\/h2>\n

Cyclodextrins are cyclic oligosaccharides produced by enzymatic conversion of starch. Their truncated-cone geometry creates a relatively hydrophilic exterior and a relatively hydrophobic cavity suited to lipophilic guests such as retinoids.<\/p>\n

\u03b1-CYCLODEXTRIN<\/p>\n

6 glucopyranose units; the smallest cavity, approximately 4.7\u20135.3 \u00c5.<\/p>\n

\"\"<\/p>\n

\u03b2-CYCLODEXTRIN<\/p>\n

7 glucopyranose units; a medium cavity, approximately 6.0\u20136.5 \u00c5.<\/p>\n

\"\"<\/p>\n

\u03b3-CYCLODEXTRIN<\/p>\n

8 glucopyranose units; the largest cavity, approximately 7.5\u20138.3 \u00c5.<\/p>\n

Cavity size affects which guests enter and how they are accommodated. In cited vitamin A tests, the larger \u03b3-cyclodextrin cavity provided greater protection than \u03b2-cyclodextrin, making cavity geometry an important formulation variable.<\/p>\n

After 48 days of UVA stress, a retinol\/\u03b3-CD complex retained 18.0% retinol, while the corresponding \u03b2-CD complex retained none (US 5,985,296, Example 3, Table 1).<\/p>\n

Structure figures: US 8,410,079 B2 (2013), Figures 1\u20133. Cavity dimensions: Loftsson T, Brewster ME. J Pharm Sci. 1996;85(10):1017\u20131025.<\/p>\n

PART II \u00b7 THE SCIENCE OF CRYSTAL RETINAL<\/p>\n

Molecular inclusion: a protective environment for retinal<\/b><\/h2>\n

\"\"<\/p>\n

HOST\u2013GUEST ASSOCIATION: SCHEMATIC<\/b><\/p>\n

Cyclodextrin host: hydrophilic exterior<\/b><\/p>\n

Hydrophobic<\/p>\n

cavity<\/p>\n

Retinal guest<\/b><\/p>\n

Noncovalent association: the guest is accommodated, not chemically modified.<\/p>\n

DYNAMIC EQUILIBRIUM<\/p>\n

Included retinal \u21cc Free retinal. As free retinal is taken up by skin during use, the equilibrium replenishes available active.<\/p>\n

HOST\u2013GUEST ASSOCIATION<\/p>\n

Hydrophobic and van der Waals interactions drive lipophilic guests into the nonpolar cavity.<\/p>\n

REDUCED ENVIRONMENTAL EXPOSURE<\/p>\n

The included fraction has reduced exposure to bulk solvent, oxygen and light, key contributors to retinal degradation.<\/p>\n

DISPERSION AND HANDLING<\/p>\n

A lipophilic crystalline active becomes a water-dispersible solid ingredient for easier weighing, dispersion and processing.<\/p>\n

EQUILIBRIUM-DRIVEN AVAILABILITY<\/p>\n

Guest release follows the association equilibrium without shell rupture or a triggered chemical reaction.<\/p>\n

DISTINCT FROM COVALENT DERIVATIVES<\/p>\n

Inclusion is a physical association. The retinal\u2013cyclodextrin hemiacetals discussed in the patent section are covalently bonded molecules of another class.<\/p>\n

Loftsson T, Brewster ME. J Pharm Sci. 1996;85(10):1017\u20131025. Yap KL et al. Eur J Pharm Sci. 2005;25(1):49\u201356. Schematic for illustration; partial inclusion geometries of polyene guests have been reported.<\/p>\n

PART II \u00b7 THE SCIENCE OF CRYSTAL RETINAL<\/p>\n

Stability through molecular design: interpreting stress tests<\/b><\/h2>\n

RETINOL RETENTION DURING OPEN STORAGE IN DAYLIGHT AT ROOM TEMPERATURE<\/p>\n

Intact retinol measured by HPLC relative to day 0. US 5,985,296, Example 4, Table 2.<\/p>\n

\"\"<\/p>\n

UVA AT 366 NM FOR 48 DAYS<\/p>\n

18.0% retinol retained in the \u03b3-CD complex<\/p>\n

0% retained in the \u03b2-CD complex under the same conditions<\/p>\n

US 5,985,296, Example 3, Table 1.<\/b><\/p>\n

Protection depends on the molecular environment. In the patent comparisons, the \u03b3-cyclodextrin complex retained most retinol after three weeks of open daylight storage, whereas the lactose triturate lost almost all of it.<\/p>\n

Under UVA stress, \u03b3-CD outperformed the smaller \u03b2-CD cavity, indicating the importance of inclusion geometry.<\/p>\n

These data concern retinol, the immediate precursor of retinal, which shares related conjugated degradation chemistry.<\/p>\n

US 5,985,296 A (Wacker-Chemie, 1999), Examples 3\u20134, Tables 1\u20132. Stability is complex-specific. These results characterize the tested materials and do not represent a particular commercial ingredient.<\/p>\n

PART II \u00b7 THE SCIENCE OF CRYSTAL RETINAL<\/p>\n

Four decades of retinal and cyclodextrin patent science<\/b><\/h2>\n

1983<\/b><\/p>\n

WATER-SOLUBLE RETINOID COMPLEXES<\/p>\n

Retinal\u2013polymer conjugates with cyclodextrin for water-compatible vitamin A systems.<\/p>\n

US 4,371,673 (Pitha): an early approach to water-compatible retinoid delivery.<\/p>\n

1999<\/b><\/p>\n

\u03b3-CD INCLUSION FOR VITAMIN A STABILITY<\/p>\n

Quantified improvements in light and storage stability of retinol\/\u03b3-CD complexes.<\/p>\n

US 5,985,296 (Wacker-Chemie): HPLC comparisons with \u03b2-CD and lactose controls.<\/p>\n

2013<\/b><\/p>\n

RETINAL\u2013CD HEMIACETAL DERIVATIVES<\/p>\n

Covalent retinal\u2013cyclodextrin structures developed for skin-tone applications.<\/p>\n

US 8,410,079 B2: chemically distinct from noncovalent inclusion complexes.<\/p>\n

2020<\/b><\/p>\n

MODERN RETINAL STABILIZATION<\/p>\n

Cyclodextrin-encapsulated retinal combined with antioxidant systems.<\/p>\n

US 10,864,148 B2: thermal and UV stress tests of encapsulated retinal gels.<\/p>\n

WHAT THE PATENT HISTORY SHOWS<\/p>\n

Successive approaches address retinoid instability through solubilization, inclusion, covalent derivatives and integrated formulations. Cyclodextrin inclusion is a route that protects the active without changing its molecular identity.<\/p>\n

\"\"<\/p>\n

General retinal\u2013cyclodextrin acetal structure<\/p>\n

CN 103987391 B, Formula (Ib).<\/p>\n

\"\"<\/p>\n

Exocyclic retinal\u2013CD hemiacetal (VIII)<\/p>\n

EP 2 755 664 B1 \/ HK 1200172 B, page 8.<\/p>\n

US 4,371,673 A (1983) \u00b7 US 5,985,296 A (1999) \u00b7 US 8,410,079 B2 (2013) \u00b7 US 10,864,148 B2 (2020).<\/p>\n

PART II \u00b7 THE SCIENCE OF CRYSTAL RETINAL<\/p>\n

Comparing retinal formulation approaches<\/b><\/h2>\n

Three approaches to retinal formulation involve different practical considerations. This table compares formulation principles rather than ranking performance.<\/p>\n

\"\"<\/p>\n

This is a qualitative comparison of formulation principles. Actual performance depends on the complex, manufacturing process and finished formulation. Validation parameters must be established during product development.<\/p>\n

PART III \u00b7 RETINAL BIOLOGY AND SKIN BENEFITS<\/p>\n

From retinal to skin renewal: the signaling cascade<\/b><\/h2>\n

\"\"<\/p>\n

DOCUMENTED IN SKIN<\/b><\/p>\n

RETINAL INCREASES CUTANEOUS RETINOIC ACID<\/p>\n

Topical retinal increased retinoic acid content and retinoid activity in mouse skin, supporting enzymatic conversion within tissue (Didierjean et al., 1996; Sorg et al., 1999).<\/p>\n

HUMAN EPIDERMAL RENEWAL MARKERS<\/p>\n

In human skin, topical retinal induced epidermal hyperplasia and increased dermal elastin with good tolerability, consistent with retinoid-mediated renewal (Saurat et al., 1994).<\/p>\n

RECEPTOR SPECIFICITY<\/p>\n

In human keratinocytes, retinoid signaling at physiological, nanomolar ligand concentrations acts mainly through RAR\u2013RXR heterodimers at \u03b2RARE elements (Xiao et al., 1995).<\/p>\n

DOWNSTREAM VISIBLE ENDPOINTS<\/p>\n

Texture, wrinkles, firmness, tone and barrier quality are mapped to human evidence in the following sections.<\/p>\n

Didierjean L et al. J Invest Dermatol. 1996;107(5):714\u2013719. Sorg O et al. Dermatology. 1999;199(Suppl 1):13\u201317. Saurat JH et al. J Invest Dermatol. 1994;103(6):770\u2013774. Xiao JH et al. J Biol Chem. 1995;270(7):3001\u20133011.<\/p>\n

PART III \u00b7 RETINAL BIOLOGY AND SKIN BENEFITS<\/p>\n

Skin texture: measurable renewal<\/b><\/h2>\n

Skin-surface refinement is an instrumentally measurable retinoid endpoint. Retinal supports orderly keratinocyte renewal, and changes can be assessed by profilometry and 3D imaging.<\/p>\n

WHY THE SURFACE RESPONDS<\/b><\/p>\n

Retinoic acid generated in skin modulates keratinocyte differentiation and epidermal turnover. Replacement of accumulated, disorganized corneocytes produces a more regular surface, measured as lower roughness in 3D imaging.<\/p>\n

Retinal\u2019s single-step conversion provides a rationale for renewal at cosmetic use concentrations.<\/p>\n

+13.7%<\/p>\n

Texture improvement with 0.1% retinal<\/p>\n

+12.6%<\/p>\n

Texture improvement with 0.05% retinal<\/p>\n

Randomized double-blind trial: 40 women with photoaged skin, twice-daily use for 3 months; texture quantified by Antera 3D imaging.<\/p>\n

BENCHMARK PROFILOMETRY STUDY<\/p>\n

Creidi et al. J Am Acad Dermatol. 1998.<\/p>\n

125 participants \u00b7 44 weeks \u00b7 0.05% retinal<\/b><\/p>\n

DESIGN<\/p>\n

Double-blind comparison of 0.05% retinal, 0.05% retinoic acid and vehicle in photoaged skin, with objective surface profilometry.<\/p>\n

RESULTS<\/p>\n

Both vitamin A groups reduced wrinkles and roughness versus vehicle, with significant improvement from week 18. Efficacy did not differ significantly between the active groups.<\/p>\n

TOLERABILITY<\/p>\n

Retinal was significantly better tolerated than retinoic acid at the same concentration.<\/p>\n

For formulation development, these results support retinal as a cosmetic option with surface efficacy comparable to retinoic acid under the tested conditions. Inclusion provides a stabilization rationale that must be verified in the formulation.<\/p>\n

Kwon HS et al. J Cosmet Dermatol. 2018;17(3):471\u2013476. Creidi P et al. J Am Acad Dermatol. 1998;39(6):960\u2013965. Studies used finished creams; results characterize the retinal active class.<\/p>\n

PART III \u00b7 RETINAL BIOLOGY AND SKIN BENEFITS<\/p>\n

Wrinkles and fine lines: clinical evidence<\/b><\/h2>\n

TWELVE WEEKS, TWO CONCENTRATIONS, FOUR ENDPOINTS<\/p>\n

Percentage change from baseline; randomized double-blind trial; 40 women; twice-daily use.<\/p>\n

\"\"<\/p>\n

All displayed changes were significant versus baseline except the 0.05% group\u2019s melanin endpoint, which was not significant and is therefore shown without a bar. Lower TEWL and melanin index indicate improvement.<\/p>\n

LONG-TERM CONTROLLED EVIDENCE<\/p>\n

Week 18: significant reduction versus vehicle<\/p>\n

44-week follow-up; n = 125<\/p>\n

Creidi P et al. J Am Acad Dermatol. 1998.<\/b><\/p>\n

At the same 0.05% concentration, retinal provided wrinkle improvement comparable to retinoic acid by profilometry, with significantly less irritation.<\/p>\n

The response persisted through the 44-week observation period, supporting a sustained rather than transient surface effect.<\/p>\n

DOSE-SELECTION RATIONALE<\/p>\n

In the reported results, 0.1% showed greater texture and pigment changes, while 0.05% showed the greater TEWL reduction. These endpoints inform different formulation concepts.<\/p>\n

Kwon HS et al. J Cosmet Dermatol. 2018;17(3):471\u2013476 (randomized double-blind trial, n = 40, 3 months; Antera 3D, corneometry, TEWL and pigment measurement). Creidi P et al. J Am Acad Dermatol. 1998;39(6):960\u2013965 (n = 125, 44 weeks; profilometry).<\/p>\n

PART III \u00b7 RETINAL BIOLOGY AND SKIN BENEFITS<\/p>\n

Dermal matrix: collagen and elastic-fiber support<\/b><\/h2>\n

Photoaging involves disrupted collagen and elastic fibers. Histology in skin explants and instrumental measurements in vivo provide evidence relevant to retinal and matrix-related care.<\/p>\n

HUMAN SKIN EXPLANTS: UVA REPAIR MODEL<\/b><\/p>\n

Fibers restored toward unexposed levels<\/b><\/p>\n

Human skin explants were photoaged with UVA in organ culture and treated with 0.05% retinal cream for 2 weeks. In all examined specimens, collagen and elastic fibers returned to unexposed-skin levels, and UVA-suppressed collagen synthesis normalized.<\/p>\n

Boisnic S et al. Dermatology. 1999;199(Suppl 1):43\u201348.<\/p>\n

CLINICAL STUDY: ULTRASOUND AND RHEOLOGY<\/b><\/p>\n

Instrumentally measured thickness and elasticity<\/b><\/p>\n

Topical 0.05% retinal significantly increased epidermal thickness and skin elasticity in aging skin, quantified by high-frequency ultrasound and rheology.<\/p>\n

Diridollou S et al. Dermatology. 1999;199(Suppl 1):37\u201341.<\/p>\n

p < 0.01<\/p>\n

Significance reported for increased epidermal thickness and elasticity with 0.05% retinal.<\/p>\n

These findings provide a rationale for firmness and density concepts alongside surface smoothing.<\/p>\n

SIGNALING BEHIND THE STRUCTURE<\/b><\/p>\n

RAR-mediated transcription in epidermal keratinocytes is the main documented pathway. Explant data show matrix recovery consistent with renewed collagen synthesis after UV damage.<\/p>\n

Active retention through stabilization is a formulation prerequisite that requires product-level confirmation.<\/p>\n

Boisnic S et al. Dermatology. 1999;199(Suppl 1):43\u201348 (human skin explants, UVA + 0.05% retinal, 2 weeks). Diridollou S et al. Dermatology. 1999;199(Suppl 1):37\u201341 (0.05% retinal; ultrasound and rheology endpoints).<\/p>\n

PART III \u00b7 RETINAL BIOLOGY AND SKIN BENEFITS<\/p>\n

Skin tone and pigmentation<\/b><\/h2>\n

MELANIN INDEX AT 12 WEEKS<\/p>\n

\u22126.5%<\/p>\n

A significant reduction in the 0.1% retinal group in the randomized double-blind photoaging trial.<\/p>\n

Kwon HS et al. J Cosmet Dermatol. 2018.<\/b><\/p>\n

The pigment endpoint was significant at 0.1% and not significant at 0.05%. This supports a concentration-specific rather than universal skin-tone claim.<\/p>\n

HOW RETINAL RELATES TO SKIN TONE<\/b><\/p>\n

PIGMENT CLEARANCE THROUGH TURNOVER<\/b><\/p>\n

Accelerated epidermal renewal replaces melanin-containing keratinocytes and reduces surface pigment residence.<\/p>\n

REPORTED DEPIGMENTING ACTIVITY<\/b><\/p>\n

A dedicated study in pigmentary disorders reported measurable depigmenting activity of topical retinal, supporting even-tone formulation development.<\/p>\n

Sorg O et al. Dermatology. 2013;227(3):231\u2013237.<\/p>\n

THE ROLE OF PHOTOSTABILITY<\/b><\/p>\n

The source proposes light-stable inclusion as a way to retain activity in tone-care products intended for daytime use. This performance must be established for the specific complex and formulation.<\/p>\n

POSITIONING<\/p>\n

Combine tone-care evidence with texture and tolerability endpoints to support an even, refined skin appearance. Final product claims require validation.<\/p>\n

Kwon HS et al. J Cosmet Dermatol. 2018;17(3):471\u2013476 (n = 40, 3 months; significant melanin reduction only at 0.1%). Sorg O et al. Dermatology. 2013;227(3):231\u2013237.<\/p>\n

PART III \u00b7 RETINAL BIOLOGY AND SKIN BENEFITS<\/p>\n

Refined skin: pores and blemish-related mechanisms<\/b><\/h2>\n

The source reports direct antibacterial activity of retinal against Cutibacterium acnes, formerly Propionibacterium acnes, distinguishing it from the retinol and retinoic acid comparators discussed.<\/p>\n

IN VITRO: MINIMUM INHIBITORY CONCENTRATION<\/b><\/p>\n

4\u20138 mg\/L<\/p>\n

Retinal MIC against three P. acnes reference strains.<\/p>\n

COMPARATOR<\/b><\/p>\n

>128 mg\/L<\/p>\n

Retinoic acid MIC against the same strains.<\/p>\n

This activity is attributed to retinal\u2019s aldehyde group, a property of the molecule rather than a finished product.<\/p>\n

Pech\u00e8re M et al. Dermatology. 1999;199(Suppl 1):29\u201331.<\/b><\/p>\n

IN VIVO: SINGLE-BLIND RANDOMIZED STUDY<\/p>\n

The source slide records the median viable-count decrease per cm\u00b2 as \u201c\u2248 \u221210\u00b2 log\u201d after 2 weeks of daily 0.05% retinal. Vehicle alone was ineffective.<\/p>\n

The numerical notation is ambiguous and is retained as written rather than converted to a different unit.<\/p>\n

COMPLEMENTARY EVIDENCE<\/b><\/p>\n

COMEDOLYTIC ACTIVITY<\/p>\n

Topical retinal reduced comedones in the rhino mouse model, providing a complementary mechanism for pore-focused concepts.<\/p>\n

Fort-Lacoste L et al. Dermatology. 1999;199(Suppl 1):33\u201335.<\/p>\n

Use as mechanistic support for clarifying and blemish-prone-skin positioning, rather than a standalone acne-treatment claim.<\/p>\n

Pech\u00e8re M et al. Dermatology. 1999;199(Suppl 1):29\u201331. Fort-Lacoste L et al. Dermatology. 1999;199(Suppl 1):33\u201335. In vitro and animal findings provide mechanistic support, not clinical acne efficacy.<\/p>\n

PART III \u00b7 RETINAL BIOLOGY AND SKIN BENEFITS<\/p>\n

Barrier function, hydration and tolerability<\/b><\/h2>\n

BARRIER FUNCTION: KWON 2018 RANDOMIZED TRIAL<\/b><\/p>\n

\u221214.5%<\/p>\n

TEWL in the 0.1% group<\/p>\n

\u221217.9%<\/p>\n

TEWL in the 0.05% group<\/p>\n

+10.2%<\/p>\n

Skin hydration in the 0.1% group<\/p>\n

+6.0%<\/p>\n

Skin hydration in the 0.05% group<\/p>\n

After 12 weeks of twice-daily retinal use, lower TEWL and greater stratum corneum hydration indicated improvements versus baseline.<\/p>\n

TOLERABILITY UNDER CHALLENGE<\/b><\/p>\n

MAXIMIZED AND LONG-TERM EXPOSURE<\/b><\/p>\n

In a tolerability study with 355 volunteers under maximized and long-term conditions, retinoic acid caused significantly more erythema and scaling, while retinal was closer to vehicle.<\/p>\n

Fluhr JW et al. Dermatology. 1999;199(Suppl 1):57\u201360.<\/p>\n

NO PHOTOTOXICITY SIGNAL<\/b><\/p>\n

A dedicated human tolerability review involving 357 subjects reported a favorable safety profile for topical retinal, including no phototoxic reactions.<\/p>\n

Sachsenberg-Studer EM. Dermatology. 1999;199(Suppl 1):61\u201363.<\/p>\n

MINIMAL SYSTEMIC EXPOSURE<\/b><\/p>\n

Plasma retinoid levels were essentially unchanged after topical use in human skin, supporting local-action positioning.<\/p>\n

Sass JO et al. Skin Pharmacol. 1996;9(5):322\u2013326.<\/p>\n

FORMULATION VALUE<\/p>\n

Tolerability is important for retinoid adherence. The cited barrier and tolerability findings inform the development of everyday retinal products.<\/p>\n

Kwon HS et al. J Cosmet Dermatol. 2018;17(3):471\u2013476. Fluhr JW et al. Dermatology. 1999;199(Suppl 1):57\u201360. Sachsenberg-Studer EM. Dermatology. 1999;199(Suppl 1):61\u201363. Sass JO et al. Skin Pharmacol. 1996;9(5):322\u2013326.<\/p>\n

PART IV \u00b7 SCALP SCIENCE AND HAIRCARE INNOVATION<\/p>\n

The scalp is skin and responds to retinoid signaling<\/b><\/h2>\n

\"\"<\/p>\n

PuriActives\u00ae Crystal Retinal: retinal held within a cyclodextrin inclusion complex.<\/p>\n

Scalp care draws on skincare concepts such as renewal, barrier support and the microbiome. The scalp is a specialized, follicle-rich skin surface with relevant retinoid biology.<\/p>\n

A RETINOID-RESPONSIVE SURFACE<\/p>\n

Scalp epidermis shares retinoid receptor mechanisms with facial skin. The retinal-to-retinoic-acid pathway can operate in keratinocytes across body sites.<\/p>\n

A MICROBIAL DIMENSION<\/p>\n

The follicle-rich scalp carries dense microbial communities, including C. acnes. Retinal\u2019s reported activity against this organism provides a follicular-environment rationale.<\/p>\n

FORMULATION CHALLENGES<\/p>\n

Scalp products are often water-rich, surfactant-containing and transparent, creating stability challenges for unprotected retinal.<\/p>\n

Retinoid skin biology: Saurat JH et al. J Invest Dermatol. 1994;103(6):770\u2013774. Antibacterial activity: Pech\u00e8re M et al. Dermatology. 1999;199(Suppl 1):29\u201331.<\/p>\n

PART IV \u00b7 SCALP SCIENCE AND HAIRCARE INNOVATION<\/p>\n

Follicular biology: interpreting receptor evidence<\/b><\/h2>\n

The follicle is a retinoid-sensitive mini-organ. Receptor genetics defines the biological rationale and the limits of scalp-care positioning.<\/p>\n

GENETIC EVIDENCE: RXR\u03b1 AND THE HAIR CYCLE<\/b><\/p>\n

Keratinocyte RXR\u03b1 is required for a normal hair cycle.<\/b><\/p>\n

Mice with targeted RXR\u03b1 loss in epidermal and follicular keratinocytes developed progressive alopecia and failed to initiate anagen, establishing a requirement for this receptor signaling in the hair cycle.<\/p>\n

Li M et al. Development. 2001;128(5):675\u2013688.<\/p>\n

REVIEW EVIDENCE: THE PILOSEBACEOUS UNIT<\/b><\/p>\n

Retinoids act on follicular glands and epithelium.<\/b><\/p>\n

An endocrine review of pilosebaceous biology discusses retinoid effects on sebocyte differentiation and follicular keratinization, processes relevant to scalp condition, oiliness and scaling.<\/p>\n

Deplewski D, Rosenfield RL. Endocr Rev. 2000;21(4):363\u2013392.<\/p>\n

POSITIONING WITHIN THE EVIDENCE<\/b><\/p>\n

Retinoid effects are dose-dependent, and excessive systemic exposure is associated with hair loss.<\/p>\n

Crystal Retinal\u2019s scalp positioning therefore concerns a balanced, comfortable scalp and follicular environment.<\/p>\n

No hair-growth, density-increase or hair-loss-prevention claim is made or implied.<\/p>\n

TAKEAWAY<\/p>\n

Follicular retinoid sensitivity is established biology; cosmetic development opportunities concern scalp condition.<\/p>\n

Li M et al. Development. 2001;128(5):675\u2013688. Deplewski D, Rosenfield RL. Endocr Rev. 2000;21(4):363\u2013392. Mechanistic evidence, not clinical validation of Crystal Retinal.<\/p>\n

PART IV \u00b7 SCALP SCIENCE AND HAIRCARE INNOVATION<\/p>\n

Scalp-care opportunities from the formulation bench<\/b><\/h2>\n

Premium haircare increasingly uses skincare actives. Retinal development requires stability in realistic scalp formats: water-rich systems with surfactants and potentially prolonged residence.<\/p>\n

THE CHALLENGE<\/b><\/p>\n

Free retinal is difficult to stabilize in scalp formats.<\/b><\/p>\n

Water, oxygen, light and surfactant environments can promote loss of unprotected retinal during product development and storage.<\/p>\n

THE INCLUSION APPROACH<\/b><\/p>\n

A protected guest available at the interface.<\/b><\/p>\n

The inclusion complex reduces exposure of retinal\u2019s conjugated system in the bulk formulation and allows guest exchange at the skin interface through water activity and lipid affinity.<\/p>\n

A BRAND DEVELOPMENT CONCEPT<\/b><\/p>\n

Skincare renewal adapted for the scalp.<\/b><\/p>\n

Scalp comfort, balance, gentle renewal and follicular-environment care are anchored in published skin biology rather than hair-growth promises.<\/p>\n

Stability engineering creates an opportunity to explore retinal in demanding scalp formats.<\/p>\n

PART V \u00b7 FORMULATION AND APPLICATIONS<\/p>\n

Formulating Crystal Retinal: working principles<\/b><\/h2>\n

Inclusion chemistry provides a stabilization rationale, but processing remains important. Confirm each of these eight principles in the customer\u2019s own stability program.<\/p>\n

01 <\/b>ADD DURING COOL-DOWN<\/p>\n

Introduce the complex below typical hot-process temperatures to protect host\u2013guest equilibrium.<\/p>\n

02 <\/b>CONTROL LIGHT FROM THE START<\/p>\n

Use amber or opaque handling through production and filling.<\/p>\n

03<\/b> BUILD ANTIOXIDANT SUPPORT<\/p>\n

Chelators and antioxidant systems remain useful for retinoids, whether included or free.<\/p>\n

04 <\/b>SET pH USING MEASUREMENTS<\/p>\n

Mildly acidic conditions are generally favorable; confirm the suitable window in the final base.<\/p>\n

05 <\/b>SCREEN COMPETING GUESTS<\/p>\n

Hydrophobic fragrance constituents and oils may compete for the cyclodextrin cavity. Check displacement risk in compatibility tests.<\/p>\n

06<\/b><\/p>\n

AVOID STRONG OXIDATIVE CHALLENGES<\/p>\n

Peroxides and aggressive preservative boosters can affect the polyene chain. Screen the full combination.<\/p>\n

07<\/b><\/p>\n

SPECIFY PROTECTIVE PACKAGING<\/p>\n

Airless, low-permeability, light-protective packaging supports shelf-life retention.<\/p>\n

08<\/b><\/p>\n

VALIDATE IN THE REAL FORMULATION<\/p>\n

Run accelerated and real-time stability tests on the finished product. Complex data guide development but do not replace product-level evidence.<\/p>\n

Principles are drawn from retinoid and cyclodextrin literature. PuriPharm technical support can advise on specific bases.<\/p>\n

Loftsson T, Brewster ME. J Pharm Sci. 1996;85(10):1017\u20131025. Yap KL et al. Eur J Pharm Sci. 2005;25(1):49\u201356. These principles are not validated specifications for a particular formulation.<\/p>\n

PART V \u00b7 FORMULATION AND APPLICATIONS<\/p>\n

Skincare concepts informed by the evidence<\/b><\/h2>\n

NIGHT RENEWAL SERUM<\/p>\n

Texture and wrinkle endpoints from randomized studies provide claim-development anchors. Inclusion is intended to support active retention during shelf life.<\/p>\n

Evidence anchors: Kwon 2018; Creidi 1998.<\/p>\n

GENTLE EVERYDAY RETINAL MOISTURIZER<\/p>\n

Barrier findings and vehicle-like tolerability support routine-use development.<\/p>\n

Evidence anchors: Fluhr 1999; Kwon 2018, TEWL and hydration.<\/p>\n

FIRMING AND DENSITY CREAM<\/p>\n

Ultrasound and explant evidence concerning thickness, elasticity and matrix recovery informs firmness concepts.<\/p>\n

Evidence anchors: Diridollou 1999; Boisnic 1999.<\/p>\n

EVEN-TONE SERUM<\/p>\n

Significant melanin-index reduction at 0.1% and reported depigmenting activity support a concentration-specific concept.<\/p>\n

Evidence anchors: Kwon 2018; Sorg 2013.<\/p>\n

CLARIFYING CARE FOR BLEMISH-PRONE SKIN<\/p>\n

C. acnes activity and comedolytic findings provide mechanistic support for pore-focused formulations.<\/p>\n

Evidence anchors: Pech\u00e8re 1999; Fort-Lacoste 1999.<\/p>\n

EYE-AREA RENEWAL CARE<\/p>\n

The source proposes retinal\u2019s efficacy and tolerability profile as a development rationale for thin, sensitive skin around the eyes.<\/p>\n

Evidence anchor: the cited tolerability literature.<\/p>\n

Concepts only. Validate all claims in the final marketed product. Evidence anchors refer to the skin-benefit studies reviewed above.<\/p>\n

PART V \u00b7 FORMULATION AND APPLICATIONS<\/p>\n

Scalp-care concepts<\/b><\/h2>\n

Four dosage-form concepts explore stabilized retinal for scalp care while retaining the limits of the evidence.<\/p>\n

LEAVE-ON SCALP SERUM<\/p>\n

A night-care concept for surface renewal and comfort, informed by retinal epidermal biology and tolerability literature.<\/p>\n

BALANCING TONIC FOR OILY, CONGESTION-PRONE SCALPS<\/p>\n

Reported C. acnes activity and follicular keratinization mechanisms support a clean, balanced follicular-environment concept.<\/p>\n

INTENSIVE PRE-WASH CARE<\/p>\n

A weekly concentrated step in an aqueous base, with active retention as a formulation-development objective.<\/p>\n

CONDITIONER AND HAIR-MASK ADDITION<\/p>\n

Explore rinse-off systems. Guest release and rinse compatibility require joint engineering by the brand and PuriPharm.<\/p>\n

Concepts only. Use scalp-condition wording. The cited evidence does not support hair-growth, density-increase or hair-loss-prevention claims.<\/p>\n

PART V \u00b7 FORMULATION AND APPLICATIONS<\/p>\n

Patent evidence: what the documents show<\/b><\/h2>\n

\"\"<\/p>\n

CN 103987391 B: a granted Chinese patent showing retinal\u2013cyclodextrin acetal conjugate structures.<\/p>\n

\"\"<\/p>\n

CN 103987391 B patent family: exocyclic retinal\u2013cyclodextrin hemiacetal structure (VIII).<\/p>\n

\"\"<\/p>\n

CN 103987391 B patent family: endocyclic structure (VII).<\/b><\/p>\n

INTERPRETING THE RECORD<\/p>\n

Patent documents cover both noncovalent inclusion complexes and covalent conjugates. PuriActives\u00ae Crystal Retinal is positioned as a molecular inclusion complex based on physical equilibrium. Related patent test data are discussed in the stability and patent-history sections.<\/p>\n

Figures reproduced from granted patent documents for technical discussion: CN 103987391 B; the source also cites the US 10,864,148 B2 family. Patent structures and comparisons are not product specifications for Crystal Retinal.<\/p>\n

PART VI \u00b7 COMMERCIAL POSITIONING<\/p>\n

One ingredient, four value pillars<\/b><\/h2>\n

MOLECULAR STABILIZATION<\/b><\/p>\n

Cyclodextrin inclusion reduces environmental exposure of retinal\u2019s conjugated system, informed by host\u2013guest chemistry and retinoid-stabilization patents.<\/p>\n

EFFICACY INFORMED BY RETINOIC ACID COMPARISONS<\/b><\/p>\n

One metabolic step from the active form, with randomized cosmetic-concentration studies on texture, wrinkles, barrier function, hydration and pigmentation.<\/p>\n

FORMULATION FLEXIBILITY<\/b><\/p>\n

Inclusion enables exploration of creams, aqueous serums and scalp formats, with guest release at the skin interface as the development rationale.<\/p>\n

A DOCUMENTED SCIENTIFIC STORY<\/b><\/p>\n

Peer-reviewed clinical literature, patent tests and receptor biology provide a framework for claim development and review.<\/p>\n

PRODUCT & PARTNERSHIP<\/p>\n

Retinal science. The possibilities of molecular inclusion.<\/b><\/h2>\n

\"\"<\/p>\n

PuriActives\u00ae Crystal Retinal Cyclodextrin-Included Retinal combines a direct cosmetic retinoid precursor with molecular stabilization for skin and scalp formulation development.<\/p>\n

PuriPharm Co., Ltd.<\/p>\n

PuriActives\u00ae Crystal Retinal \u00b7 INCI: RETINAL<\/p>\n

Samples, technical documentation and development support available on request.<\/p>\n

www.puriactives.com<\/p>\n

This report is intended for professionals and summarizes published research and granted patent documents. Data characterize the retinal active class and the cited test materials. Finished-product claims require product-level validation.<\/p>\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\n\t\t\n\t<\/div>\n\n<\/article>\n\n\t\n\t\t\n

\n\n\t\n\t
\n\n\t\t\n\t\t
\n\t\t\t\n\t\t\t

NanoActive Oleu™<\/a><\/h1>\n\n\t\t\t\t\t\t\t
\n\t\t\t\t\tPosted on L, Y<\/a><\/span><\/span> \t\t\t\t<\/div>\n\t\t\t\n\t\t<\/header>\n\n\t\t\t\t\t
\n\t\t\t\t

NanoActive Oleu™<\/b><\/h2>\n

\"\"<\/p>\n

PuriPharm Co., Ltd. \u00b7 Technical Report<\/b><\/p>\n

Liposomal Oleuropein<\/b><\/p>\n

Mediterranean polyphenol defense<\/p>\n

Enhanced by delivery science<\/p>\n

INCI: OLEA EUROPAEA (OLIVE) LEAF EXTRACT<\/p>\n

Powered by PURISOME\u00ae FlexVes™ Liposome Technology<\/p>\n

01 \u00b7 INGREDIENT OVERVIEW<\/p>\n

NanoActive Oleu™ at a glance<\/b><\/h2>\n

PRODUCT NAME\uff1aNanoActive Oleu™ Liposomal Oleuropein<\/b><\/p>\n

INCI NAME\uff1aOlea Europaea (Olive) Leaf Extract<\/b><\/p>\n

BOTANICAL SOURCE\uff1aLeaves of Olea europaea L.<\/b><\/p>\n

KEY PHYTOCHEMICAL\uff1aOleuropein, a secoiridoid polyphenol<\/b><\/p>\n

DELIVERY PLATFORM\uff1aPURISOME\u00ae FlexVes™ Liposome Technology<\/b><\/p>\n

PHYSICAL FORM\uff1aLiposomal dispersion for aqueous and emulsified systems<\/b><\/p>\n

APPLICATION AREAS\uff1aSkincare \u00b7 Oral care \u00b7 Hair and scalp care<\/b><\/p>\n

PRODUCT POSITIONING\uff1aAn oleuropein-rich olive leaf extract encapsulated in flexible liposomal vesicles. NanoActive Oleu™ brings Mediterranean polyphenol science to formulation-ready skin, oral and scalp care concepts, informed by human, in vivo and mechanistic research.<\/b><\/p>\n

\"\"<\/p>\n

Young olive leaves (Olea europaea L.), the botanical source of the actives.<\/p>\n

02 \u00b7 BOTANICAL ORIGIN<\/p>\n

Olive leaves: a concentrated source of polyphenols<\/b><\/h2>\n

Olive branch with young leaves and fruit. Leaves are the tree\u2019s richest source of phenolic compounds.<\/p>\n

60\u201390 mg oleuropein per g of dry leaves<\/b><\/p>\n

The olive tree concentrates its defensive chemistry in its leaves. Oleuropein, the predominant secoiridoid polyphenol, can reach 60\u201390 mg\/g of dry leaves, alongside hydroxytyrosol, verbascoside and flavonoid glycosides.<\/p>\n

This phytochemical system evolved under sunlight, microbial and oxidative stress, providing a botanical rationale relevant to daily challenges faced by skin, oral mucosa and scalp.<\/p>\n

Nediani C, et al. Antioxidants. 2019;8(12):578. doi:10.3390\/antiox8120578<\/p>\n

Omar SH. Sci Pharm. 2010;78(2):133\u2013154.<\/p>\n

03 \u00b7 KEY ACTIVE MOLECULE<\/p>\n

Oleuropein: secoiridoid chemistry for redox activity<\/b><\/h2>\n

\"\"<\/p>\n

Oleuropein (molecular weight 540.5): hydroxytyrosol + elenolic acid + glucose. Nediani C, et al. Antioxidants. 2019;8:578.<\/p>\n

CATECHOL CORE<\/b><\/p>\n

The catechol hydroxyls of the hydroxytyrosol moiety donate hydrogen atoms to neutralize free radicals.<\/p>\n

ACTIVE PRODUCTS OF HYDROLYSIS<\/b><\/p>\n

Ester hydrolysis releases hydroxytyrosol and elenolic acid, extending the molecule\u2019s functional profile.<\/p>\n

NATURAL HYDROPHILICITY<\/b><\/p>\n

A water-soluble glycoside with biological activity, but limited passage through lipid-rich barriers without delivery support.<\/p>\n

This chemistry provides the rationale for complementary delivery engineering.<\/p>\n

04 \u00b7 DELIVERY CHALLENGES<\/p>\n

Active polyphenols face practical delivery challenges<\/b><\/h2>\n

CHEMICAL INSTABILITY<\/b><\/p>\n

Oleuropein\u2019s ester bonds and catechol groups are susceptible to hydrolysis and oxidation, potentially reducing activity during shelf life.<\/p>\n

BARRIER MISMATCH<\/b><\/p>\n

Hydrophilic glycosides partition poorly into lipid-rich stratum corneum and mucosal surfaces, limiting local bioavailability.<\/p>\n

SHORT RESIDENCE TIME<\/b><\/p>\n

Unencapsulated polyphenols can be diluted, metabolized or washed away quickly, particularly in the oral environment.<\/p>\n

FORMULATION CONSTRAINTS<\/b><\/p>\n

Oxidation-sensitive polyphenols constrain pH, processing, packaging and preservative-system design.<\/p>\n

DELIVERY APPROACH<\/b><\/p>\n

Delivery science aims to turn a fragile molecule into a robust, formulation-ready ingredient.<\/p>\n

PURISOME\u00ae FlexVes™ Liposome Technology<\/b><\/p>\n

The proprietary liposomal platform behind the NanoActive™ ingredient range is introduced below.<\/p>\n

Stability reference: Perugini P, et al. Int J Cosmet Sci. 2008;30(2):113\u2013120.<\/p>\n

05 \u00b7 DELIVERY PLATFORM<\/p>\n

PURISOME\u00ae FlexVes™ Liposome Technology<\/b><\/h2>\n

Flexible phospholipid vesicles: PuriPharm\u2019s delivery architecture.<\/p>\n

PuriPharm\u2019s proprietary platform encapsulates oxidation-sensitive polyphenols in flexible liposomal vesicles, with four proposed formulation benefits.<\/p>\n

01 \u00b7 PROTECTION<\/b><\/p>\n

Protect actives vulnerable to oxidation and degradation to support shelf life.<\/p>\n

02 \u00b7 PENETRATION<\/b><\/p>\n

Promote stratum corneum penetration and improve bioavailability.<\/p>\n

03 \u00b7 RELEASE<\/b><\/p>\n

Provide sustained, controlled release to reduce irritation risk.<\/p>\n

04 \u00b7 COMPATIBILITY<\/b><\/p>\n

Improve formulation compatibility and skin feel.<\/b><\/p>\n

PuriPharm Co., Ltd. has more than ten years of liposome R&D experience.<\/p>\n

06 \u00b7 INTEGRATED VALUE<\/p>\n

One ingredient, a complete value framework<\/b><\/h2>\n

01<\/b><\/p>\n

OLIVE LEAVES<\/b><\/p>\n

BOTANICAL SOURCE<\/b><\/p>\n

Olea europaea L. leaves, the tree\u2019s most polyphenol-rich plant part.<\/p>\n

02<\/b><\/p>\n

PHYTOCHEMISTRY<\/b><\/p>\n

ACTIVE FOUNDATION<\/b><\/p>\n

An oleuropein-rich polyphenol system with published evidence across multiple pathways.<\/p>\n

03<\/b><\/p>\n

PURISOME\u00ae<\/b><\/p>\n

DELIVERY ENGINEERING<\/b><\/p>\n

FlexVes™ liposomal protection, penetration and controlled release.<\/p>\n

04<\/b><\/p>\n

FORMULATION FIT<\/b><\/p>\n

FLEXIBLE USE<\/b><\/p>\n

Dispersion for incorporation into emulsions, gels, serums and oral-care bases.<\/p>\n

05<\/b><\/p>\n

SKIN \u00b7 ORAL \u00b7 SCALP<\/b><\/p>\n

APPLICATION AREAS<\/b><\/p>\n

Three care areas, each with its own relevant evidence base.<\/b><\/p>\n

Botanical chemistry informs delivery engineering, delivery supports formulation design, and formulations translate the concept into three care areas.<\/p>\n

07 \u00b7 MECHANISM OVERVIEW<\/p>\n

Five pillars of cellular defense<\/b><\/h2>\n

WHY FIVE PILLARS?<\/b><\/p>\n

UV exposure, pollution, microorganisms and mechanical stress can occur together and converge on shared cellular mechanisms.<\/p>\n

Oleuropein research addresses this network from radical scavenging to cellular quality control.<\/p>\n

Mechanisms and supporting evidence are reviewed below.<\/b><\/p>\n

REDOX DEFENSE<\/b><\/p>\n

Direct radical scavenging and support for endogenous antioxidant systems.<\/p>\n

INFLAMMATORY MODULATION<\/b><\/p>\n

Modulation of NF-\u03baB-related signaling and key inflammatory mediators.<\/p>\n

CELLULAR QUALITY CONTROL<\/b><\/p>\n

Autophagy and proteostasis pathways involving AMPK, mTORC1, SIRT1 and TFEB.<\/p>\n

TISSUE REPAIR<\/b><\/p>\n

Support for re-epithelialization, collagen deposition and VEGF signaling.<\/p>\n

MICROBIAL BALANCE<\/b><\/p>\n

Published inhibitory activity against biofilm-forming, cariogenic oral bacteria.<\/p>\n

Mechanistic framework: Nediani C, et al. Antioxidants. 2019;8(12):578.<\/p>\n

07 \u00b7 MECHANISM: REDOX DEFENSE<\/p>\n

Quantifying radical-scavenging activity<\/b><\/h2>\n

IN VITRO EVIDENCE<\/b><\/p>\n

Oleuropein scavenges DPPH radicals in a concentration-dependent manner, with a curve approaching that of the reference antioxidant ascorbic acid. Complementary ABTS assays also support anti-radical activity.<\/p>\n

CHEMICAL RATIONALE<\/p>\n

\u00b7 Catechol hydroxyl groups donate hydrogen atoms to neutralize radicals.<\/p>\n

\u00b7 The resulting ortho-quinone structure is resonance-stabilized.<\/p>\n

\u00b7 Hydrolysis releases hydroxytyrosol, contributing further activity.<\/p>\n

In vitro radical-scavenging activity provides a rationale for using PURISOME\u00ae delivery to improve contact with sites of UV- and pollution-related oxidative stress.<\/p>\n

\"\"<\/p>\n

DPPH radical-scavenging activity: oleuropein (\u25cf) versus ascorbic acid (\u25cb, reference). Perugini P, et al. Int J Cosmet Sci. 2008;30(2):113\u2013120.<\/p>\n

Dose-dependent radical scavenging is the first mechanistic step, upstream of inflammation, barrier damage and visible aging.<\/p>\n

07 \u00b7 MECHANISM: INFLAMMATORY MODULATION<\/p>\n

Interrupting the oxidative stress\u2013inflammation cycle<\/b><\/h2>\n

\"\"<\/p>\n

Oxidative stress\u2013autophagy\u2013inflammation network. The indicated molecular markers are discussed in the oleuropein literature. Adapted from Nediani C, et al. Antioxidants. 2019;8(12):578.<\/p>\n

NF-\u03baB SIGNALING<\/b><\/p>\n

Modulated upstream of cytokine-cascade amplification.<\/b><\/p>\n

COX-2 AND iNOS<\/b><\/p>\n

These inflammatory enzymes are downregulated in experimental models.<\/p>\n

IL-6 \u00b7 TNF-\u03b1 \u00b7 IL-1\u03b2<\/b><\/p>\n

Key inflammatory mediators are reduced in cellular and tissue studies.<\/p>\n

ICAM-1 \u00b7 VCAM-1<\/b><\/p>\n

Reduced adhesion-molecule expression is associated with less immune-cell recruitment and inflammation.<\/p>\n

Oleuropein acts at the oxidative entry point of the cycle, providing an upstream intervention rationale.<\/p>\n

07 \u00b7 MECHANISM: CELLULAR QUALITY CONTROL<\/p>\n

Autophagy as a quality-control mechanism<\/b><\/h2>\n

Autophagy is the cellular recycling system that identifies and clears damaged proteins and organelles. Oleuropein has been reported as an autophagy inducer in several experimental models.<\/p>\n

01<\/b><\/p>\n

STRESS SENSING<\/b><\/p>\n

AMPK activation increases, while the mTORC1 brake on autophagy is reduced.<\/p>\n

AMPK \u2191 \u00b7 mTORC1 \u2193<\/b><\/p>\n

02<\/b><\/p>\n

AUTOPHAGY INITIATION<\/b><\/p>\n

Beclin-1 participates; LC3-I converts to LC3-II as autophagosomes form.<\/p>\n

Beclin-1 \u00b7 LC3-II \u2191<\/b><\/p>\n

03<\/b><\/p>\n

SUBSTRATE CLEARANCE<\/b><\/p>\n

p62 directs damaged proteins and organelles toward lysosomal degradation.<\/p>\n

p62 turnover \u2191<\/b><\/p>\n

04<\/b><\/p>\n

CELLULAR RENEWAL<\/b><\/p>\n

SIRT1 and TFEB support lysosomal biogenesis and cellular renewal.<\/p>\n

SIRT1 \u00b7 TFEB \u2191<\/b><\/p>\n

This cellular clearance mechanism provides a distinctive basis for botanical active development.<\/p>\n

Autophagy markers: Nediani C, et al. Antioxidants. 2019;8(12):578. doi:10.3390\/antiox8120578<\/p>\n

07 \u00b7 MECHANISM: PROTEOSTASIS<\/p>\n

Proteostasis support for lasting skin quality<\/b><\/h2>\n

\"\"<\/p>\n

THE PROTEOSTASIS PERSPECTIVE<\/b><\/p>\n

The proteostasis network, including synthesis, folding, repair and degradation, maintains functional proteins. Under chronic environmental stress, damaged material can accumulate faster than cells can clear it.<\/p>\n

Oleuropein is positioned on both sides of this balance: antioxidant defense slows damage formation, while autophagy induction supports clearance.<\/p>\n

Formulation implication: ingredients that support cellular quality control provide a rationale for long-term skin resilience as well as repair.<\/p>\n

Proteostasis and autophagy framework: Nediani C, et al. Antioxidants. 2019;8(12):578.<\/p>\n

08 \u00b7 SKINCARE: HUMAN EVIDENCE<\/p>\n

Human evidence under UVB stress<\/b><\/h2>\n

STUDY DESIGN<\/b><\/p>\n

MODEL<\/b><\/p>\n

UVB-induced erythema in human volunteers, a controlled photobiology challenge model.<\/p>\n

TEST FORMULATIONS<\/b><\/p>\n

Topical oleuropein emulsions and emulgels applied after UVB exposure.<\/p>\n

REFERENCE<\/b><\/p>\n

Vitamin E, a topical antioxidant benchmark.<\/b><\/p>\n

OBJECTIVE ENDPOINTS<\/b><\/p>\n

\u00b7 Erythema index: reflectance colorimetry<\/p>\n

\u00b7 TEWL: transepidermal water loss<\/p>\n

\u00b7 Skin blood flow: laser Doppler flowmetry<\/p>\n

WHY THE DESIGN MATTERS<\/b><\/p>\n

The controlled UVB challenge uses objective biophysical measurements in human volunteers rather than self-assessment.<\/p>\n

It evaluates whether the test formulations can help limit redness and preserve barrier function after a defined oxidative challenge.<\/p>\n

Perugini P, et al. Int J Cosmet Sci. 2008;30(2):113\u2013120. doi:10.1111\/j.1468-2494.2007.00416.x<\/p>\n

08 \u00b7 SKINCARE: HUMAN EVIDENCE<\/p>\n

Approximately 35% lower TEWL after UVB exposure<\/b><\/h2>\n

\u201335%<\/b><\/p>\n

TEWL: measurable preservation of barrier function<\/b><\/p>\n

\u201322%<\/b><\/p>\n

Erythema index: reduced visible redness<\/b><\/p>\n

\u201330%<\/b><\/p>\n

Skin blood flow: reduced hyperemic response<\/b><\/p>\n

Approximate mean reductions versus the UVB-exposed control, for oleuropein emulsions and emulgels. Perugini P, et al. Int J Cosmet Sci. 2008;30(2):113\u2013120.<\/p>\n

\"\"<\/p>\n

Transepidermal water loss (TEWL)<\/b><\/p>\n

\"\"<\/p>\n

Erythema index (colorimetry)<\/b><\/p>\n

\"\"<\/p>\n

Blood flow (laser Doppler)<\/b><\/p>\n

Three instrumental endpoints support reduced redness, barrier disruption and vascular response under the tested conditions.<\/p>\n

08 \u00b7 SKINCARE: HUMAN EVIDENCE<\/p>\n

From acute photostress to photoaging care<\/b><\/h2>\n

\"\"<\/p>\n

The controlled UVB study provides a rationale for daily photoaging care. Longer-term human data on an olive leaf extract cream extend the evidence beyond an acute challenge.<\/p>\n

LONGER-TERM HUMAN DATA: OLIVE LEAF EXTRACT CREAM<\/b><\/p>\n

36 female volunteers; twice daily for 2 months:<\/p>\n

\u00b7 TEWL decreased significantly (p = 0.007), with the effect maintained 1 month after discontinuation.<\/p>\n

\u00b7 Skin hydration increased (p = 0.004).<\/p>\n

\u00b7 Wrinkle parameters improved (p < 0.001).<\/p>\n

\"\"<\/p>\n

Visioscan\u00ae skin surface images: baseline (A), 1 month (B), 2 months (C), and 1 month after discontinuation (D).<\/p>\n

Wanitphakdeedecha R, et al. J Cosmet Dermatol. 2020. doi:10.1111\/jocd.13457<\/p>\n

08 \u00b7 SKINCARE: PRECLINICAL EVIDENCE<\/p>\n

Tissue repair and matrix renewal<\/b><\/h2>\n

\"\"<\/p>\n

Van Gieson staining of collagen deposition in healing skin: oleuropein-treated versus control groups. Mehraein F, et al. Cell J. 2014;16(1):25\u201330.<\/p>\n

\"\"<\/p>\n

VEGF protein expression by Western blot: oleuropein group (Tg) versus control group (Cg).<\/p>\n

Increased VEGF supports microvascular supply to repairing tissue and provides a mechanistic link with matrix renewal.<\/p>\n

RESULTS IN AN AGED-SKIN MODEL<\/b><\/p>\n

Wound closure at day 3: 29.0% versus 19.2% in controls.<\/p>\n

At day 7: 55.3% versus 45.3% in controls.<\/p>\n

Re-epithelialization was complete by day 7 in treated skin.<\/b><\/p>\n

Collagen deposition increased; VEGF increased (p < 0.05).<\/b><\/p>\n

Patent support: EP2570124A1 covers oleuropein compositions for repair of aged and fragile skin.<\/p>\n

Intradermal model in aged mice: preclinical evidence, not a human efficacy claim.<\/p>\n

08 \u00b7 SKINCARE: HUMAN AND IN VITRO EVIDENCE<\/p>\n

Even skin tone: observations in melanin biology<\/b><\/h2>\n

\"\"<\/p>\n

Melanin content in primary human melanocytes (in vitro).<\/b><\/p>\n

\"\"<\/p>\n

Intracellular glutathione (in vitro).<\/b><\/p>\n

\"\"<\/p>\n

Age-spot melanin index versus baseline (D0) in a 12-week human study.<\/p>\n

\"\"<\/p>\n

Placebo versus test product at week 12.<\/b><\/p>\n

IN VITRO: HUMAN MELANOCYTES<\/b><\/p>\n

Melanin content decreased by up to approximately 65%, while intracellular glutathione increased by 55%, supporting the cellular redox-buffering system.<\/p>\n

HUMAN STUDY: AGE SPOTS<\/b><\/p>\n

In a 12-week double-blind, placebo-controlled study of 12 women aged 46\u201372 years, the age-spot melanin index decreased by 34.8% at week 12 versus baseline, with visible lightening.<\/p>\n

The source connects skin-tone care with the redox rationale used for barrier defense.<\/p>\n

Standardized olive polyphenol extract. Lueder M. Cosmet Sci Technol. 2011.<\/p>\n

09 \u00b7 ORAL CARE<\/p>\n

The mouth: a redox\u2013microbial ecosystem<\/b><\/h2>\n

Biofilms reform within hours, saliva continuously dilutes actives, and soft tissues face daily mechanical, chemical and microbial stress. Oral care therefore requires both suitable chemistry and effective delivery.<\/p>\n

BIOFILM AND PLAQUE<\/b><\/p>\n

Bacterial biofilms drive plaque accumulation and acid challenges. Daily biofilm control provides an application opportunity for polyphenols.<\/p>\n

GINGIVAL ENVIRONMENT<\/b><\/p>\n

The gingival margin lies at the intersection of microbial and oxidative stress. Redox support and inflammatory modulation provide relevant development pathways.<\/p>\n

SOFT-TISSUE REPAIR<\/b><\/p>\n

Mucosal tissues face daily irritation and discomfort after care procedures. Repair support is a relevant consumer-care concept.<\/p>\n

Three application opportunities share the same polyphenol rationale: antioxidant activity, inflammatory modulation and microbial inhibition.<\/p>\n

09 \u00b7 ORAL CARE: IN VITRO EVIDENCE<\/p>\n

Published activity against key oral bacteria<\/b><\/h2>\n

\"\"<\/p>\n

In vitro data support a biofilm-management concept and do not constitute therapeutic claims.<\/p>\n

Karygianni L, et al. Biomed Res Int. 2014;2014:839019. doi:10.1155\/2014\/839019.<\/p>\n

S. mutans: Golestannejad Z, et al. Dent Res J (Isfahan). 2020;17(3):179\u2013185. doi:10.4103\/1735-3327.284730 (acid production and adhesion: p < 0.001).<\/p>\n

09 \u00b7 ORAL CARE: HUMAN EVIDENCE<\/p>\n

Biofilm management beyond disinfection<\/b><\/h2>\n

PLAQUE REGROWTH: CROSSOVER CONTROLLED STUDY, N = 17<\/b><\/p>\n

36% lower plaque index versus water rinsing<\/b><\/p>\n

After rinsing with a virgin olive oil preparation containing oleuropein, the plaque index was 1.48 \u00b1 0.36 versus 2.30 \u00b1 0.39 with water (p < 0.001), measured in a plaque-regrowth crossover design.<\/p>\n

Volunteers suspended oral hygiene and underwent objective plaque-regrowth scoring, providing a direct measure of biofilm management under the study conditions.<\/p>\n

Math MV, et al. Int J Dent Health Sci. 2017;4(4).<\/b><\/p>\n

THE POLYPHENOL RATIONALE FOR BIOFILM CARE<\/b><\/p>\n

INTERFERING WITH ADHESION<\/b><\/p>\n

Olive leaf polyphenols reduce S. mutans surface adhesion (p < 0.001).<\/p>\n

MODULATING ACID PRODUCTION<\/b><\/p>\n

Reduced acid production by cariogenic bacteria supports a daily-care rationale relevant to enamel.<\/p>\n

REDOX SUPPORT AT THE GINGIVAL MARGIN<\/b><\/p>\n

Antioxidant activity at the biofilm\u2013gingiva interface provides a rationale for comfort-oriented care.<\/p>\n

Golestannejad Z, et al. Dent Res J (Isfahan). 2020;17(3):179\u2013185.<\/p>\n

09 \u00b7 ORAL CARE: CLINICAL AND PRECLINICAL EVIDENCE<\/p>\n

Oral soft-tissue defense: cytokines and comfort<\/b><\/h2>\n

\"\"<\/p>\n

Mucosal histopathology scores over time: oleuropein versus controls in a mucositis model.<\/p>\n

\"\"<\/p>\n

Tissue MDA, a marker of oxidative damage: oleuropein versus controls (reported p = 0.000).<\/p>\n

CLINICAL: RANDOMIZED CROSSOVER TRIAL, 25 PATIENTS<\/b><\/p>\n

Olive leaf extract mouthwash reduced salivary IL-1\u03b2 and TNF-\u03b1 and was associated with lower mucositis severity scores in chemotherapy patients.<\/p>\n

PRECLINICAL: MUCOSITIS MODEL<\/b><\/p>\n

Oleuropein ointment reduced histopathology scores and tissue MDA (reported p = 0.000), indicating less tissue damage and oxidative stress in the experimental mucosal challenge.<\/p>\n

Positioning: supportive oral care and comfort. Use adjunctive wording rather than therapeutic claims.<\/p>\n

Ahmed KM. Saudi Dent J. 2013;25(4):141\u2013147. doi:10.1016\/j.sdentj.2013.09.001.<\/p>\n

Showraki N, et al. J Dent (Shiraz). 2016;17(4):334\u2013342.<\/p>\n

09 \u00b7 ORAL CARE: DELIVERY SCIENCE<\/p>\n

Why delivery matters in oral care<\/b><\/h2>\n

FOUR ORAL-ENVIRONMENT CHALLENGES<\/b><\/p>\n

Continuous dilution: saliva washes actives away.<\/b><\/p>\n

Short contact time: rinsing lasts minutes rather than hours.<\/p>\n

Oxidative exposure: polyphenols are vulnerable to degradation in aqueous systems.<\/p>\n

Dosage-form constraints: clear rinses, gels and pastes have different formulation requirements.<\/p>\n

THE PURISOME\u00ae APPROACH<\/b><\/p>\n

\u00b7 Vesicles protect polyphenols within the formulation.<\/p>\n

\u00b7 Controlled release aims to extend availability after use.<\/p>\n

\u00b7 The dispersion format suits rinses, gels and pastes.<\/p>\n

SUPPORTING LITERATURE<\/b><\/p>\n

Liposomal encapsulation of olive leaf polyphenols preserved, and under some conditions enhanced, antibacterial activity against S. aureus, including MRSA (MIC 140\u2013240 \u00b5g\/mL). Vesicles remained stable for up to 90 days at 4 \u00b0C.<\/p>\n

Prevete G, et al. ACS Appl Mater Interfaces. 2024;16(50):68850\u201368863. doi:10.1021\/acsami.4c13302<\/p>\n

10 \u00b7 HAIR AND SCALP CARE<\/p>\n

The scalp: a stressed follicular environment<\/b><\/h2>\n

The scalp is skin with approximately 100,000 follicles, abundant sebum and direct UV exposure, creating a concentrated set of environmental challenges.<\/p>\n

PHOTOSTRESS<\/b><\/p>\n

UV exposure is particularly relevant at partings and areas of thinning hair.<\/p>\n

SEBUM OXIDATION<\/b><\/p>\n

Lipid peroxidation at follicular openings increases the oxidative load.<\/p>\n

MICROBIAL PRESSURE<\/b><\/p>\n

A dense, sebum-supported microbial community contributes to ongoing surface challenges.<\/p>\n

FOLLICULAR CYCLE<\/b><\/p>\n

Transition into anagen is sensitive to oxidative and inflammatory signaling.<\/p>\n

Scalp care can draw on the same defensive mechanisms relevant to skin care.<\/p>\n

10 \u00b7 HAIR AND SCALP CARE<\/p>\n

Oleuropein as a rationale for scalp resilience<\/b><\/h2>\n

REDOX DEFENSE<\/b><\/p>\n

Radical scavenging at the scalp surface, where sebum oxidation and UV exposure converge.<\/p>\n

Supporting evidence: in vitro and human skin data.<\/b><\/p>\n

INFLAMMATORY MODULATION<\/b><\/p>\n

A rationale for perifollicular comfort through modulation of inflammatory mediators.<\/p>\n

Supporting evidence: mechanistic studies and human oral-care data.<\/p>\n

MICROBIAL BALANCE<\/b><\/p>\n

Published antibacterial activity against biofilm-forming organisms.<\/p>\n

Supporting evidence: in vitro MIC data.<\/b><\/p>\n

QUALITY CONTROL<\/b><\/p>\n

Autophagy support as a concept for rapidly dividing cells in the follicular environment.<\/p>\n

Supporting evidence: mechanistic literature.<\/b><\/p>\n

FOLLICULAR SIGNALING<\/b><\/p>\n

Wnt\/\u03b2-catenin activation in dermal papilla cells, detailed below.<\/p>\n

Supporting evidence: preclinical data.<\/b><\/p>\n

Each scalp-care pillar is presented with its supporting evidence type.<\/p>\n

10 \u00b7 HAIR AND SCALP: PRECLINICAL EVIDENCE<\/p>\n

Follicular biology: Wnt\/\u03b2-catenin activation<\/b><\/h2>\n

\"\"<\/p>\n

Nanovesicle enrichment through the follicular route: a PURISOME\u00ae delivery concept.<\/p>\n

HUMAN DERMAL PAPILLA CELLS: IN VITRO<\/b><\/p>\n

Oleuropein promoted dermal papilla cell proliferation, increased LEF1 and Cyclin D1, and drove nuclear \u03b2-catenin accumulation, consistent with Wnt pathway activation.<\/p>\n

TELOGEN MOUSE MODEL: TOPICAL APPLICATION FOR 28 DAYS<\/b><\/p>\n

Anagen entry accelerated, with larger and more numerous follicles. Wnt10b, FzdR1, LRP5, IGF-1, KGF, HGF and VEGF increased in skin tissue.<\/p>\n

Evidence level: preclinical. These findings support scalp-care positioning and further development, not a human hair-growth claim.<\/p>\n

Tong T, Kim N, Park T. PLoS ONE. 2015;10(6):e0129578. doi:10.1371\/journal.pone.0129578<\/p>\n

11 \u00b7 APPLICATIONS<\/p>\n

Three application areas, one technology platform<\/b><\/h2>\n

SKINCARE<\/b><\/p>\n

DEFENSE AND REPAIR<\/b><\/p>\n

\u00b7 Human UVB study: TEWL \u201335%; erythema \u201322%.<\/p>\n

\u00b7 Photoaging care: TEWL p = 0.007; wrinkles p < 0.001.<\/p>\n

\u00b7 Even tone: age-spot melanin index \u201334.8%.<\/p>\n

\u00b7 Tissue repair: preclinical wound models.<\/p>\n

ORAL CARE<\/b><\/p>\n

BIOFILM AND SOFT-TISSUE BALANCE<\/b><\/p>\n

\u00b7 Antibacterial activity: published MIC\/MBC values.<\/p>\n

\u00b7 Human crossover study: plaque regrowth \u201336%.<\/p>\n

\u00b7 Clinical rinse study: reduced salivary IL-1\u03b2 and TNF-\u03b1.<\/p>\n

\u00b7 Mucosal comfort: preclinical mucositis model.<\/p>\n

HAIR AND SCALP<\/b><\/p>\n

RESILIENCE AND FOLLICULAR SUPPORT<\/b><\/p>\n

\u00b7 Wnt\/\u03b2-catenin activation: preclinical.<\/p>\n

\u00b7 Follicular delivery: PURISOME\u00ae concept.<\/p>\n

\u00b7 Redox and microbial rationale: evidence from skin and oral studies.<\/p>\n

One ingredient concept connects three care areas through a shared scientific rationale.<\/p>\n

11 \u00b7 APPLICATIONS<\/p>\n

From ingredient to formulation: product concepts<\/b><\/h2>\n

SKINCARE<\/b><\/p>\n

Daily defense serum<\/p>\n

After-sun repair emulgel<\/p>\n

Even-tone concentrate<\/p>\n

Barrier-support lotion<\/p>\n

Informed by human UVB, photoaging and skin-tone studies.<\/b><\/p>\n

ORAL CARE<\/b><\/p>\n

Daily defense mouthwash<\/p>\n

Gingival-care gel<\/p>\n

Biofilm-management toothpaste<\/p>\n

Soothing rinse after care procedures<\/p>\n

Informed by antibacterial, plaque and cytokine evidence.<\/b><\/p>\n

HAIR AND SCALP<\/b><\/p>\n

Pre-wash scalp concentrate<\/p>\n

Leave-on scalp serum<\/p>\n

Clarifying antioxidant shampoo<\/p>\n

Informed by preclinical follicular data and the scalp-stress rationale.<\/p>\n

These are concepts for joint development. Final product claims require testing of the finished formulation.<\/p>\n

11 \u00b7 APPLICATIONS<\/p>\n

NanoActive Oleu™ formulation guidance<\/b><\/h2>\n

HANDLING PRINCIPLES<\/b><\/p>\n

Supplied as an aqueous liposomal dispersion, with no reconstitution required.<\/p>\n

Add during cool-down. Avoid prolonged high shear to protect vesicle integrity.<\/p>\n

Suitable formulation areas include emulsions, serums, gels and oral-care systems.<\/p>\n

Use mild temperatures and pH conditions; validate the preservative system in the complete formulation.<\/p>\n

Detailed specifications, recommended use levels and starter formulations are available from PuriPharm technical services.<\/p>\n

WORKING WITH PURIPHARM<\/b><\/p>\n

Ingredient supply with joint development support.<\/b><\/p>\n

PuriPharm provides application expertise, formulation guidance and supporting evidence documentation, from the first prototype to market-registration materials.<\/p>\n

Contact PuriPharm Co., Ltd. for technical services and joint development.<\/p>\n

NANOACTIVE OLEU™ LIPOSOMAL OLEUROPEIN<\/p>\n

Protect \u00b7 Balance \u00b7 Renew<\/b><\/h2>\n

PHYTOCHEMISTRY: oleuropein-rich Mediterranean polyphenols<\/p>\n

DELIVERY: PURISOME\u00ae FlexVes™ Liposome Technology<\/p>\n

EVIDENCE: published human, in vivo and mechanistic studies<\/p>\n

PARTNERSHIP: joint development with PuriPharm Co., Ltd.<\/p>\n

NanoActive Oleu™<\/p>\n

Powered by PURISOME\u00ae FlexVes™ Liposome Technology<\/p>\n

PuriPharm Co., Ltd.<\/p>\n

REFERENCES<\/p>\n

Key references<\/b><\/h2>\n

01 Perugini P, et al. Lenitive effect of oleuropein on UVB-induced erythema. Int J Cosmet Sci. 2008;30(2):113\u2013120. doi:10.1111\/j.1468-2494.2007.00416.x<\/p>\n

02 Nediani C, et al. Oleuropein, autophagy and oxidative stress\u2013inflammation interplay. Antioxidants. 2019;8(12):578. doi:10.3390\/antiox8120578<\/p>\n

03 Wanitphakdeedecha R, et al. Olive leaf extract cream: TEWL, hydration and wrinkle outcomes. J Cosmet Dermatol. 2020. doi:10.1111\/jocd.13457<\/p>\n

04 Mehraein F, et al. Oleuropein and skin tissue recovery in an aged-mouse model. Cell J. 2014;16(1):25\u201330.<\/p>\n

05 Lueder M. Standardized olive polyphenol extract: melanin, glutathione and age-spot studies. Cosmet Sci Technol. 2011.<\/p>\n

06 Karygianni L, et al. Olive leaf extract against oral pathogens. Biomed Res Int. 2014;2014:839019. doi:10.1155\/2014\/839019<\/p>\n

07 Golestannejad Z, et al. Olive leaf extract vs Streptococcus mutans. Dent Res J (Isfahan). 2020;17(3):179\u2013185. doi:10.4103\/1735-3327.284730<\/p>\n

08 Math MV, et al. Plaque regrowth crossover with virgin olive oil rinse. Int J Dent Health Sci. 2017;4(4).<\/p>\n

09 Ahmed KM. Olive leaf extract mouth rinse: IL-1\u03b2, TNF-\u03b1 and mucositis severity. Saudi Dent J. 2013;25(4):141\u2013147. doi:10.1016\/j.sdentj.2013.09.001<\/p>\n

10 Showraki N, et al. Oleuropein in a chemotherapy-induced mucositis model. J Dent (Shiraz). 2016;17(4):334\u2013342.<\/p>\n

11 Tong T, Kim N, Park T. Oleuropein and hair-follicle Wnt\/\u03b2-catenin signaling. PLoS ONE. 2015;10(6):e0129578. doi:10.1371\/journal.pone.0129578<\/p>\n

12 Prevete G, et al. Liposomal encapsulation of olive leaf polyphenols. ACS Appl Mater Interfaces. 2024;16(50):68850\u201368863. doi:10.1021\/acsami.4c13302<\/p>\n

13 Omar SH. Oleuropein in olive and its pharmacological effects. Sci Pharm. 2010;78(2):133\u2013154.<\/p>\n

14 EP2570124A1. Oleuropein compositions for healing wounds and ulcers in elderly people and\/or diabetics.<\/p>\n

These references concern oleuropein or olive leaf preparations in published studies and patent documents. Evidence types are identified in the relevant sections. PURISOME\u00ae, FlexVes™, NanoActive™ and Oleu™ are trademarks of PuriPharm Co., Ltd.<\/p>\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\n\t\t\n\t<\/div>\n\n<\/article>\n\n\t\n\t\t\n

\n\n\t\n\t
\n\n\t\t\n\t\t
\n\t\t\t\n\t\t\t

PuriActives\u00ae AlgiSulf<\/a><\/h1>\n\n\t\t\t\t\t\t\t
\n\t\t\t\t\tPosted on L, Y<\/a><\/span><\/span> \t\t\t\t<\/div>\n\t\t\t\n\t\t<\/header>\n\n\t\t\t\t\t
\n\t\t\t\t

PuriActives\u00ae AlgiSulf<\/b><\/h2>\n

PURIPHARM CO., LTD.<\/b><\/p>\n

Sodium Algin Sulfate \u00b7 INCI: SODIUM ALGIN SULFATE<\/b><\/p>\n

Marine sulfated polysaccharide technology for premium skin and scalp care<\/p>\n

For cosmetic formulators, R&D scientists, innovation teams and brand developers \u00b7 www.puriactives.com<\/p>\n

OVERVIEW<\/p>\n

From marine chemistry to skin and scalp applications<\/b><\/h2>\n

PuriActives\u00ae AlgiSulf (INCI: Sodium Algin Sulfate) is a marine-derived sulfated polysaccharide built on a brown-algal alginate backbone.<\/p>\n

This article reviews alginate sulfation chemistry, structure\u2013activity relationships and published evidence relevant to moisturization, barrier support, soothing, antioxidant activity and extracellular matrix care, with extensions to scalp health and hair conditioning.<\/p>\n

Research findings are integrated into the mechanisms described below. Source notes accompany each section, with the reference list at the end.<\/p>\n

I \u00b7 SCIENTIFIC FOUNDATIONS<\/b><\/p>\n

Marine polysaccharide science<\/p>\n

Product introduction and INCI identity<\/p>\n

Alginate structure and sulfation<\/p>\n

Structure\u2013activity relationships<\/p>\n

Integrated mechanisms<\/p>\n

II \u00b7 SKIN APPLICATIONS<\/b><\/p>\n

Skin moisturization and conditioning<\/p>\n

Skin barrier support<\/p>\n

Soothing and inflammatory pathways<\/p>\n

Antioxidant protection<\/p>\n

Skin aging and the extracellular matrix<\/p>\n

Key scientific evidence<\/p>\n

III \u00b7 SCALP AND HAIR<\/b><\/p>\n

Rationale for scalp care<\/p>\n

Scalp hydration and comfort<\/p>\n

Scalp oxidative stress<\/p>\n

Hair conditioning<\/p>\n

Skin\u2013scalp synergy<\/p>\n

IV \u00b7 APPLICATIONS<\/b><\/p>\n

Technical properties<\/p>\n

Formulation and processing<\/p>\n

Application areas<\/p>\n

Evidence matrix<\/p>\n

Value proposition and references<\/p>\n

01 \u00b7 MARINE SCIENCE<\/p>\n

Brown-algal chemistry refined through sulfation<\/b><\/h2>\n

\"\"<\/p>\n

Kelp forests: source ecosystems for brown-algal polysaccharides<\/p>\n

Marine algae produce structurally distinctive carbohydrates. Brown algae (Phaeophyceae) use alginate in cell walls and intercellular matrices. This linear polyuronide provides both strength and flexibility in moving seawater.<\/p>\n

Marine sulfated polysaccharides, including fucoidan, carrageenan and ulvan, have been widely studied for skin-related benefits. Associations between sulfate content and biological activity are frequently reported.<\/p>\n

MARINE CARBOHYDRATE LANDSCAPE<\/b><\/p>\n

\"\"<\/p>\n

Sodium Algin Sulfate combines an alginate backbone with sulfation characteristic of marine polysaccharides.<\/p>\n

Sources: Ngo & Kim, Int. J. Biol. Macromol. 2013; Kim et al., Mar. Drugs 2018.<\/p>\n

02 \u00b7 PRODUCT IDENTITY<\/p>\n

One ingredient for skin and scalp care<\/b><\/h2>\n

PuriActives\u00ae AlgiSulf is the sodium salt of sulfated alginic acid: a water-soluble anionic polysaccharide produced by controlled sulfation of brown-algal alginate.<\/p>\n

Sulfate half-esters introduced onto the uronic-acid backbone increase anionic charge density, giving the structural polymer glycosaminoglycan-like and heparin-like biological interaction properties.<\/p>\n

FUNCTIONAL PROFILE<\/b><\/p>\n

\u25cf Moisturization and film formation: the hydroxyl-rich polyuronide binds water at the skin surface.<\/p>\n

\u25cf Soothing and antioxidant properties: chemokine affinity and sulfation-associated radical scavenging.<\/p>\n

\u25cf ECM biomimetic support: heparin-like affinity for matrix-related proteins.<\/p>\n

\u25cf Skin and scalp versatility: one INCI for facial, scalp and hair applications.<\/p>\n

PRODUCT IDENTIFICATION<\/b><\/p>\n

\"\"<\/p>\n

Distinct from unmodified alginate (INCI: Algin \/ Sodium Alginate), which contains no sulfate groups.<\/p>\n

Source: Arlov & Skj\u00e5k-Br\u00e6k. Molecules 2017;22:778.<\/p>\n

03 \u00b7 MOLECULAR STRUCTURE<\/p>\n

The alginate backbone and what sulfation changes<\/b><\/h2>\n

\"\"<\/p>\n

Schematic: (1\u21924)-linked \u03b2-D-mannuronic acid (M) and \u03b1-L-guluronic acid (G) residues. Gold bonds indicate sulfate half-esters at C2\/C3 hydroxyl groups.<\/p>\n

\"\"<\/p>\n

Published figure: chemical sulfation routes for alginate M\/G residues (HClSO\u2083\/formamide; SO\u2083\/pyridine; H\u2082SO\u2084\/DMF). Arlov & Skj\u00e5k-Br\u00e6k. Molecules 2017;22:778 (CC BY).<\/p>\n

BACKBONE STRUCTURE<\/b><\/p>\n

Alginate is a linear copolymer of M and G units arranged in MM, GG and alternating MG blocks. Block composition affects chain flexibility and ion binding. G blocks associate around Ca\u00b2\u207a to form the classic \u201cegg-box\u201d gel structure.<\/p>\n

SULFATION CHEMISTRY<\/b><\/p>\n

Chemical sulfation converts C2\/C3 hydroxyl groups into sulfate half-esters (\u2013O\u2013SO\u2083\u207bNa\u207a), introducing additional anionic groups on the residues and producing a strongly acidic polyelectrolyte with a heparin-like spatial charge distribution.<\/p>\n

Sources: Arlov & Skj\u00e5k-Br\u00e6k. Molecules 2017. DOI: 10.3390\/molecules22050778; Mutch et al. 2024.<\/p>\n

04 \u00b7 STRUCTURE\u2013ACTIVITY RELATIONSHIPS<\/p>\n

Degree of sulfation shapes biological properties<\/b><\/h2>\n

Charge density influences protein affinity. Greater sulfation increases anionic charge along the chain and strengthens interactions with heparin-binding proteins, including growth factors, chemokines and coagulation factors (Biomacromolecules 2014).<\/p>\n

Radical scavenging increases with sulfation. In human chondrocyte and macrophage models, superoxide scavenging by sulfated alginate correlates directly with the degree of substitution: more sulfate groups produce a stronger antioxidant response (Biomater. Sci. 2017).<\/p>\n

Sequence and molecular weight regulate performance. M\/G composition, block length and molecular weight shape chain conformation, flexibility and binding geometry. Sequence-defined samples show measurable differences in heparin-like behavior (Molecules 2017).<\/p>\n

SODIUM ALGIN SULFATE VS UNMODIFIED SODIUM ALGINATE<\/b><\/p>\n

\"\"<\/p>\n

Sources: Arlov et al. Biomacromolecules 2014; Kerschenmeyer et al. Biomater. Sci. 2017.<\/p>\n

05 \u00b7 MECHANISMS<\/p>\n

Integrated mechanisms of action<\/b><\/h2>\n

\"\"<\/p>\n

Sodium Algin Sulfate<\/p>\n

Anionic sulfated polyuronide<\/p>\n

HYDRATION AND FILM FORMATION<\/p>\n

Hydroxyl and ionic groups bind water. The polymer forms a flexible, breathable conditioning film at the surface.<\/p>\n

SOOTHING SIGNALS<\/p>\n

Heparin-like affinity can sequester pro-inflammatory chemokines (IL-8, MCP-1) and modulate inflammatory cell behavior.<\/p>\n

ANTIOXIDANT DEFENSE<\/p>\n

Sulfate-rich chains scavenge superoxide radicals in a sulfation-dependent manner.<\/p>\n

ECM BIOMIMETIC SUPPORT<\/p>\n

Glycosaminoglycan-like interactions with matrix proteins and growth factors (FGF-2, VEGF, TGF-\u03b21) support the dermal matrix environment.<\/p>\n

One anionic backbone provides four complementary mechanisms relevant to skin and scalp care.<\/p>\n

Sources: Huang et al. J. Nanobiotechnol. 2023; Freeman et al. Biomaterials 2008.<\/p>\n

06 \u00b7 SKIN APPLICATIONS: HYDRATION<\/p>\n

Skin moisturization and conditioning<\/b><\/h2>\n

The structure of sulfated polyuronides supports water management. Dense hydroxyl, carboxylate and sulfate groups form hydrogen-bonding and ion\u2013dipole interactions with water at the skin surface.<\/p>\n

MOLECULAR WATER BINDING<\/b><\/p>\n

Each residue carries hydroxyl groups, a carboxylate group and up to two sulfate half-esters. The source positions this as a high charge density among cosmetic polysaccharides, supporting hydrophilicity and moisture retention.<\/p>\n

SURFACE FILM<\/b><\/p>\n

Alginate materials have long been used in wound dressings for their ability to maintain a moist interface. As a topical film former, the polymer can reduce water loss and smooth surface roughness.<\/p>\n

SENSORY CONDITIONING<\/b><\/p>\n

Reviews of marine carbohydrates report moisturizing, soothing and anti-aging benefits of algal polysaccharides. Alginate-family materials are known for moisture-retaining protective films.<\/p>\n

FORMULATION IMPLICATIONS<\/b><\/p>\n

AlgiSulf can serve as a moisturizing framework in water-based serums, concentrates, gel masks and scalp treatments, providing hydration, slip and a soft-focus film without a heavy occlusive feel. Its anionic character also supports pairing with cationic conditioning complexes in rinse-off products.<\/p>\n

Sources: Kim et al. Mar. Drugs 2018;16:459; Yao & Xu. Polysaccharides 2022.<\/p>\n

07 \u00b7 SKIN APPLICATIONS: BARRIER<\/p>\n

Skin barrier support<\/b><\/h2>\n

Barrier care begins at the surface. A coherent, hydrated polymer film protects the compromised stratum corneum, while related chemical interactions may modulate inflammatory and oxidative signals that interfere with recovery.<\/p>\n

Moist protective interface. Alginate dressings maintain a moist, protected wound environment. Sulfated alginate hydrogels extend this platform in deep partial-thickness burn models, reducing excessive inflammation and supporting organized repair (preclinical).<\/p>\n

Fibroblast compatibility. Alginate sulfate showed no cytotoxicity in mouse and human fibroblasts at 0.5\u20132% w\/v, while reducing inflammatory mediator levels in the same cells. This provides a rationale for barrier-care development for reactive skin (in vitro).<\/p>\n

Bioadhesive residence. Alginate-family polymers exhibit mucoadhesion and bioadhesion, potentially extending surface film residence, a useful property for leave-on barrier products and overnight masks (material-class evidence).<\/p>\n

Barrier support through signaling. By binding IL-8 and MCP-1 and promoting a shift from M1 toward M2 macrophage phenotypes, sulfated alginate acts upstream of low-grade inflammation associated with disrupted barrier homeostasis (preclinical).<\/p>\n

Sources: Huang et al. J. Nanobiotechnol. 2023; Balde & Nazeer. Colloids Surf. B 2025.<\/p>\n

08 \u00b7 SKIN APPLICATIONS: SOOTHING<\/p>\n

Soothing and inflammatory pathways<\/b><\/h2>\n

Sulfated alginate mimics heparan sulfate. Its negative charge distribution attracts positively charged chemokine domains, potentially intercepting signals before inflammatory cells are recruited into tissue.<\/p>\n

\"\"<\/p>\n

Published figure: unmodified sodium alginate from E. amentacea suppresses LPS-induced IL-1\u03b2, IL-6, IL-8, TNF-\u03b1 and MCP-1 in THP-1 macrophages. Mar. Drugs 2026;24:41 (CC BY). DOI: 10.3390\/md24010041.<\/p>\n

CHEMOKINE SEQUESTRATION<\/b><\/p>\n

\u25cf Sulfated alginate hydrogel platforms have high affinity for IL-8 and MCP-1 and reduce inflammatory cell infiltration (preclinical).<\/p>\n

\u25cf Macrophage phenotypes shift from M1 toward M2, favoring resolution rather than escalation (preclinical).<\/p>\n

INFLAMMATORY MEDIATOR MODULATION<\/b><\/p>\n

\u25cf Alginate sulfate (0.5\u20132% w\/v) reduces inflammatory mediators in mouse and human fibroblasts and inhibits protein denaturation (in vitro).<\/p>\n

\u25cf Sulfated alginate hydrogels suppress IL-1\u03b2-induced inflammatory responses in human chondrocytes (in vitro).<\/p>\n

BACKBONE EVIDENCE: UNMODIFIED SODIUM ALGINATE<\/b><\/p>\n

For unmodified E. amentacea sodium alginate, reductions in THP-1 macrophages were IL-6: 46%; IL-8: 46%; MCP-1: 81%; TNF-\u03b1: 23%. iNOS inhibition in RAW 264.7 cells was 70\u201383%. These data describe the unsulfated backbone. The source separately proposes further enhancement through sulfation.<\/p>\n

Sources: Huang 2023; Balde 2025; Arlov 2017; Mar. Drugs 2026;24:41.<\/p>\n

09 \u00b7 SKIN APPLICATIONS: ANTIOXIDANT ACTIVITY<\/p>\n

Antioxidant protection<\/b><\/h2>\n

Reactive oxygen species contribute to skin aging and inflammation. Sulfation adds radical-scavenging activity to the alginate film platform, with activity increasing as sulfate content rises.<\/p>\n

\"\"<\/p>\n

Published figure: DPPH scavenging (a), ferric reducing power (b) and NO scavenging (c) of unmodified E. amentacea sodium alginate. Mar. Drugs 2026;24:41 (CC BY). DOI: 10.3390\/md24010041.<\/p>\n

SULFATION-DEPENDENT SCAVENGING<\/b><\/p>\n

Across sulfated alginate derivatives tested with human chondrocytes and macrophages, superoxide scavenging correlated directly with degree of sulfation, demonstrating a structure\u2013activity relationship (in vitro).<\/p>\n

The same study reported immunomodulatory effects, linking antioxidant activity with modulation of inflammatory signaling.<\/p>\n

MARINE SULFATED POLYSACCHARIDES AS RADICAL SCAVENGERS<\/b><\/p>\n

Sulfated polysaccharides from Laminaria japonica showed greater reducing power and radical scavenging at higher sulfate content and lower molecular weight. These are structural variables relevant to alginate sulfation (chemical assays).<\/p>\n

QUANTITATIVE BACKBONE DATA: SODIUM ALGINATE<\/b><\/p>\n

For the unsulfated backbone, DPPH scavenging reached 91% at 1.25 mg\/mL (IC\u2085\u2080 \u2248 0.410 mg\/mL). NO scavenging IC\u2085\u2080 was approximately 0.417 mg\/mL. Ferric reducing power increased with dose to A\u2087\u2080\u2080 = 1.06. The source cites sulfation literature as a rationale for exceeding this baseline; the plotted data concern unsulfated alginate (chemical assays).<\/p>\n

Sources: Kerschenmeyer 2017; Zhao et al. 2008; Mar. Drugs 2026;24:41.<\/p>\n

10 \u00b7 SKIN APPLICATIONS: AGING AND ECM<\/p>\n

Skin aging and the extracellular matrix<\/b><\/h2>\n

Sulfated glycosaminoglycans participate in dermal matrix functions. Sulfated alginate uses related sulfate-patterned protein interactions and was originally developed for tissue repair applications.<\/p>\n

\"\"<\/p>\n

Published figure: in vivo closure of deep partial-thickness burn wounds over days 0\u201321 using a tunable sulfated alginate hydrogel platform. Huang et al. J. Nanobiotechnol. 2023;21:305 (CC BY). DOI: 10.1186\/s12951-023-02144-2.<\/p>\n

GROWTH FACTOR AFFINITY<\/b><\/p>\n

Sulfated alginate hydrogels bind heparin-binding growth factors, including FGF-2, VEGF and TGF-\u03b21, with high affinity and provide sustained release, mimicking the ECM\u2019s storage of regenerative signals (in vitro).<\/p>\n

REPAIR KINETICS<\/b><\/p>\n

Connective tissue growth factor-loaded alginate sulfate nanoparticles achieved 79.49% wound closure at 72 hours with 5 \u00b5g\/mL CTGF, the fastest among the tested groups (in vitro scratch assay).<\/p>\n

ENZYME-RELATED PROTECTION: RELATED SULFATED POLYSACCHARIDES<\/b><\/p>\n

Marine sulfated polysaccharides from green and red algae inhibit elastase, collagenase and hyaluronidase in vitro, enzymes relevant to wrinkle formation and loss of firmness. The source uses this material-class behavior as a rationale for AlgiSulf\u2019s sulfate-rich surface.<\/p>\n

Sources: Freeman 2008; Karam 2024; Huang 2023; Falcao 2020.<\/p>\n

11 \u00b7 EVIDENCE REVIEW<\/p>\n

Key scientific evidence and quantitative findings<\/b><\/h2>\n

<\/p>\n

These studies used research-grade sulfated alginate or related sulfated polysaccharides. The findings characterize the material class and support the mechanistic rationale for PuriActives\u00ae AlgiSulf.<\/p>\n

SCALP & HAIR SCIENCE<\/p>\n

PART II \u00b7 SCALP AND HAIR SCIENCE<\/b><\/h2>\n

The scalp is skin.<\/p>\n

The hair shaft is keratin.<\/p>\n

Hydration, soothing and antioxidant mechanisms relevant to facial skin also inform scalp microenvironment care, with further applications based on the electrostatics of the keratin hair surface.<\/p>\n

12 \u00b7 RATIONALE FOR SCALP CARE<\/p>\n

The scientific rationale for scalp care<\/b><\/h2>\n

The scalp has dense follicles, greater sebum production and a resident microbiota, all relevant to hair condition. Common concerns, including tightness, itching, flaking and oiliness, involve hydration, barrier function and inflammation, areas relevant to sulfated polysaccharide research.<\/p>\n

SCALP STRESSORS<\/b><\/p>\n

\u25cf Sebum oxidation and UV exposure create oxidative stress in scalp skin and hair.<\/p>\n

\u25cf Malassezia metabolites, such as oleic acid, disrupt barrier homeostasis and promote flaking.<\/p>\n

\u25cf Surfactant cleansing and styling remove surface lipids and water.<\/p>\n

WHERE ALGISULF FITS<\/b><\/p>\n

\u25cf A moisturizing film addresses scalp dehydration and tightness.<\/p>\n

\u25cf Chemokine affinity provides a rationale for targeting the itch\u2013inflammation axis.<\/p>\n

\u25cf Sulfation-related radical scavenging may buffer oxidative stress.<\/p>\n

\u25cf A non-biocidal polymer approach is positioned for ongoing scalp care.<\/p>\n

PATENT PRECEDENT<\/b><\/p>\n

A patent claims sulfated polysaccharides as non-irritating anti-dandruff actives to prevent Malassezia-associated excessive flaking. Reconstructed skin data show complete suppression of oleic-acid-induced desquamation (EP2794012B1).<\/p>\n

This provides a cosmetic application precedent for sulfated polysaccharides in scalp care.<\/p>\n

<\/p>\n

Patent figure: the first page of EP2794012B1, claiming sulfated polysaccharides as cosmetic anti-dandruff actives (international classifications A61Q 5\/00 and A61K 8\/73).<\/p>\n

Sources: Tr\u00fceb. Int. J. Trichology 2009; EP2794012B1; DeAngelis et al. 2005.<\/p>\n

13 \u00b7 SCALP HYDRATION<\/p>\n

Scalp hydration and comfort<\/b><\/h2>\n

A dehydrated scalp can feel tight or itchy and show fine flaking after frequent washing. AlgiSulf\u2019s polymer-based rationale is to bind water, maintain a film and modulate associated signals.<\/p>\n

A surface water reservoir. The sulfate\u2013carboxylate\u2013hydroxyl network binds water without relying on heavy emollients, an important consideration for scalp products that should not weigh down hair.<\/p>\n

Comfort through chemokine modulation. IL-8 and MCP-1 help recruit inflammatory cells in irritated skin. Demonstrated sulfated alginate affinity for these chemokines provides a mechanistic route relevant to scalp comfort (preclinical).<\/p>\n

A non-stripping approach to flaking. In a patent model, sulfated polysaccharides prevented oleic-acid-induced desquamation in reconstructed skin, reducing the score from 3 to 0. The approach addresses flaking pathways rather than killing scalp microorganisms (patent, ex vivo).<\/p>\n

Gentle wash-day feel. A smooth anionic film can reduce friction during massage and rinsing, supporting comfort in shampoos, scalp treatments and pre-wash products for sensitive scalps.<\/p>\n

Sources: Huang et al. 2023; EP2794012B1.<\/p>\n

14 \u00b7 SCALP MICROENVIRONMENT<\/p>\n

Scalp oxidative stress and the microenvironment<\/b><\/h2>\n

Oxidative stress is a documented contributor to scalp and hair aging. UV exposure and sebum lipid peroxidation increase ROS at the follicular environment, affecting scalp condition and the quality of emerging hair.<\/p>\n

THE SCALP OXIDATIVE CASCADE<\/b><\/p>\n

\"\"<\/p>\n

UV + SEBUM<\/p>\n

Light exposure and sebum peroxidation generate ROS at the scalp surface and follicular openings.<\/p>\n

OXIDATIVE STRESS<\/p>\n

ROS irritate scalp skin, contribute to microinflammation and oxidize hair surface lipids.<\/p>\n

VISIBLE EFFECTS<\/p>\n

Scalp sensitivity, dull hair and progressive loss of hair quality.<\/p>\n

ALGISULF BUFFERING CONCEPT<\/p>\n

Sulfation-associated radical scavenging is proposed to interrupt the cascade at the surface.<\/p>\n

MICROBIOME-FRIENDLY POSITIONING<\/b><\/p>\n

Dandruff-associated dysbiosis involves Malassezia and Staphylococcus overgrowth. The source describes recurrence after stopping conventional antifungal treatment. Sulfated polysaccharides offer a proposed complementary, non-biocidal pathway: limiting metabolite-triggered flaking while preserving the resident ecosystem.<\/p>\n

Sources: Tr\u00fceb. Int. J. Trichology 2009; Kerschenmeyer 2017; EP2794012B1.<\/p>\n

15 \u00b7 HAIR SHAFT<\/p>\n

Hair conditioning through electrostatic interactions<\/b><\/h2>\n

Hair keratin has a net negative charge at cosmetic pH. Anionic polysaccharides can reach the hair surface through association with cationic conditioning polymers, which promote deposition and retention.<\/p>\n

COMPLEXATION IMPROVES SUBSTANTIVITY<\/b><\/p>\n

Complexing anionic glycosaminoglycan-like polysaccharides with cationic cellulose (polyquaternium-type polymers) increased keratin-bound polymer after rinsing by up to tenfold, with zeta-potential evidence of deposition (in vitro, hair tresses). The source proposes the same architecture for anionic sulfated polyuronides.<\/p>\n

FILM-BASED CONDITIONING<\/b><\/p>\n

After deposition, the sulfated film provides the conditioning functions associated with hair-care polysaccharides: cuticle smoothing, improved combability, moisture retention and slip, without the heavy feel associated with silicone oils.<\/p>\n

The water-binding network helps maintain hair hydration between washes.<\/p>\n

FORMULATION TIP<\/b><\/p>\n

Pair AlgiSulf with cationic conditioners in conditioners and hair masks to engineer deposition. In leave-on scalp serums, the anionic film may function independently. One ingredient supports two delivery approaches.<\/p>\n

Source: Pavlichko et al. Int. J. Cosmet. Sci. 1994; PMID 19250478.<\/p>\n

16 \u00b7 SYNERGY<\/p>\n

Skin\u2013scalp synergy: one INCI across facial, scalp and hair care<\/b><\/h2>\n

\"\"<\/p>\n

For brand developers, this alignment supports a consistent ingredient story across facial care, scalp care and hair care product lines.<\/p>\n

17 \u00b7 TECHNICAL PROPERTIES<\/p>\n

Documented technical properties<\/b><\/h2>\n

\"\"<\/p>\n

Full specifications, including appearance, content, viscosity and microbial limits, are provided in the product COA\/TDS and can be requested from PuriPharm technical support. The spectra shown characterize the alginate backbone in a related material.<\/p>\n

\"\"<\/p>\n

Published figure: FTIR fingerprint of the brown-algal sodium alginate backbone. Mar. Drugs 2026;24:41 (CC BY). DOI: 10.3390\/md24010041.<\/p>\n

\"\"<\/p>\n

Published figure: \u00b9H NMR anomeric-region spectrum used to resolve alginate M\/G composition (same source). The presentation states that comparable COA-level characterization supports each AlgiSulf batch.<\/p>\n

18 \u00b7 FORMULATION<\/p>\n

Formulation compatibility and processing<\/b><\/h2>\n

The following guidance is based on established polyelectrolyte chemistry of alginate-family polymers. Confirm specific parameters in pilot batches with PuriPharm technical support.<\/p>\n

COMPATIBLE SYSTEMS<\/b><\/p>\n

\u25cf Water-based and hydrogel systems: serums, concentrates, masks and scalp treatments.<\/p>\n

\u25cf Nonionic and anionic ingredients: polyols, humectants and anionic surfactant bases.<\/p>\n

\u25cf Oil-in-water emulsions: add to the aqueous phase for a light structural contribution.<\/p>\n

\u25cf Cationic conditioners, when deliberately designed: controlled complexation for hair deposition.<\/p>\n

\u25cf Near-neutral pH: a typical range for leave-on skin and scalp products.<\/p>\n

HANDLE WITH CARE<\/b><\/p>\n

\u25cf Strongly cationic ingredients: spontaneous polyelectrolyte complexation can be useful in hair care but should be avoided in clear gels.<\/p>\n

\u25cf Low pH: uronic-acid protonation reduces charge and solubility; avoid strongly acidic systems.<\/p>\n

\u25cf High electrolyte loading: charge screening can reduce viscosity and film quality.<\/p>\n

\u25cf Multivalent cations, such as Ca\u00b2\u207a: G-block \u201cegg-box\u201d gelation can be used deliberately as a texture tool.<\/p>\n

PROCESSING<\/p>\n

Add to the aqueous phase under moderate stirring and hydrate fully. A pre-dissolved solution may suit cold processing. Use levels depend on formulation goals; contact PuriPharm technical support.<\/p>\n

19 \u00b7 APPLICATIONS: SKINCARE<\/p>\n

Skincare formulation opportunities<\/b><\/h2>\n

MOISTURIZING SERUMS \/ CONCENTRATES<\/b><\/p>\n

A water-binding polyuronide film for a hydrated, plump feel with non-sticky slip.<\/p>\n

SOOTHING GELS FOR SENSITIVE SKIN<\/b><\/p>\n

Chemokine-affinity positioning for reactive, redness-prone or stressed skin in a lightweight hydrogel format.<\/p>\n

BARRIER REPAIR CREAMS<\/b><\/p>\n

Film-forming support inspired by dressings for compromised-barrier care and overnight repair masks.<\/p>\n

ANTIOXIDANT DAY CARE<\/b><\/p>\n

Sulfation-related radical scavenging as a concept for daily urban and photo-oxidative stress care.<\/p>\n

FIRMING \/ ECM CARE CREAMS<\/b><\/p>\n

GAG biomimetic positioning for matrix-care concepts in anti-aging and firming products.<\/p>\n

SHEET MASKS AND ESSENCE SYSTEMS<\/b><\/p>\n

A marine polysaccharide story with immediate surface smoothing and a soft after-feel.<\/p>\n

CLAIM FRAMEWORK<\/p>\n

Hydration \u00b7 Barrier comfort \u00b7 Soothing \u00b7 Antioxidant defense \u00b7 Matrix support. Each concept links to the mechanisms reviewed above.<\/p>\n

20 \u00b7 APPLICATIONS: SCALP AND HAIR<\/p>\n

Hair and scalp formulation opportunities<\/b><\/h2>\n

SOOTHING SCALP SERUMS \/ TREATMENTS<\/b><\/p>\n

Leave-on aqueous formats address tightness and itching through hydration and chemokine-affinity concepts.<\/p>\n

FLAKING-CONTROL SCALP TREATMENTS<\/b><\/p>\n

Patent precedent for sulfated polysaccharides supports a non-biocidal approach to flaking in daily scalp care.<\/p>\n

SCALP HYDRATION MASKS<\/b><\/p>\n

Pre-wash or overnight hydration for dry, tight scalps, with a light lotion texture and fresh feel.<\/p>\n

CONDITIONERS \/ HAIR MASKS<\/b><\/p>\n

Cationic complexation and deposition for cuticle smoothing, combability and sustained hair hydration.<\/p>\n

AFTER-SUN SCALP SPRAYS<\/b><\/p>\n

Antioxidant and soothing support for UV-exposed scalp partings, positioned as an emerging product opportunity.<\/p>\n

GENTLE DAILY SHAMPOOS<\/b><\/p>\n

Compatibility with anionic surfactants adds slip and post-wash comfort to mild, sulfate-free cleansing systems.<\/p>\n

CLAIM FRAMEWORK<\/p>\n

Scalp hydration and comfort \u00b7 Flaking-control support \u00b7 Oxidative stress defense \u00b7 Hair conditioning.<\/p>\n

Sources: EP2794012B1; Pavlichko et al. 1994; Tr\u00fceb 2009.<\/p>\n

21 \u00b7 EVIDENCE LANDSCAPE<\/p>\n

Scientific evidence and application matrix<\/b><\/h2>\n

\"\"<\/p>\n

\u25cf\u25cf\u25cf Primary application area \u00b7 \u25cf\u25cf Strong supporting fit \u00b7 \u25cf Emerging rationale. These symbols reflect the depth of public evidence reviewed in the source presentation.<\/p>\n

22 \u00b7 VALUE PROPOSITION<\/p>\n

What differentiates AlgiSulf<\/b><\/h2>\n

Beyond sodium alginate. Sulfation transforms a commodity texture polymer into a material with biological affinity, higher charge density, chemokine interactions and radical-scavenging properties, with a distinct INCI identity.<\/p>\n

Characterized heparin-like chemistry. Two decades of peer-reviewed work on sulfated alginate, covering synthesis, sequence characterization, protein binding and cellular models, provide a substantial mechanistic literature for formulation concepts.<\/p>\n

Continuity from skin to scalp. One ingredient carries a consistent marine polysaccharide story across facial, scalp and hair products, simplifying ingredient selection, claims development and supply chains.<\/p>\n

Marine sourcing with contemporary relevance. Renewable brown-algal biomass, biodegradable polymer chemistry and a non-biocidal scalp-care concept align with responsible formulation goals.<\/p>\n

PuriActives\u00ae AlgiSulf: marine sulfation science for formulation development.<\/p>\n

23 \u00b7 CONCLUSION AND REFERENCES<\/p>\n

PuriActives\u00ae AlgiSulf: ready for your next formulation<\/b><\/h2>\n

A marine sulfated polysaccharide with a defined INCI identity, mechanistic literature and a combined skin\u2013scalp application rationale. Technical support, samples and documentation are available from PuriPharm.<\/p>\n

SELECTED REFERENCES<\/b><\/p>\n

1. Arlov \u00d8, Skj\u00e5k-Br\u00e6k G. Sulfated alginates as heparin analogues: chemical and functional properties. Molecules 2017, 22(5), 778. DOI 10.3390\/molecules22050778<\/p>\n

2. Arlov \u00d8 et al. Heparin-like properties of sulfated alginates with defined sequences and sulfation degrees. Biomacromolecules 2014, 15(7). DOI 10.1021\/bm500602w<\/p>\n

3. Kerschenmeyer A et al. Anti-oxidant and immune-modulatory properties of sulfated alginate derivatives on human chondrocytes and macrophages. Biomater. Sci. 2017, 5, 1756\u20131764. DOI 10.1039\/C7BM00341B<\/p>\n

4. Freeman I, Kedem A, Cohen S. Sulfation of alginate hydrogels: specific binding and controlled release of heparin-binding proteins. Biomaterials 2008, 29(22).<\/p>\n

5. Huang C et al. Tunable sulfated alginate-based hydrogel platform for burn wound repair. J. Nanobiotechnology 2023, 21, 305. DOI 10.1186\/s12951-023-02144-2<\/p>\n

6. Balde A, Nazeer RA. In vitro anti-inflammatory effects of alginate sulfate; AlgS\/PVA\/CA microneedle system. Colloids Surf. B Biointerfaces 2025.<\/p>\n

7. Karam M et al. Alginate and alginate sulfate\/PCL nanoparticles for growth-factor delivery in wound healing. Biomed. Pharmacother. 2024.<\/p>\n

8. Zhao X, Xue CH, Li BF. Antioxidant activities of sulfated polysaccharides from Laminaria japonica. J. Appl. Phycol. 2008. DOI 10.1007\/s10811-007-9282-4<\/p>\n

9. Mutch AL et al. Sulfated alginate for biomedical applications. Macromol. Biosci. 2024. DOI 10.1002\/mabi.202400237<\/p>\n

10. Kim JH et al. Beneficial effects of marine algae-derived carbohydrates for skin health. Mar. Drugs 2018, 16(11), 459. DOI 10.3390\/md16110459<\/p>\n

11. Ngo DH, Kim SK. Sulfated polysaccharides as bioactive agents from marine algae. Int. J. Biol. Macromol. 2013, 62.<\/p>\n

12. Tr\u00fceb RM. Oxidative stress in ageing of hair. Int. J. Trichology 2009, 1(1), 6\u201314.<\/p>\n

13. Pavlichko JP et al. Enhanced substantivity of hyaluronic acid on keratin substrates via polymer complexation. Int. J. Cosmet. Sci. 1994, 16(6). PMID 19250478<\/p>\n

14. Use of sulphated polysaccharides as antidandruff agent. EP2794012B1 \/ WO2013093307A1 \u00b7 Sodium alginate from E. amentacea: characterization & anti-inflammatory profile. Mar. Drugs 2026, 24(1), 41. DOI 10.3390\/md24010041<\/p>\n

PURIPHARM CO., LTD.<\/p>\n

www.puriactives.com \u00b7 service@puripharm.com \u00b7 +86-572-2745768<\/p>\n

Building 6, No. 1366 Hongfeng Road, Huzhou, Zhejiang, China<\/p>\n

PuriActives\u00ae is a registered trademark of PuriPharm Co., Ltd.<\/p>\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\n\t\t\n\t<\/div>\n\n<\/article>\n\n\t\n\t\t\n

\n\n\t\n\t
\n\n\t\t\n\t\t
\n\t\t\t\n\t\t\t

NanoActive™ Harpa<\/a><\/h1>\n\n\t\t\t\t\t\t\t
\n\t\t\t\t\tPosted on L, Y<\/a><\/span><\/span> \t\t\t\t<\/div>\n\t\t\t\n\t\t<\/header>\n\n\t\t\t\t\t
\n\t\t\t\t

NanoActive™ HarpaLiposomal Devil\u2019s Claw Phytocomplex for Skin & Scalp Resilience<\/p>\n

BRAND & PRODUCT<\/p>\n

NanoActive™ Harpa \u00b7 Liposomal Harpagoside Botanical Complex<\/b><\/h2>\n

\"\"<\/p>\n

Liposomal Devil\u2019s Claw Phytocomplex for Skin & Scalp Resilience<\/p>\n

Powered by PURISOME\u00ae FlexVes™ Liposome Technology<\/p>\n

Soothe inflammatory signals, restore barrier resilience and revitalize the scalp<\/p>\n

PuriPharm Co., Ltd.<\/p>\n

PRODUCT OVERVIEW<\/p>\n

African desert botanical resilience meets modern nano-delivery<\/b><\/h2>\n

TRADE NAME<\/p>\n

NanoActive™ Harpa<\/p>\n

PRODUCT POSITIONING<\/p>\n

Liposomal harpagoside botanical complex<\/p>\n

INCI NAME<\/p>\n

HARPAGOPHYTUM PROCUMBENS ROOT EXTRACT<\/p>\n

BOTANICAL SOURCE<\/p>\n

Devil\u2019s claw root<\/p>\n

MARKER ACTIVES<\/p>\n

Harpagoside and other iridoid glycosides<\/p>\n

DELIVERY TECHNOLOGY<\/p>\n

PURISOME\u00ae FlexVes™ flexible vesicle liposome technology<\/p>\n

APPLICATIONS<\/p>\n

Skincare \u00b7 Scalp care \u00b7 Hair care<\/p>\n

KEY BENEFITS<\/p>\n

▪ Soothing and redness care<\/p>\n

▪ Barrier recovery<\/p>\n

▪ Reduced water loss<\/p>\n

▪ Inflamm-aging care<\/p>\n

▪ Scalp comfort<\/p>\n

▪ Root vitality<\/p>\n

PRODUCT VALUE<\/p>\n

\"\"<\/p>\n

Botanical actives<\/p>\n

FlexVes™ flexible liposomes<\/p>\n

Skin and scalp applications<\/p>\n

NanoActive™ Harpa<\/p>\n

MARKET INSIGHT<\/p>\n

Skin and scalp face shared inflammatory stress<\/b><\/h2>\n

DAILY STRESSORS<\/p>\n

▪ Air pollution<\/p>\n

▪ UV exposure and heat<\/p>\n

▪ Extreme temperature changes<\/p>\n

▪ Frequent cleansing<\/p>\n

▪ Surfactant irritation<\/p>\n

▪ Cosmetic procedures<\/p>\n

▪ Shaving<\/p>\n

▪ Hair coloring, bleaching and perming<\/p>\n

▪ Heat styling<\/p>\n

▪ Sleep and lifestyle stress<\/p>\n

\"\"<\/p>\n

BOTANICAL ORIGIN<\/p>\n

Devil\u2019s claw: resilience from the African desert<\/b><\/h2>\n

Harpagophytum procumbens grows mainly in arid southern Africa, including Namibia, Botswana, South Africa, Angola and parts of Zimbabwe.<\/p>\n

\u201cHarpago\u201d derives from the Latin word for \u201chook.\u201d The fruit\u2019s sharp hooks give the plant its common name, devil\u2019s claw.<\/p>\n

Adapted to extreme dryness: defensive secondary metabolites accumulate under desert heat and water stress.<\/p>\n

Secondary storage roots are the traditional plant material used and contain concentrated actives.<\/p>\n

Burgundy flowers and hooked fruits create a distinctive visual identity for the African desert botanical story.<\/p>\n

Traditional use and scientific interest connect southern African botanical practice with modern inflammation research.<\/p>\n

\"\"\"\"<\/p>\n

Namib Desert landscape; devil\u2019s claw flowers, hooked fruits, secondary roots and dried roots (reference images).<\/p>\n

Source: Zuplex Botanicals. Rosacalm Product Brochure. 2019 [5].<\/p>\n

PHYTOCHEMICAL PROFILE<\/p>\n

Beyond harpagoside: a multi-active botanical matrix<\/b><\/h2>\n

IRIDOID GLYCOSIDES<\/p>\n